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Summary
Toxoplasma gondii, a protozoan parasite, can cause severe, life-threatening disease, 
especially in newborns and immunosuppressed patients. It is an important cause o f ocular 
disease and is considered to be the most common recognisable cause o f posterior uveitis 
in immunocompetent individuals. The clinical and pathological manifestations of 
congenital toxoplasmosis in infants, children and adults are well characterised. However, 
until now, this disease has not been extensively studied in fetuses and there remain 
certain gaps in our understanding of the earliest stages of congenital disease. The first 
section of this thesis describes the early pathological changes in the eyes o f fetuses and 
infants. The second section provides evidence for two novel biochemical pathways in 
T.gondii. These pathways are more commonly associated with plants and algae and may 
provide new targets for antimicrobial agents.
This study of fetal and infant eyes represents the biggest most comprehensive study o f its 
kind to date. Eyes from 10 fetuses and 2 infants with congenital toxoplasmosis were 
studied by light microscopy. In addition, immunohistochemistry was performed for 
infiltrating inflammatory cells and T.gondii antigens. The characteristic findings were of 
retinitis, retinal necrosis, disruption o f the retinal pigment epithelium and choroidal 
inflammation and congestion. Optic neuritis was present in 5 fetal eyes. The eye obtained 
from a 32 week old fetus showed a well established retinochoroidal scar. At the edge of 
the scar the retinal architecture was disrupted with formation of rosettes. This was 
interpreted as focal retinal dysplasia. Mechanisms leading to abnormal retinal 
development is discussed. T cells, in particular CD4+ T cells, predominated within the 
retinal lesions and choroid. This demonstrates that the fetus is capable o f mounting an
immune response to T.gondii. However, this immune response may be less effective than 
in the child or adult. T gondii organisms were identified in 5 fetuses and two infants by 
immunohistochemical staining. In one infant eye and one fetal eye parasites were 
identified in a perivascular location supporting a haematogenous route of dissemination 
to the eye. These findings demonstrate that ocular toxoplasmosis causes severe 
irreversible damage to the retina in utero. The significance of these findings to current 
strategies for prenatal diagnosis and management is discussed.
Current treatments are only effective against the rapidly dividing tachyzoite form 
associated with active disease. There are no treatments capable o f eliminating the 
quiescent cystic bradyzoite stage. This is the source o f disease reactivation in the 
congenitally infected and immunocompromised host. A combination of pyrimethamine 
and sulphadiazine, both anti-folate agents, is the most effective therapy for active disease 
currently available. However, there are significant side effects associated with both these 
drugs. For these reasons, new antimicrobial agents are urgently needed for the treatment 
o f this disease.
In recent years there has been considerable interest in the vestigial plastid organelle of 
T. gondii and Apicomplexans (the subphylum of parasites which include Plasmodium, 
Theileria, Babesia, Eimeria, Hepatozoon, Sarcocystis and T.gondii) in general. In 
addition certain other plant-like characteristics have been reported in Apicomplexans. 
These observations may provide exploitable differences between these parasites and their 
mammalian hosts. In the second part of this thesis, the possibility that T.gondii may 
depend on biochemical processes more normally restricted to plants is investigated.
The shikimate pathway occurs within the plastid o f plants and algae. It is a seven step 
reaction which catalyses the conversion of phosphoenol pyruvate to chorismate. 
Chorismate is then used for the synthesis of virtually all aromatic compounds, notably, 
p-aminobenzoic acid which is required for de novo folic acid synthesis; ubiquinone an 
essential component o f the mitochondrial electron transport chain; and the aromatic 
amino acids.
The studies described in this section o f the thesis provide chemotherapeutic and genetic 
evidence for the shikimate pathway in T. gondii. Firstly, the in vitro growth o f T. gondii 
was inhibited by the herbicide glyphosate, also known as N-(phosphonomethyl)glycine 
(NPMG), a well characterised inhibitor of the shikimate pathway enzyme 5-enolpyruvyl 
shikimate 3-phosphate (EPSP) synthase. Furthermore, the effect o f NPMG on T.gondii 
was reversed by treatment with p-aminobenzoic acid, which suggests that the shikimate 
pathway supplies folate precursors for their growth. NPMG in combination with 
pyrimethamine was able to protect mice from death. Finally the gene encoding 
chorismate synthase, the final shikimate pathway enzyme was cloned and sequenced form 
T.gondii.
Another plant pathway which was investigated was the alternative pathway of 
respiration. This pathway is present on the inner mitochondrial membrane o f plants, 
Trypanosoma, certain fungi and green algae. The alternative pathway o f respiration 
branches from the cytochrome pathway after the ubiquinone complex and channels 
electrons through the alternative oxidase. Evidence is also presented for the presence o f 
this pathway in T.gondii. Thus, in vitro growth of T.gondii was inhibited by two 
recognised inhibitors o f alternative oxidase, salicylhydroxamic acid and
8-hydroxyquinoline. In addition, antibodies to the alternative oxidase o f Trypanosoma 
bruceii and the Voodoo lily, Sauromatum guttatum, recognised a band o f 66 kD by 
Western blotting o f electrophoresed parasites. Under rigorous reducing conditions a 
band o f 33 kD was also recognised suggesting that, like alternative oxidase o f T. bruceii 
and Voodoo lily, T.gondii alternative oxidase is a dimeric protein. The description o f 
these two plant like biochemical pathways in T.gondii not only increases our knowledge 
of Apicomplexan biochemical processes, but also provides a rational for the development 
o f novel antimicrobial targets for the treatment o f toxoplasmosis.
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CHAPTER 1
DISEASE CAUSED BY TOXOPLASMA GONDII
1
1.1 History
Toxoplasma gondii was first discovered in the spleen of the north African rodent, the 
gondii (Ctenodactylus gundi) (Nicolle & Manceaux, 1908). Initially naming this 
parasite Leishmania gondii, Nicolle and Manceaux later recognised it as a separate 
genus renaming it Toxoplasma gondii (Nicolle & Manceaux, 1909). In the same year 
the parasite was also seen by Splendore, (1908) in tissues o f a rabbit in Brazil. A 
paper by Janku in 1923 is accepted as the first report o f human disease although a 
number of earlier cases describing disease, which at that time was apparently due to 
other organisms, were later re-identified as T.gondii (Kean, 1972). Congenital 
toxoplasmosis was first reported in 1937 (Wolf & Cowen, 1937; Wolf el al., 1939) 
and in 1941 Sabin described the classical tetrad of symptoms, (meningoencephalitis, 
hydrocephalus, intracranial calcifications and retinochoroiditis), associated with 
congenital infection. In 1940 the first fatal case of acquired toxoplasmosis in an adult 
was described (Pinkerton & Weinman, 1940).
Serological tests for T.gondii became available in the 1940s. In 1948 the introduction 
o f the Sabin-Feldman dye test (Sabin & Feldman, 1948) allowed large scale 
epidemiological studies of toxoplasmosis. Use of this test confirmed world-wide 
distribution o f T.gondii and showed that there were many asymptomatic carriers both 
in humans and domestic animals. However, for around 60 years after its discovery, the 
life-cycle of T.gondii remained unknown.
A report by Weinman and Chandler in 1954 claimed that undercooked meat may be a 
source o f infection. This claim was substantiated by Desmonts et al., (1965) who 
observed almost 100% seroconversion in children fed raw meat in a Parisian
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‘consumption’ (tuberculosis) hospital. In contradiction to this Rawal, (1959) showed 
that prevalence rates in vegetarians and non-vegetarians were similar.
Attempts to demonstrate infection in excretions and secretions of animals initially 
failed. However, in 1965, Hutchison showed that cat faeces could be infective to 
laboratory mice and in 1969 the cat was identified as the definitive host (Hutchison et 
al., 1970; Hutchison et al., 1969; Hutchison et al., 1971). Subsequent work 
confirmed the cat as the definitive host and identified most mammals, including man, 
as intermediate hosts (Frenkel et al., 1970; Miller et al., 1972; Jewell et al., 1972; 
Janitchke & Werner, 1972).
1.2 Epidemiology
T.gondii infects humans throughout the world. World-wide prevalence of antibodies 
to T.gondii is estimated at 33% although there is considerable variation within and 
between groups studied (reviewed, Jackson & Hutchison, 1989). Thus, the presence 
of T.gondii antibodies in different populations varies with socio-economic factors, 
age, and geographical location. For example, infection rates are higher where 
undercooked meat is frequently consumed or where there is environmental 
contamination with cat excrement. Geographically, prevalence is highest in tropical 
areas and is relatively low in hot, arid areas or cold regions (Wallace, 1969). People 
living at high altitudes have lower rates of infection than those living at sea level 
(Yamaoka & Konishi, 1993). These variations are attributed to the effects o f 
environmental conditions on oocyst survival. Prevalence of human toxoplasmosis in 
various groups based on serological evidence is shown in Table 1.1.
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Table 1.1 Sero-prevalence of T.gondii antibodies in various groups
of people (updated from Jackson & Hutchison, 1989)____________
GROUP REGION PREVALENCE REFERENCES
(% )
Women of India 7.7 Mittal et al., 1995
childbearing Mali 34 Maiga et al., 1984
age Turkey 39.9 Durmaz etal., 1995
Senegal 40.3 Diallo eta l, 1996
Pregnant
women
Thailand 13-15 Taechowisan et al., 
1997
Glasgow, Scotland 13.4 Williams el al, 1981
England 14.9 Jackson et al., 1987
Southern Finland 20.3 Lappalainen et al, 1992
Denmark 27.4 Lebeche/a/., 1995
Southern Spain 30 Gutierrez et al, 1996
Tanzania 34-37 Doehring et al, 1995
Slovenia 37 Logare/a/., 1992
Brussels, Belgium 53 Foulon eta l, 1984
Cuba 70.9 Gonzalez-Morales et 
al, 1995
Paris, France 84 Desmonts & 
Couvreur, 1974
Blood Donors Thailand 1.2-4.6 Morakote et al, 1984
Scotland 7.6-7.8 Jackson et al, 1987
Kenya 42 Griffin & Williams, 
1983
Saudi Arabia 52.1 Al-Amari, 1994
Veterinarians New York, USA 8.3 Sengbusch & 
Sengbusch, 1976
California, USA 43.7 Behymer etal., 1973
A battoir workers Brazil 60-92 Riemann et al, 1975
M ilitary Recruits USA 3-20
3-14
Feldman, 1965 
Smith eta l, 1996
C at owners Washington 
County, USA
20.9 Peterson et al, 1972
England 35.8 W oodruffs al, 1982
w ithout dogs Iceland 18.3 Woodruff et al, 1982
4
Table 1.I continued:
GROUP REGION PREVALENCE
(% )
REFERENCES
Isolated island 
populations
with cats Pacific(tropics) 43 and 56 Wallace, 1969
without cats Pacific(tropics) 7 Wallace, 1969
Isolated jungle Brazil(tropics) 39-77 Lovelace et al, 1978
populations Brazil(tropics) Ferraroni & Marzochi, 
1980
Populations at
high altitude Japan 5 Yamaoka & Konishi,
sea level Japan 10.6 1993
Populations with
high rainfall Japan 16.8 Yamaoka & Konishi,
low rainfall Japan 8.6 1993
Populations
within Arctic Alaska, USA 28 Peterson et al., 1974
Northern Sweden 12 Ljungstrom et al, 
1995
outwith Arctic Gotland Island, 
Southern Sweden
26 Ljungstrom et al, 
1995
Asymptomatic United Kingdom 27 Holliman, 1990
HIV infected Mexico 50 Galvan Ramirez et al, 
1997
AIDS patients Zaire 24-33 De Clerq et al, 1986
Medical England 35.7 Jackson et al, 1987
outpatients
Travelling Scotland 28 Jackson et al, 1987
people
Population Calcutta, India 23.8 Haidar et al, 1993
surveys Chile 36.9 Contreras et al, 1996
Parma, Italy 48.5 Valcavi e ta l, 1995
Nepal 48 Rai eta l, 1996
Ethiopia 74.4 Guevre-Xabier et al, 
1993
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Table 1.2 Estimated incidence of human congenital toxoplasmosis in
different countries (updated from Jackson & Hutchison, 1989)
REGION INCIDENCE 
PER 1000
REFERENCES
Germany 5.3 Kraubig, 1966
Mexico City 2 Roch & Varela, 1966
New York 0.7 Kimball et al., 1971
London 0 Ruoss & Buorne, 1972
Vienna 6-7 Thalhammer, 1973
The Netherlands 6.5 K oppee/a/., 1974
Paris 10 Desmonts & Couvreur, 1974
United Kingdom 0.07-0.25 Fleck, 1974
Birmingham, Alabama 1.3 Alford et al, 1974
Austria 8.6 Thalhammer & Heller-Szollosy, 1979
Glasgow >0.5 Williams et al, 1981
Europe 3-6a Williams et al, 1981
USA l-2a Williams et al, 1981
Great Britain 0.9 Henderson et al, 1984
Brussels > 2 Foulonefa/., 1984
USA 1-8 McCabe & Remington, 1988
Slovenia 3 Logaretal, 1992
Southern Finland 0.96 Lappalainen et al, 1992
Guatemala 10.9 Sinibaldi & De, 1992
United Arab Emirates 12 Dar et al, 1997
a Computed averages
The incidence o f congenital infection is difficult to estimate due to inadequate 
screening in many countries, but reports world-wide vary between 0.07 and 10 per 
1000 births (Table 1.2). However, the incidence o f ocular toxoplasmosis is 
considerably greater than the stated incidence of congenital infection (reviewed, 
Cook, 1990; Jackson & Hutchison, 1989). Since many of these cases represent 
previously undiagnosed congenital infection, it is likely that the true incidence o f 
congenital infection is underestimated.
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1.3 Clinical Disease
Infection in the im m unocom petent host
In the immunocompetent host primary infection with T.gondii is frequently 
asymptomatic (Hughes, 1985). Occasionally it is associated with a febrile illness with 
or without lymphadenopathy (McCabe et al., 1987). T.gondii has been estimated to 
cause between 3 and 7 % of clinically significant lymphadenopathy in adults (McCabe 
et al., 1987). Far less commonly toxoplasmosis results in severe illness affecting any 
organ and in extreme cases can be fatal (Pinkerton & Weinman, 1940; Townsend et 
al., 1975). Manifestations of severe disease include encephalitis (Grant & Klein, 1987; 
Lescop et al., 1995; Townsend et a l , 1975), myocarditis (Montoya et al., 1997), 
pneumonitis (Candolfi et al., 1993; Pomeroy & Filice, 1992) and hepatitis (Masur & 
Jones, 1979; Sijpkens et a l, 1994; Weitberg et al., 1979). Ocular disease can also 
occur in the immunocompetent individual and is described below.
Infection in the im m unosuppressed host
T.gondii is a common opportunistic pathogen among immunosuppressed patients. It is 
a particularly serious problem in patients with HIV-infection (Zangerle et al., 1991), 
but also affects patients taking immunosuppressive agents following transplant 
surgery (Israelski & Remington, 1993) or patients receiving chemotherapy for 
malignancy (Klastersky, 1985).
Toxoplasmosis is believed to be the most common non-viral infection of the brain in 
patients with AIDS. Without prophylactic chemotherapy, encephalitis eventually 
develops in up to 50% of AIDS patients with antibodies against T.gondii (Zangerle et 
al., 1991). Whilst cerebral involvement is most frequent in AIDS patients any organ
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may be involved and toxoplasmosis may present as a multisystem disease (reviewed, 
Holliman, 1988; Mariuz etal., 1994).
Toxoplasmosis following transplant surgery is affected by two main factors, the type 
o f organ graft (solid organ or bone marrow) and the degree o f immunosuppression 
associated with the post-operative management (Israelski & Remington, 1993). The 
organ graft type determines the risk o f contamination with T.gondii (Sweny, 1993). 
Most cases o f toxoplasmosis associated with solid organ transplant such as heart 
(Gallino et al., 1996; Holliman et al., 1991), lung (Couvreur et al., 1992; Wreghitt et 
al., 1989) and to a lesser extent liver (Mayes et al., 1995; Singh et al., 1996) or 
kidney (Renoult et al., 1997) arise from reactivation o f cysts within the graft itself. In 
contrast, toxoplasmosis following bone marrow transplantation is usually caused by 
reactivation of the recipient’s own previously quiescent T.gondii cysts (Chandrasekar 
et al., 1997; Derouin et al., 1992). This is related to the more intensive 
immunosuppressive therapy required following bone marrow transplantation. Ocular 
toxoplasmosis in the immunocompromised host is discussed below.
Congenital infection
Transplacental infection of T.gondii to the fetus most frequently occurs when a 
woman is infected for the first time during pregnancy (reviewed, Roberts et al., 
1998a). On rare occasions, congenital infection also can occur if an 
immunocompetent woman acquires toxoplasmosis 6 to 8 weeks prior to conception 
(Desmonts et al., 1990; Vogel et al., 1996). Less commonly an immunocompromised 
mother with chronic toxoplasmosis may transmit this disease to her fetus (D'Ercole et
8
her fetus (D'Ercole et al., 1995; Desmonts et al., 1990). Congenital infection develops 
in between 30 to 50% of infants born to mothers who have serological evidence o f 
acute toxoplasmosis during pregnancy (reviewed, Stray-Pedersen, 1993). As with 
other congenital infections this varies depending which trimester infection of the 
mother occurred (reviewed, Haggerty, 1985). During the first trimester while the 
infection rate is approximately 10 to 15%, disease manifestations are severe. 
Conversely in the third trimester almost two thirds of fetuses will be infected but 
symptoms are usually mild (Table 1.3).
Table 1.3 Inverse relationship between the incidence of fetal infection 
and severity of fetal damage following acutely acquired maternal 
infection with T.gondii at different stages of gestation (from Remington 
et al., 1995)
TRIM ESTER OF 
PREGNANCY
FETUSES 
IN FE C TED (% )
SEVERITY OF 
ILLNESS
1 17 Most severe
2 25 Intermediate severity
3 65 Least severe or 
subclinical
T.gondii infection of the fetus may result in damage to any organ, but most frequently 
involves the eye and the brain (reviewed, Swisher et al., 1994). The classical tetrad of 
congenital toxoplasmosis, first described by Sabin, (1941), consists of 
meningoencephalitis, hydrocephalus, intracranial calcifications and retinochoroiditis. 
Lesions in the brain are most marked in the cortex, basal ganglia and periventricular 
areas (reviewed, Remington etal., 1995; Weber, 1983). Extensive necrosis can occur
9
especially in peri-aqueductal and periventricular regions, where sloughing o f necrotic 
brain tissue into the ventricles may result in obstructive hydrocephalus (reviewed, 
Frenkel & Friedlander, 1951). Calcifications occur within areas of necrosis 
(Rosenberg & Kessler, 1993). In surviving children these frequently regress with 
treatment (Patel et al., 1996).
Ocular infection
Ocular toxoplasmosis is the most common manifestation o f congenital infection 
(Koppe el al., 1986; Remington et al., 1995). Most infants who present with 
generalised or neurological disease at birth already have extensive ocular disease 
(Mets el aI., 1996). Conversely, ocular disease may be the only sign of congenital 
infection (Guerina et al., 1994). Serological screening of neonates in Massachusetts, 
USA showed that 20% of asymptomatic infants, with congenital toxoplasmosis 
infection, already had ocular involvement (Guerina et a l , 1994). Furthermore, 
longitudinal studies have shown that more than 82% of congenitally infected 
individuals not treated as infants develop retinochoroidal lesions by adolescence 
(Koppe et al., 1986; Wilson et al., 1980).
It is commonly believed that most cases of ocular toxoplasmosis are the result o f 
congenital infection. This is based on epidemiological studies in areas o f the world 
such as Micronesia where, despite high seroprevalence, ocular toxoplasmosis is rarely 
seen (Darrell et al., 1964). In these populations high rates o f acquired disease in 
childhood means that first exposure to T.gondii usually occurs before pregnancy and 
consequently congenital transmission is uncommon. The low rate of ocular disease in
10
these populations argues against acquired ocular toxoplasmosis. Perkins, (1973) 
reviewed case reports where acquired toxoplasmosis appeared to be well documented 
and estimated that ocular involvement occurred in 2 to 3% of patients with 
symptomatic acquired toxoplasmosis. Perkins assumed that acquired ocular 
toxoplasmosis without systemic manifestations should be even less common. 
However, over a period of 13 years, a French epidemiological study identified 43 
cases o f acquired toxoplasmosis in immunocompetent patients complicated by isolated 
ocular lesions (Couvreur & Thulliez, 1996). Routine serological screening for 
toxoplasmosis has been compulsory in France since 1978 and the immune status o f 
the patient’s mother was documented in many cases, thus eliminating congenital 
infection. In addition to serological evidence o f recent infection the diagnosis was 
confirmed by identifying specific local antibody synthesis in the aqueous humor o f the 
eye. This French study suggested that acquired ocular toxoplasmosis was more 
frequent than had been previously estimated.
In contrast to intracranial disease, which occurs in up to 50% of those with antibodies 
to T.gondii, ocular toxoplasmosis appears to be uncommon in patients with AIDS 
accounting for between 1 and 3% of retinal infections (Cochereau Massin et al., 1992; 
Jabs, 1995). In two small studies o f patients with both AIDS and intracranial 
toxoplasmosis, ocular infection occurred in 10 and 20%, respectively (Luft et al., 
1983; Snider et al., 1983). In addition, ocular toxoplasmosis may develop without 
evidence of intracranial disease. Ocular toxoplasmosis following bone marrow 
transplant (Elkins et al., 1994), chemotherapy (Yeo et al., 1983) or long term 
corticosteroids (Nicholson & Wolchok, 1976) also has been described.
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T.gondii causes a progressive and recurring retinochoroiditis (Holland et al., 1996; 
Roberts & McLeod, 1998). Patients suffering from active retinochoroiditis usually 
present with blurred vision and floaters attributable to foci o f active retinal 
inflammation (Figure 1.1 A). Lesions heal to leave retinochoroidal scars, which are 
pale and atrophic with a variable amount of pigmentation at the margins (Figure 
1.1B). A retrospective clinical review by the ‘Chicago Toxoplasmosis Study Group’, 
defined the ocular manifestations of congenital toxoplasmosis in individuals treated or 
untreated during the first year o f life (Mets et a l , 1996). This group o f patients 
included infants, children and adults with congenital toxoplasmosis. The typical 
ophthalmological presentation, course and sequela o f this disease were documented. 
Their findings are summarised in Table 1.4. Retinochoroidal scars were the most 
common finding, present in 79% of patients. These scars involved the peripheral 
retina and macula in 64% and 58% of patients, respectively. If one considers the 
smaller area of the macula this suggests a definite predilection for the macula in 
congenital ocular toxoplasmosis. Furthermore, there was significant bilateral visual 
loss in 29% of patients, and a further 28% had unilateral visual loss.
The clinical presentation o f acquired toxoplasmic retinochoroiditis differs from 
congenital ocular disease. These patients are usually older with unilateral ocular 
disease and a single, active, retinochoroidal lesion (Montoya & Remington, 1996). 
Macular involvement is uncommon. This is in contrast to the clustering o f lesions, 
retinochoroidal scars and macular involvement more characteristic o f congenital 
infection.
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Figure 1.1 Fundoscopic photographs of toxoplasmic 
retinochoroiditis with acute lesion (A) and macular sc a r  (B). 
The acute lesion (A) appears white with an indistinct border 
(arrow). The retinochoroidal sc a r  (B) is sharply demarcated 
with a white centre and hyper-pigmented border. There is 
focal reactivation at the edge of the scar  (arrow).
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Table 1.4 The ophthalmological manifestations of congenital 
toxoplasmosis (adapted from Mets etaI., 1996)_____________
Finding Num ber of patients(% ), 
total=94
N um ber of patients with 
bilateral findings (% )
Strabismus 31(33) -
Nystagmus 25(27) -
Microphthalmia 12(13) 4/12(33)
Phthisis 4(4) 2/4(50)
Microcornea 18(19) 9/18(50)
Cataract 9(10) 3/9(33)
Vitritis(active) 5(5) 5/12(42)
Retinitis(active) 10(11) 2/9(22)
Chorioretinal Scars 74(79) 48/74(65)
Macular 52(58) 19/52(37)
Juxtapapillary 46(52) 20/46(43)
Peripheral 57(64) 23/57(40)
Retinal Detachment 9(10) 5/9(56)
Optic Atrophy 19(20) 9/19(47)
The histological features of congenital ocular lesions and their reactivations in adults 
have been described in reports by (Hogan, 1951; Wilder, 1952; Hogan, 1958; 
Zimmerman, 1961; Perkins, 1973; Rao & Font, 1977). Histologically, acute lesions 
show a well defined area of retinal necrosis or inflammatory infiltration. Tachyzoites 
are occasionally identified in areas of necrosis (Rao & Font, 1977). Tissue cysts may 
be found at the edge of a lesion or remote from the lesion within apparently normal 
retina (McMenamin et al., 1986). Distant from the active lesion the retina may show 
perivascular lymphocytic infiltration, oedema, gliosis, and neuronal degeneration. 
Usually there is associated choroidal inflammation. Active lesions heal to leave a 
retinochoroidal scar which consists of gliosis, obliteration of vessels and scattered 
inflammatory cells. Secondary changes including retinal detachment (Mets et al.,
1996), iridocyclitis (Friedmann & Knox, 1969) and cataracts (Mets et al., 1996) have 
been described. Papillitis, papilloedema and optic atrophy are recognised clinical 
manifestations of toxoplasmic encephalitis (Mets et al., 1996; Perkins, 1973).
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Microphthalmos or microcornea occasionally follows severe congenital infection 
(Heath & Zueler, 1944; Koch et a l , 1943).
In contrast to congenital ocular lesions in children and adults, the early stages o f 
ocular toxoplasmosis during acute infection of the fetus have not been extensively 
studied. In 1951 Hogan stated that ‘There have as yet been no descriptions o f the 
earliest stages o f toxoplasmic chorioretinitis’. Since then, there has been only one 
study o f ocular lesions in four fetuses between the ages of 22 to 27.5 weeks (Brezin et 
al., 1994). In two of these cases the eyes were normal, however the other two cases 
showed retinal necrosis, neovascularisation and marked chorioretinal inflammation.
In AIDS related ocular toxoplasmosis the lesions differ both clinically and 
histologically from those o f immunocompetent patients (reviewed, Holland, et al., 
1988a; Holland, 1989). There is usually no evidence that the disease originated in pre­
existing retinochoroidal scars. This suggests that most ocular lesions result from 
newly acquired disease or organisms which disseminate to the eye from non-ocular 
sites o f reactivation. Lesions are frequently bilateral and multifocal and extensive 
retinal necrosis is common. Histopathological examination demonstrates scant retinal 
inflammation in these areas o f necrosis with large numbers of parasite similar to that 
seen in the brain lesions o f AIDS associated toxoplasmic encephalitis (Holland et al., 
1988a).
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1.4 Antimicrobial Treatment of Toxoplasmosis
Anti-folate agen ts
The most effective available therapeutic regimen is the combination o f pyrimethamine 
and a sulphonamide, usually sulphadiazine (reviewed, Roberts et al., 1998a). 
Although still unlicensed for the treatment of toxoplasmosis in the United Kingdom, 
these anti-folate agents have been used since the early 1950’s . Both are active against 
tachyzoites and show synergism with each other (Eyles & Coleman, 1953). 
Pyrimethamine is a competitive antagonist o f dihydrofolate reductase (DHFR) which 
converts dihydrofolate to tetrahydrofolate (Williams, 1996a). Although more active 
against parasite DHFR, pyrimethamine is also active against human DHFR and 
consequently a common side effect o f treatment is bone marrow suppression 
(Williams, 1996a). This can in part be counteracted by simultaneous administration o f 
folinic acid. T.gondii is unable to use host cell folinic acid (Giles, 1971). 
Sulphadiazine blocks an earlier stage in folate synthesis than pyrimethamine: the 
condensation of p-aminobenzoic acid (PABA) with 6-hydroxymethyl-dihydropterin 
diphosphate to form dihydropteroic acid (Williams, 1996a). Sulphadiazine is, in fact, 
metabolised to an analogue of PABA which then competes with PABA for the 
enzyme site on dihydropteroate synthase. Side effects include hypersensitivity 
reactions, bone marrow suppression, and both hepatic and renal toxicity (Williams, 
1996a).
Recent studies have investigated the use of DHFR inhibitors which are more active 
against T.gondii DHFR than host cell DHFR (Brun Pascaud et al., 1996; Gangjee et 
al., 1997; Martinez et al., 1996). These new DHFR inhibitors are as effective as 
pyrimethamine, when combined with sulphadiazine or dapsone, in the treatment o f
16
mice with acute toxoplasmosis (Martinez et al., 1996). In addition, epiroprim, for 
example, is 650 times more active against T.gondii DHFR compared with human 
DHFR (Martinez et al., 1996). These new DHFR inhibitors are therefore, a 
potentially less toxic alternative to pyrimethamine.
Clindamycin
Clindamycin has been shown to prevent replication of T.gondii grown in vitro 
(Pfefferkorn et al., 1992). Clindamycin is also effective against acute and chronic 
toxoplasmosis in mice (Hofflin & Remington, 1987; McMaster et al., 1973). The 
mechanism of its action against T.gondii is unclear. In bacteria it inhibits protein 
synthesis on prokaryotic ribosomes (Williams, 1996b). Ribosomal DNA sequences 
believed to be derived from the T.gondii mitochondrial genome predict resistance to 
this drug (Beckers et al., 1995). This suggests that clindamycin may act by preventing 
organellar synthesis in T.gondii.
Clinically, it has been used in combination with pyrimethamine for the treatment of 
AIDS related toxoplasmic encephalitis (Katlama et al., 1996). A randomised, 
prospective study compared combination pyrimethamine-clindamycin with 
pyrimethamine-sulphadiazine therapy for the treatment and maintenance o f AIDS- 
related toxoplasmic encephalitis (Katlama et al., 1996a). Pyrimethamine-clindamycin 
was found to be as effective as pyrimethamine-sulphadiazine during acute therapy. 
However during maintenance therapy, patients receiving pyrimethamine-clindamycin 
were twice as likely to relapse than those receiving pyrimethamine-sulphadiazine.
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Clindamycin has also been used to treat ocular toxoplasmosis. Oral clindamycin 
appears to be as effective as pyrimethamine when given in combination with 
sulphadiazine and corticosteroids for the treatment of active toxoplasmic 
retinochoroiditis (Rothova et al., 1993). Other studies have suggested that 
subconjunctival injections of clindamycin may be as effective as combined oral 
pyrimethamine and sulphadiazine for the treatment of ocular toxoplasmosis (Colin & 
Harie, 1989; Jeddi et al., 1997). In these studies subconjunctival administration o f 
clindamycin did not produce any side effects which were common with oral 
pyrimethamine and sulphadiazine. Furthermore, in the short term, recurrences were 
less common with this therapy. However, these studies involved small numbers o f 
patients in whom the diagnosis o f toxoplasmic retinochoroiditis was presumed but not 
confirmed.
To date, clindamycin is usually recommended as an alternative therapy in conjunction 
with pyrimethamine, if sulphadiazine therapy cannot be tolerated. However, it must be 
used with caution in view of the uncommon but serious side effect of 
pseudomembranous colitis (Swartzberg et al., 1977).
Atovaquone
Atovaquone, a hydroxynaphthoquinone, was considered a major breakthrough when 
it was suggested that it was effective against bradyzoites within cysts, in vitro (Araujo 
et al., 1991; Huskinson Mark et al., 1991). It also appears to prolong survival and 
decrease cyst numbers in mice infected with the Me49 strain o f T.gondii (Araujo et 
al., 1992a). However, ultrastructural studies on the brains o f these mice suggest that
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this drug is only active against metabolically active, immature bradyzoites rather than
the mature organisms (Ferguson et al., 1994).
Atovaquone inhibits the enzyme dihydroorotate dehydrogenase (Ittarat et al., 1994). 
This enzyme is linked to the mitochondrial electron transport chain by ubiquinone. 
Thus, atovaquone interferes with oxidative respiration. Despite its apparent success in 
vitro and in animal models, it has proved less effective in clinical trials. In these trials, 
after successful induction over 26% of patients receiving maintenance atovaquone 
therapy for the treatment of AIDS associated toxoplasmic encephalitis relapsed 
(Katlama et al., 1996b). Lopez et al., (1992) described the successful treatment o f 
ocular toxoplasmosis in a patient with AIDS using atovaquone. However, in view o f 
the high relapse rate seen in AIDS related toxoplasmic encephalitis, it is unlikely to 
prevent recurrent retinochoroiditis.
Spiramycin
Spiramycin is a macrolide antibiotic which in viti 
growth on T.gondii although it does not kill 
Pechere, 1988a; Chang & Pechere, 1988b). The I 
prevent transplacental transmission of T.gondii. 
placenta and treatment is based on the observ 
maternal and fetal infection (Remington et a!., i 
congenital toxoplasmosis, subinoculation of the placenta into mice was negative in 
25% of spiramycin treated mothers compared with 11% of untreated mothers 
(Couvreur et al., 1988). If spiramycin therapy was combined with pyrimethamine and 
a sulphonamide 50% of placentas were uninfected. Spiramycin does not however alter
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this drug is only active against metabolically active, immature bradyzoites rather than
the mature organisms (Ferguson et al., 1994).
Atovaquone inhibits the enzyme dihydroorotate dehydrogenase (Ittarat et al., 1994). 
This enzyme is linked to the mitochondrial electron transport chain by ubiquinone. 
Thus, atovaquone interferes with oxidative respiration. Despite its apparent success in 
vitro and in animal models, it has proved less effective in clinical trials. In these trials, 
after successful induction over 26% of patients receiving maintenance atovaquone 
therapy for the treatment of AIDS associated toxoplasmic encephalitis relapsed 
(Katlama et al., 1996b). Lopez et al., (1992) described the successful treatment o f 
ocular toxoplasmosis in a patient with AIDS using atovaquone. However, in view o f 
the high relapse rate seen in AIDS related toxoplasmic encephalitis, it is unlikely to 
prevent recurrent retinochoroiditis.
Spiramycin
Spiramycin is a macrolide antibiotic which in vitro has some inhibitory effect on the 
growth on T.gondii although it does not kill the parasite effectively (Chang & 
Pechere, 1988a; Chang & Pechere, 1988b). The main clinical use o f spiramycin is to 
prevent transplacental transmission of T.gondii. Spiramycin is concentrated in the 
placenta and treatment is based on the observation that there is a lag between 
maternal and fetal infection (Remington et al., 1995). In a study o f 223 cases o f 
congenital toxoplasmosis, subinoculation of the placenta into mice was negative in 
25% of spiramycin treated mothers compared with 11% of untreated mothers 
(Couvreur et al., 1988). If spiramycin therapy was combined with pyrimethamine and 
a sulphonamide 50% of placentas were uninfected. Spiramycin does not however alter
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the course of the disease if the fetus is already infected. In a rhesus monkey model of 
congenital toxoplasmosis, spiramycin was found in some fetal tissues although at 
lower concentration than maternal tissues (SchoondermarkVan et al., 1994). 
However, no spiramycin was found in the fetal brains, one o f the most severely 
affected sites in congenital infection.
Corticosteroids
Corticosteroids have been used in combination with pyrimethamine and sulphadiazine 
to treat retinitis and vitritis which threaten vision. Corticosteroids do not have any 
action on the parasite but are used to decrease problems associated with 
inflammation. There is little controlled data to demonstrate the additional benefit 
afforded by corticosteroids, but in one small study, worsening o f  signs and symptoms 
were not observed when corticosteroid treatment was added to conventional 
antimicrobial therapy (Acers, 1964). Immunosuppression may potentiate replication of 
T.gondii and, given alone, corticosteroids will exacerbate ocular lesions (O’Connor, 
1974; van den Bosch & Rothova, 1997)
Other antimicrobial agents
Many other antimicrobial agents have been shown to be effective against T.gondii in 
vitro or in vivo. These include new macrolides such as roxithromycin (Chan & Luft, 
1986; Romand et al., 1995), clarithromycin (Alder et a!., 1994; Araujo et al., 1992b), 
azithromycin (Araujo et al., 1988; Dumas et al., 1994) and ketolides (Araujo et al.,
1997). In bacteria these drugs inhibit ribosomal protein synthesis and may inhibit 
organellar protein synthesis in T.gondii (Beckers et al., 1995). Clarithromycin has
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been used to treat patients with AIDS related toxoplasmic encephalitis (Raffi et al., 
1995). Use of the anti-leprosy sulphone drug, dapsone has been described (Derouin et 
al., 1991; Girard et al., 1993). Similar to sulphadiazine this drug is an inhibitor o f 
dihydropteroate synthase (Williams, 1996a). The anti-malarials, artemisinin ether and 
cycloguanil, have also been shown to be effective against T.gondii in vitro (Holfels et 
al., 1994). In addition, the anti-HIV drug 2’3’dideoxyinosine has recently been shown 
to inhibit the growth of T.gondii in vitro and to reduce cyst burden in vivo (Sarciron 
et al., 1997). The clinical role of this drug in AIDS patients with toxoplasmic 
encephalitis has not yet been evaluated.
All the aforementioned drugs have been shown to be more effective when combined 
with conventional anti-folate drugs. They appear to offer few advantages over existing 
conventional therapies although they may prove useful where allergy or intolerance 
limits the use of pyrimethamine or sulphadiazine. Drugs used in the treatment o f 
toxoplasmosis are summarised in Table 1.5.
1.5 Treatment in Specific Clinical Settings
In most symptomatic cases T.gondii infection is self-limiting. Furthermore there are 
no drugs which eliminate tissue cysts and therefore treatment cannot prevent chronic 
infection. Current guidelines suggest that active treatment is not required for the 
majority of T.gondii infections (reviewed, Boyer & McLeod, 1996; Roberts et al., 
1998a). There are specific situations in which treatment is extremely important and 
may prevent death or blindness. These include infections in pregnant women, newborn 
infants, immunosuppressed patients and recurrent ocular disease. Table 1.6 
summarises the currently recommended therapies for each clinical setting.
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Congenital infection
For acute infection during the first or second trimester of pregnancy initial therapy 
involves administration of spiramycin to prevent transmission of T.gondii to the fetus. 
If the fetus is infected or if maternal infection occurs in the third trimester then the 
fetus may be treated by administering pyrimethamine, sulphadiazine and folinic acid to 
the mother. Studies suggest that this treatment, in conjunction with close clinical 
follow up may improve the outcome of pregnancy.
For example, Daffos et al., (1988) reported a prospective study of 746 cases o f acute 
maternal toxoplasmosis. Congenital infection occurred in 42 fetuses and was 
diagnosed antenatally in 39 fetuses. Of these 39 pregnancies, 24 were terminated and 
15 were continued to term. The mothers were treated with spiramycin, pyrimethamine 
and either sulphadoxine or suphadiazine. Eleven of the 15 infants with congenital 
toxoplasmosis were asymptomatic at birth. The other 4 had intracranial calcifications 
and retinochoroiditis. A further 2 infants developed retinochoroiditis during an 18 
month follow-up. Couvreur et al., (1993) compared 52 infected infants whose 
mothers received pyrimethamine, sulphadiazine and spiramycin with 51 infected 
fetuses whose mothers received only spiramycin. Treatment with pyrimethamine and 
sulphadiazine reduced the incidence of placental infection from 77% to 42%. 
Antibody titres (IgG and IgM) were also significantly lower in the group treated with 
pyrimethamine and sulphadiazine. However, there was no difference in clinical 
outcome between the groups. More recently, a prospective study by Berrebi & 
Kobuch, (1994) examined the outcome of pregnancy for 163 mothers with acute 
toxoplasmosis. There were 162 liveborn infants and 3 deaths in utero. Only 27 of 
these 162 infants had proven congenital toxoplasmosis. All 27 infants were free of
24
symptoms and had normal neurological development at 15 to 71 months of age. 
However, many of these studies do not take into account the most severely affected 
fetuses which may be aborted, either spontaneously or therapeutically. Furthermore, 
the longterm outcome for these infants is not yet known.
It is recommended that newborn infants with congenital infection are treated 
throughout the first year of life, regardless of apparent disease activity (McAuley et 
al., 1994). Infants treated throughout the first year of life show better neurological 
and developmental outcomes (Roizen et al., 1995), as well as a reduction in 
intracranial calcifications (Patel et al., 1996), when compared with untreated infants 
or those treated for only one month. Similar to in utero treatment, the long term 
outcome particularly as regards ocular disease is as yet unknown.
Infection in the im m unosuppressed host
Similar to congenital infection, the first line therapy for AIDS associated 
toxoplasmosis is pyrimethamine in combination with sulphadiazine (Behbahani et al.,
1995). Lifelong maintenance therapy is essential (Wong & Remington, 1994). The 
relapse rate approaches 100% on withdrawal of therapy, which, as with other 
recurrent T.gondii infections, is attributed to cyst rupture (Cohn et al., 1989). 
Approximately 20-30% of patients on maintenance therapy relapse, but this may 
reflect non-compliance (Renold et al., 1992). The use o f primary prophylaxis for 
toxoplasmic encephalitis has also been advocated for patients with CD4 counts lower 
that lOOcells/mm3 who are seropositive for T.gondii (Freedberg et al., 1998). 
However, no single maintenance regimen that is both efficacious and without adverse
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reaction has yet been identified. Pyrimethamine and sulphadiazine have been 
associated with the lowest relapse rate (Katlama et al., 1996). A higher relapse rate 
has been reported with pyrimethamine and clindamycin maintenance therapy (Katlama 
et al., 1996). Patients receiving trimethoprim and sulphamethoxazole for 
Pneumocystis carinii maintenance therapy also have a reduced incidence of 
toxoplasmic encephalitis (Carr et al., 1992). Similar to pyrimethamine and 
sulphadiazine, these drugs are associated with adverse reactions.
Ocular infection
Recurrent ocular disease is due to proliferation and tissue invasion by the parasite 
which usually results from cyst rupture (Mets et al., 1996). In addition, it has been 
suggested that the immune response to these organisms can also result in additional 
damage to intra-ocular tissues (Dutton, 1986). In most cases toxoplasmic 
retinochoroiditis is a self limiting disease albeit with significant pathology. Untreated 
lesions begin to heal after 1 to 2 months, although the time course is variable 
(Rothova et al., 1993). The most reliable predictor of disease duration is the size of 
lesions, with larger lesions taking longer to heal (Rothova et al., 1993). As already 
mentioned, currently available drugs cannot treat tissue cysts and therefore cannot 
prevent future recurrences. The goal of therapy is to minimise damage to the retina 
and optic nerve, thereby preventing permanent visual loss. It is recommended that 
active lesions are treated with pyrimethamine and sulphadiazine for one month. With 
early treatment there is usually rapid resolution of active lesions often without 
associated visual loss (Mets et al., 1996). The controversial role of corticosteroids in 
ocular toxoplasmosis has been discussed.
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1.6 Disease Prevention and Screening
Humans become infected either through ingestion of the parasite in raw or 
undercooked meat or from contact with cat faeces or contaminated soil (reviewed, 
Jackson & Hutchison, 1989). Avoidance of infection therefore involves ensuring that 
all meat is thoroughly cooked and that fruit and vegetables are washed to remove all 
traces of soil. In addition wearing gloves for gardening and cleaning cat litter trays 
may prevent infection. Outdoor sand pits should be covered to prevent cats defecating 
in them. Cat litter trays should be cleaned frequently to prevent oocysts sporulating. 
Certain occupations may also carry a risk of infection for example, butchers or meat 
handlers. In addition, farmers may become infected from sheep at lambing time.
Prenatal screening for toxoplasmosis has existed in France and Austria for many years 
(reviewed, Hall, 1992). The screening is based on determining, by antibody 
measurement, whether a pregnant woman has a current infection, latent infection, or 
has not yet been exposed to the parasite. Those with latent infection are immune and 
require no further screening. Susceptible women require repeated serological testing 
because o f the lack of symptoms or the non-specific nature o f symptoms associated 
with most T.gondii infections.
If acute infection occurs during the first or second trimester of pregnancy initial 
therapy involves administration of spiramycin to prevent transmission of infection to 
the fetus (Daffos et al.t 1988). At 18 weeks gestation amniocentesis may be 
performed to diagnose fetal infection, either by isolation of the parasite in amniotic 
fluid or by demonstration of the T.gondii B 1 gene by the polymerase chain reaction. 
In France the sensitivity and specificity o f amniotic fluid PCR has approached 100%
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(Hohlfeld et al., 1994). If the amniocentesis is positive or maternal infection occurs in 
the third trimester then the fetus should be treated by administration of sulphadiazine 
and pyrimethamine to the mother (Couvreur et al., 1993). In addition to 
chemotherapy, repeated fetal ultrasound is performed to detect hydrocephalus 
(Berrebi et al., 1994). If the fetus is severely affected termination of pregnancy may 
be recommended (Berrebi et al., 1994).
Screening programmes have proven effective in countries such as France where 80% 
of women of childbearing age are already seropositive. However, they would be 
extremely costly in countries such as the United Kingdom where most o f the 
population is still susceptible. Early postnatal treatment also can improve outcome 
from congenital toxoplasmosis (McAuley et al., 1994). However, significant ocular 
pathology is already present at birth in 20% of otherwise asymptomatic infants 
(Guerina et al., 1994). Techniques for measuring T.gondii specific IgM in the Guthrie 
blood spot have been described (Lebech & Petersen, 1992; Parker & Cubitt, 1992; 
Guerina et al., 1994). However, the reliability of these techniques has not been 
confirmed.
1.7 Summary
T.gondii, a protozoan parasite can cause severe life threatening disease especially in 
newborns and immunosuppressed patients. It is an important cause of ocular disease 
and is considered the most common recognisable cause of posterior uveitis 
(McCannel etal., 1996). Toxoplasmic retinochoroiditis is a progressive and recurring 
disease often resulting in loss of vision. Although the pathology of established ocular
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toxoplasmosis is well described, the earlier lesions in the fetus have not been 
extensively studied and this will be addressed in this thesis.
There is no cure for T.gondii infection and current treatments are based on controlling 
disease reactivation. Acute acquired infection in the immunocompetent host does not 
usually require any treatment. However active treatment is required for congenital 
infection of the fetus or infant, infection in the immunosuppressed host and for 
recurrent ocular toxoplasmosis. A combination of pyrimethamine and sulphadiazine, 
both antifolate agents, is the most effective therapy currently available. There are 
significant side effects associated with both these drugs. Pyrimethamine may cause 
bone marrow toxicity. Allergy and intolerance associated with sulphadiazine is 
common. These drugs are active against the tachyzoite, the rapidly dividing form of 
T.gondii. The quiescent form of T.gondii, which resides in tissue cysts, is resistant to 
all known drugs. New antimicrobial agents and targets are therefore urgently needed.
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CHAPTER 2 
THE PARASITE, TOXOPLASMA GONDII
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2.1 Life-Cycle
T. gondii is an obligate, intracellular, protozoan parasite. Its full taxonomic 
classification is phylum Protozoa, subphylum Apicomplexa, class Sporozoasida and 
order Euccidiorida. It undergoes a complicated life-cycle which includes both sexual 
and non-sexual reproduction with two distinct cycles: (i) The entero-epithelial cycle 
which only occurs in the small intestines o f cats and other members o f the Felidae 
(Miller et al., 1972) and (ii) The extra-intestinal cycle which takes place in any warm 
blooded host (reviewed, Jackson & Hutchison, 1989) (Figure 2.1).
The entero-epithelial cycle
Cats shed oocysts (Figure 2.2A), the product of sexual reproduction, after ingesting 
any developmental stage of T.gondii (Dubey et al., 1970). Most commonly they 
become infected after ingestion of tissue cysts (Figure 2.2B) from flesh o f infected 
birds or rodents. These tissue cysts, which contain the bradyzoite stage, appear to 
promote the production of oocysts most effectively (Dubey et al., 1970).
Infection tends to be concentrated in the ileum and occurs in cells at the tips of 
intestinal villi. Organisms can undergo sexual or asexual reproduction with both 
processes occurring at the same time (reviewed, Hutchison et al., 1971). In sexual 
reproduction gametogeny gives rise to microgametes and macrogametes. In asexual 
reproduction repeated cycles of endopologeny, a modification of schizogony, give rise 
to merozoites. Merozoites are capable of sexual reproduction on re-invasion o f a cell. 
Microgametes fertilise macrogametes giving rise to oocysts containing two 
sporocysts. The oocyst is released by rupture of the host cell and is shed from the
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Figure 2.1 The life-cycle of Toxoplasma gondii
The sexual cycle is initiated in the ileum of the cat upon ingestion of 
tissue cysts, or occasionally oocysts. This results in release of oocysts 
in the faeces which are infective to intermediate hosts upon 
sporulation. After ingestion by the intermediate host these sporocysts 
transform to tachyzoites and undergo a brief period of rapid 
multiplication in the reticuloendothelial system, before forming tissue 
cysts containing many bradyzoites. These cysts are infective to both 
the intermediate and definitive host upon ingestion. Vertical 
transmission to the fetus via the placenta can occur in intermediate 
hosts.
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Figure 2.2 A Oocysts (arrows) in cat faeces. B Bradyzoites 
(arrows) within a tissue  cyst. C Tachyzoites (arrow) within a 
parasitophorous vacuole (pv) of host cell.
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intestine of the cat in the form of a non-infectious, unsporulated oocyst. During 
sporulation, each sporocyst gives rise to 8 sporozoites.
Excretion of oocysts may begin within 3 days and for up to 24 days after ingestion, 
depending on the developmental stage of T.gondii ingested by the cat (Dubey et al., 
1970). This time is shortest following infection with tissue cysts and longest following 
infection with oocysts. A cat sheds as many as 10 million oocysts per day, for up to 
24 days after initial infection. Oocysts are then shed in lesser numbers for an 
additional 1 to 3 weeks (Dubey & Frenkel, 1972). Further oocyst shedding may occur 
if the cat is co-infected with the closely related coccidian parasite, Isospora felis 
(Chessum, 1972). Following excretion sporulation occurs over 2 to 21 days, 
depending on the ambient temperature. Oocysts can persist and remain infectious in 
warm moist soil for up to 18 months (Frenkel et al., 1975).
The extra-intestinal cycle
This cycle occurs in any warm blooded host usually following ingestion of oocysts or 
tissue cysts (reviewed, Jackson & Hutchison, 1989). Tachyzoites (Figure 2.2C), the 
rapidly dividing stage of the parasite responsible for acute infection, are subsequently 
released and invade host cells. They replicate within host cells by endodyogeny 
approximately every 4-6 hours. Following 4 to 5 divisions they destroy the host cell 
and invade adjacent cells. The differentiation o f tachyzoites to bradyzoites occurs 
around day 10 to 14 following infection and coinciding with the onset o f protective 
immunity. Bradyzoites (Figure 2.2B) are located within tissue cysts. These tissue 
cysts appear to have a predilection for the central nervous system, skeletal and cardiac
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muscle (Jacobs et al., 1960; Remington & Cavanaugh, 1965), although they have 
been found in almost every tissue including the eye (Rao & Font, 1977) and visceral 
organs (Jackson & Hutchison, 1989) These tissue cysts may rupture during the 
lifetime of the host (Pavesio et al., 1992) and released organisms can cause 
recrudescent infection in the congenitally infected or immunocompromised host.
Other forms of transm ission
Congenital transmission of the parasite can occur during primary infection o f the 
mother (reviewed, Jackson & Hutchison, 1989). Tachyzoites invade the placenta to 
infect the developing fetus. Infrequent forms of transmission include infection 
following organ transplantation (Israelski & Remington, 1993) or blood transfusion 
(Siegal et al., 1971) and experimental laboratory accidents (Field et al., 1972).
2.2 Parasite Virulence
All isolates of Toxoplasma whether originating from animals or humans have been 
grouped into a single species based on morphological grounds. Studies on strain 
diversity by restriction fragment length polymorphism (RFLP) analysis have shown 
that the population structure of T.gondii is essentially clonal (Sibley & Boothroyd, 
1992). Despite the presence of a sexual stage in the life-cycle, sexual recombination 
occurs much less frequently than would be expected and most isolates appear to arise 
by mitotic expansion of a limited number of genotypes. For example RFLP analysis 
shows that there are over 1700 different possible combinations o f alleles at six 
independent loci, yet only 15 combinations were identified in a study o f over 100 
independent strains (Howe & Sibley, 1995). This population clonality comprises three
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predominant, clonal lineages which correspond with biological behaviour (Howe & 
Sibley, 1995). Type I strains account for a significant percentage of human congenital 
infection. They show the greatest pathogenicity to mice. Type II strains are most 
commonly associated with human disease in both congenitally infected and 
immunocompromised patients. They produce high cyst burdens and chronic 
encephalitis in mice. Type III strains are largely confined to animals.
Table 2.1 Virulence of T.gondii based on clonal lineages and 
zymodeme groups______________________________________
GROUP* STRAIN DISEASE VIRULENCE ZYM ODENE
GROUP*
I RH Human, Kills all strains of 1
II Me49, RRA
congenital
Human
mice 
Kills some mice, 3,4
III C56 Animals
strain dependent 
Less virulent than 
Groups I and II
2
Howe & Sibley, 1995; # Dard&etal., 1992
Iso-enzyme analysis also supports data suggesting a mainly clonal population for 
T.gondii. Darde et al., (1992) were able to identify 4 main parasite groups in 35 
T.gondii isolates based on polymorphisms in 6 parasite enzyme systems, known as 
zymodeme groups. These correspond with the 3 main groups described by (Howe & 
Sibley, 1995). Type I strains belong to zymodeme 1, type II to zymodeme 2 and 4 and 
type III to zymodeme 3 (Table 2.1). Two single isolates with different iso-enzyme 
profiles have also been described, zymodeme 5 (Darde et al., 1992) and zymodeme 6 
(Darde et al., 1998).
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Although minor differences have been noted in the biochemistry and therefore, 
potentially the metabolism of different clonal lineages, currently available drugs are 
effective against all strains of T.gondii.
2.3 T.gondii Cell Biology
T.gondii is an obligate intracellular parasite and to survive must invade the cells of the 
host. Invasion is a rapid process taking less than 10 seconds and is energy dependent 
(reviewed, Joiner & Dubremetz, 1993; Dubremetz, 1998). It can be envisaged as a 
complex cascade of events with each individual event triggering the next. These 
events include; target recognition and attachment; invasion; secretion; and formation 
of the parasitophorous vacuole. Once inside the cell the parasite resides and replicates 
within a specialised membrane, the parasitophorous vacuole. As the host develops 
immunity to the acute infection the tachyzoite converts to the bradyzoite form. 
Understanding these processes is pertinent for rational design of new therapies.
Attachm ent
In contrast to most other intracellular parasites, T.gondii can invade virtually all cells. 
This suggests that the receptors mediating attachment are ubiquitous or that a variety 
o f different receptors can be utilised. Thus the ultimate goal o f designing a therapeutic 
intervention aimed at blocking attachment will be difficult. Recent work has suggested 
that parasite-bound, host-cell laminin (Furtado et al., 1992); lectin-like molecules 
(Robert et al., 1991); and the tachyzoite major surface protein p30 (SAG-1) 
(Grimwood & Smith, 1992) participate in the attachment process. These studies are 
based on addition of antibody or peptide to parasites in vitro. However, mutant
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parasites deficient in SAG-1 show reduced attachment, but can still invade host cells 
suggesting this is not the only mechanism for parasite attachment (Mineo & Kasper, 
1994). Another surface protein SAG-3, expressed by both tachyzoites and 
bradyzoites, may also have a role in attachment. Mutant parasites in which the SAG-3 
gene is disrupted show reduced attachment and invasion of host cells (Tomavo,
1996). SAG-3 shows some structural homology to SAG-1 suggesting a similar 
function for these proteins (Cesbron Delauw et al., 1994).
Invasion
The morphological steps involved in T.gondii invasion are well described (reviewed, 
Werk, 1985). Following attachment of the tachyzoite, the conoid, positioned at the 
anterior end o f the parasite protrudes forming an indentation in the host cell. A tight 
junction forms between parasite and host cell which moves posteriorly as the parasite 
invades. The parasite then shows a series of twisting and gliding movements until it 
comes to lie within the parasitophorous vacuole.
Invasion can be inhibited by addition of cytochalasin D, which disrupts actin filaments, 
to parasites in culture (Dobrowolski & Sibley, 1996). Furthermore, cytochalasin D 
resistant T.gondii which have a mutation in their actin gene can invade in the presence 
o f cytochalasin D (Dobrowolski & Sibley, 1996). This confirms that action of 
cytochalasin D is on the parasite and not the host cell. Myosin also appears to have a 
role in host cell invasion. Addition of butanedione monoxime (a myosin ATPase 
inhibitor) to parasites in culture inhibits parasite gliding motility and invasion 
(Dobrowolski et al, 1997). Invasion is therefore an active process powered by the 
cytoskeleton of the parasite.
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Secretion
T.gondii contains three specialised secretory organelles which have a role in invasion 
and intracellular survival; micronemes, rhoptries and dense granules. Secretion is a 
regulated, sequential process which begins with exocytosis o f the micronemes 
(Carruthers & Sibley, 1997). Their contents, the MIC proteins, are discharged on 
initial contact with host cells but ultimately are excluded from the parasitophorous 
vacuole. Their role may be associated with the attachment process.
Following microneme exocytosis, secretion from the rhoptries begins coincident with 
the formation o f the tight junction with the host cell (Carruthers & Sibley, 1997). The 
rhoptries are club-shaped apical organelles and are the source o f penetration 
enhancing factor (Lycke & Norrby, 1966), now known as ROP-1. The rhoptries also 
contain a large amount o f lipid, 75% of which is phosphotidylcholine, a major 
component of plasma membrane and cholesterol which is known to stabilise plasma 
membranes (Foussard et at., 1991). These components may have a role in formation 
of the parasitophorous vacuole. Secretion from the rhoptries is completed by the time 
the parasite is fully enclosed in the parasitophorous vacuole.
Finally, secretion from the dense granules does not begin until several minutes after 
invasion and continues until around 20 minutes post-invasion (Carruthers & Sibley,
1997). The contents of the dense granules appear to be important for modifying the 
parasitophorous vacuole for intracellular survival (Cesbron Delauw, 1994; Cesbron 
Delauw et al., 1996).
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In theory, interfering with any of these processes may be a useful strategy for drug 
development. However, attachment, invasion and to a lesser extent secretion are rapid 
processes and may be difficult to target. The molecules and regulatory factors 
involved in attachment and secretion are as yet poorly understood. In addition, 
invasion utilises the actin cytoskeleton also present in human cells and drugs aimed at 
this process are unlikely to be parasite specific. However, although these processes 
are unlikely targets for new drugs, they may prove suitable candidates for 
development of protective vaccines.
The parasitophorous vacuole
The parasitophorous vacuole allows T.gondii to resist microbicidal activity and 
destruction (Joiner et a/., 1990; Jones et al., 1972; Sibley et al., 1985). The 
parasitophorous vacuole membrane (PVM) is a highly specialised membrane in which 
transmembrane proteins are reduced or absent and host cell surface markers are 
rapidly excluded (Jones et al., 1972). Current evidence suggests that it is formed from 
host cell plasma membrane and pinches off via a fission pore (Suss Toby et al., 1996).
The parasitophorous vacuole does not completely isolate the parasite from the host 
cell. Interactions between the parasite and the host are important for parasite survival. 
T.gondii is a purine auxotroph and purines needed for growth must therefore be 
salvaged from the host cell (Schwab et al., 1995). It is likely that T.gondii also obtains 
small molecules such as amino acids, monosaccharides and lipids from the host cell. 
Interactions between the parasite and the host cell are assisted by small pores within 
the PVM which allow passage of small molecules (13-19kD) in either direction
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between the host cell and the parasite (Schwab et al., 1994). The presence o f these 
small pores within the PVM also provides a means of facilitating drug delivery to this 
intracellular compartment.
In the infected cell, host mitochondria and endoplasmic reticulum are seen to surround 
the parasitophorous vacuole (Sinai et al., 1997). The small pores in the PVM may 
therefore allow the parasite to utilise host cell molecules such as ATP either to meet 
its energy requirements or for purine synthesis. Recent studies have identified a novel 
nucleoside triphosphate hydrolase (NTPase) which could utilise ATP as a substrate 
(Sibley et al., 1994). Constituting 3-4% of parasite protein, it exists in 2 isoforms and 
appears to have a role in parasite virulence (Asai et al., 1995). These NTPases are 
located within the dense granule organelles and are secreted into the vacuolar space 
(Sibley et al., 1994). The type 11 NTPase is present in all strains o f the parasite 
however the more active type 1 isoform, is only present in the most virulent strains 
(Asai et al., 1995). Expression of this highly active NTPase isoform may contribute to 
intracellular survival and virulence of T.gondii.
The vacuolar space and membrane are extensively modified by parasite proteins after 
T.gondii invasion (Sibley & Krahenbuhl, 1988). In addition there is formation o f a 
network of membranous tubules within the lumen of the vacuole which connect with 
the vacuolar membrane (Sibley et al., 1986). Most of these proteins are derived from 
the dense granule organelles and are designated GRA proteins. At least 7 GRA 
proteins are found in the dense granules. Following secretion they are all associated 
with the parasitophorous vacuole and are either rapidly redistributed on the tubular 
network or on the vacuolar membrane (reviewed, Cesbron Delauw, 1994).
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No definite function has yet been assigned to proteins present within the 
parasitophorous vacuole space and PVM. GRA 4,5 and 6 show weak homology with 
extracellular matrix proteins so may have a structural or supportive role (Lecordier el 
al., 1993; Lecordier el al., 1995). GRA 1 is a calcium binding protein which may have 
a role in modulating the calcium concentration within the parasitophorous vacuole 
(Cesbron Delauw, 1994; Charif et al., 1990). GRA 2 is secreted as both a soluble 
protein from the dense granules and with multilamellar vesicles released from a 
specialised posterior invagination of the parasite (Sibley et al., 1995). These 
multilamellar vesicles assemble to form the intravacuolar network which contains an 
integral membrane form of GRA2 (Sibley et al., 1995). Size polymorphism of the 
dense granule proteins GRA5 and GRA6 is correlated with parasite virulence
(Rauscher et al., 1996). This size variation may be related to different post-
translational modifications. However, the role of GRA5 and GRA6 size
polymorphism in virulence is unclear. GRA 7 has been recently described (Fischer et 
al., 1998; Jacobs et al., 1998). In tachyzoites it is associated with the parasitophorous 
vacuolar membrane. However, in bradyzoite infected cells, GRA 7 is present within 
the host cell cytoplasm. It has been suggested that this intracellular translocation of 
GRA 7 may be coupled with parasite stage conversion (Fischer et al., 1998).
Tissue cyst formation
Since all currently available drugs treat only the tachyzoite stage o f the parasite the 
interconversion o f tachyzoites and bradyzoites is of considerable interest. The
differentiation o f tachyzoites to bradyzoites occurs, at around day 10-14 following 
infection, with the onset of protective immunity. While tachyzoites divide rapidly and 
synchronously until they lyse the host cell, the slower growing bradyzoites form tissue
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cysts which are long lived (Pavesio et al., 1992). These tissue cysts are considered to 
be responsible for reactivation of disease in the congenitally infected or 
immunocompromised patient.
Electron microscopic studies have shown that the cyst wall is an adaptation o f the 
parasitophorous vacuole membrane (Ferguson & Hutchison, 1987). This membrane 
develops invaginations and is thickened on the vacuolar side with a homogeneous, 
osmiophilic material. In older cysts a number of parallel tubular structures run from 
the cyst wall to the bradyzoite. Bradyzoite division is infrequent and in older cysts 
many bradyzoites degenerate and fragment (Pavesio et al., 1992). Ultrastructural 
studies o f the bradyzoite show that the nucleus is more posteriorly situated, the 
rhoptries are more electron dense and micronemes are increased in number compared 
with tachyzoites (Ferguson & Hutchison, 1987; reviewed, Dubey et al., 1998). In 
addition amylopectin granules develop in the cytoplasm.
Not surprisingly, as well as morphological differences there are differences in gene 
and antigen expression between bradyzoites and tachyzoites (Table 2.2). The main 
tachyzoite specific surface proteins SAG1 and SAG2 are down-regulated or absent 
from bradyzoites (Smith, 1995). Several bradyzoite stage-specific molecules have 
been described. These include surface antigens of 18kD, 21kD, 34kD and 36kD 
(Tomavo et al., 1991) of which, only the 18kD protein, known as SAG 4, has been 
studied in detail (Odberg-Ferragut et al., 1996). MAGI is a 65kD protein which is 
secreted by the bradyzoite and appears to form part o f the cyst matrix or cyst wall 
(Parmley et al., 1994). Two other apparent cyst wall proteins of 116kD (Weiss et al., 
1992) and 29kD (Zhang & Smith, 1995) have been studied at the protein level. BAG1
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is a 28-30 kD cytoplasmic protein, which has been shown to be related to a plant heat 
shock protein (Parmley et al., 1995). The BAG1 gene has also been identified in a 
cDNA library prepared from pH-shocked tachyzoites (Bohne et al., 1995) and it has 
been suggested that stress conditions may trigger expression of this gene and thus 
bradyzoite conversion. That said, BAG1 is not only expressed during conversion to 
bradyzoites, but also in mature cysts (Parmley et al., 1995). Finally, there are two 
isoforms of a lactate dehydrogenase (LDH) enzyme. The genes encoding these 
enzymes, designated LDH1 and LDH2, respectively, have been cloned and 
characterised (Yang & Parmley, 1997). While the mRNA of LDH1 is detected in both 
the bradyzoite and tachyzoite stages, the mRNA of LDH2 is only detected in the 
bradyzoite stage (Yang & Parmley, 1997). However, only one LDH isoform is 
expressed in each stage, LDH 1 in tachyzoites and LDH 2 in bradyzoites (Yang & 
Parmley, 1997). The functional activity o f LDH has been found to be greater in 
bradyzoites than tachyzoites (Denton et al., 1996). Furthermore, pyruvate kinase 
activity is higher in bradyzoites compared with tachyzoites (Denton et al., 1996). 
These enzymes are required for lactate production. Lactate production does not 
require the mitochondrial electron transport chain. Based on this data, it has been 
suggested that bradyzoites lack a functional citric acid cycle and may rely upon 
glycolysis for energy production.
Much recent work has focused on factors involved in tachyzoite to bradyzoite 
transformation and bradyzoite reactivation. Factors which promote conversion of 
tachyzoites to bradyzoites appear to be related to the immune system or to nutritional 
and metabolic factors in the host environment which stress the parasite. Parasites 
grown in vitro convert from tachyzoites to bradyzoites following heat shock of
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cultures (Soete et al., 1994). A high or low pH environment also favours stage 
conversion (Soete et al., 1994). For example, using a reporter gene construct, Yang 
& Parmley, (1997) demonstrated upregulation of LDH2 by growing parasites in tissue 
culture media with alkaline pH while LDH1 was down-regulated. Addition o f IFNy to 
infected macrophage cultures can also induce tachyzoites to express bradyzoite 
antigens (Bohne et a/., 1993). In addition, nitric oxide (NO) production appears to 
trigger stage conversion through its action on the electron transport chain (Bohne et 
al., 1994). In support of this, drugs, such as atovaquone or arsenicals, that interfere 
with conventional mitochondrial electron transport can trigger bradyzoite formation in 
vitro (Soete et al., 1994; Tomavo & Boothroyd, 1995). This may relate to the 
suggested increased reliance on glycolysis for energy production in the bradyzoite 
stage. Humoral immunity may also play a role in the encystment process, as addition 
o f complement and specific antibody against T.gondii to infected cultures, stimulates 
formation o f tissue cysts (Shimada et al., 1974).
The rate and frequency of conversion to bradyzoites is also dependent on the strain of 
the parasite (Soete & Dubremetz, 1996). Expression o f bradyzoite antigens in vitro is 
lower for rapidly growing strains such as RH when compared with slower growing 
strains. The reconversion of bradyzoites to tachyzoites has not been studied in vitro, 
although releasing the culture from any external stress usually leads to rapid 
resumption o f tachyzoite multiplication (reviewed, Soete & Dubremetz, 1996).
In vivo murine studies have done little to confirm the factors that favour bradyzoite 
formation. However, neutralisation o f IFNy, TNFa or inhibition o f NO production all 
allow reactivation of chronic disease resulting in active disease with tachyzoite
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multiplication (Gazzinelli et al., 1992a; Gazzinelli et al., 1994; Hayashi et al., 1996; 
Suzuki et al., 1989).
The plastid organelle and plant-like properties of T.gondii
One o f the most successful currently available drugs, pyrimethamine, is aimed at 
inhibiting a biochemical process which also occurs in host cells, the conversion of 
dihydrofolate to tetrahydrofolate. Although the host cell can be rescued by 
administering exogenous folinic acid, there is potential for drug toxicity. Ideally, new 
drugs would target pathways which differ between host and parasite.
It has recently emerged that T.gondii, in common with other Apicomplexan parasites, 
has three genomes (Wilson & Williamson, 1997). Animal, fungi and most protozoans 
have only two genomes, one within the nucleus and the other within mitochondria. 
T.gondii also has a nuclear and mitochondrial genome but, in addition, has a second 
extra-nuclear genome (Wilson & Williamson, 1997). The mitochondrial genome of 
T.gondii has yet to be isolated and sequenced. The second extra-nuclear genome of 
35kB has recently been localised to the plastid organelle (McFadden et al., 1996). 
Recognition o f this third genetic compartment offers alternative approaches for drug 
design.
The plastid organelle was first identified in Apicomplexan parasites in the 1960s. At 
this time the nature of this organelle was not recognised and historically it has been 
given various names including Hohozylinder, Golgi Adjunct and Lamellarer Korper 
(Siddall, 1992). It is now known as the plastid organelle and its presence has been
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confirmed in all major Apicomplexans including Plasmodium, Theileria, Babesia, 
Eimeria, Hepatozoon, Sarcocystis and T.gondii (McFadden et al., 1997). The 
evolutionary origin of the plastid has been a subject of much controversy. Some 
electron microscopic studies have shown the presence of four membranes enclosing 
the plastid suggesting that it originated as a secondary endosymbiont, derived by 
ingestion of a eukaryote that itself contained a plastid (McFadden et al., 1996; Wilson 
et al., 1994). Consistent with this, work on the plasmodium 35kB genome has shown 
homology with a gene present in the plastid of red algae (Williamson et al., 1994). 
More recently three different phylogenetic analytical methods strongly suggest a green 
algal origin for the plastid (Kohler et al., 1997).
As yet no definitive function has been assigned to the plastid. However, the parasite 
faithfully replicates this organelle and the plastid genome is transcribed (Kohler et al., 
1997). It therefore appears to be essential for survival. Furthermore, recent work has 
demonstrated that the plastid is present in both tachyzoites (reviewed, McFadden et 
al., 1996) and bradyzoites (Roberts et al., 1998b) (Figure 2.3). Photosynthesis is the 
most familiar function of plastids in higher plants (where they are known as 
chloroplasts) and evidence for a chlorophyll binding protein in Apicomplexans has 
been reported (Hackstein et al., 1995). Photosynthesis seems an unlikely function 
since the parasites spend most or all o f their life-cycle in a dark environment. 
Furthermore, there are no genes encoding products known to be involved in 
photosynthesis within the 35kB genome of Plasmodium (Wilson et al., 1996) or 
T.gondii (Kohler et al., 1997). However, several non-photosynthetic eukaryotes 
maintain their plastids which have other key metabolic roles. For example, 
biosynthetic pathways for porphyrins are confined to the plastid of plants rather than
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F ig u re  2 .3  Electron micrographs which dem onstrate  the 
apicomplexan plastid in bradyzoites, within tissue  cyst of a 
m ouse brain. The plastid is marked with an arrow (low power, 
A and high power, B). Other characteristic organelles are the 
conoid (C), dense  granules (D), golgi (G), microneme (M) and 
mitochondrion (Mi), amylopectin granule (P). (Kindly provided 
by D.Ferguson, Oxford, UK)
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mitochondria as in animals (Howe & Smith, 1991; Kannagara et al., 1988). 
Biosynthetic pathways for certain amino acids, ubiquinone, nucleotides, lipid and 
starch also occur in plant plastids (Hrazdina & Jensen, 1992; Wallsgrove, 1991).
Although the function of the Apicomplexan plastid is unknown, it has already been 
suggested as a target for antimicrobial agents, in particular macrolide antibiotics 
(Beckers et al., 1995; Fichera et al., 1995; Fichera & Roos, 1997). Earlier work has 
focused on determining the sequence and function o f the Apicomplexan plastid 
genome with the intent that this would provide novel drug targets. Potential targets 
based on genes identified in the plastid include plastid ribosomes (Beckers et al.,
1995), rifampin-sensitive RNA polymerase (Wilson et al., 1991) the chaperonin-like, 
a/w6A homologue (Hackstein et al., 1995) and the ORF 470 gene that has conserved 
homology with a rhodophyte plastid gene o f unknown function (Williamson et al., 
1994). This approach of focusing on functions determined by the residual plastid 
genome may prove a fruitful approach for drug discovery. An alternative approach 
may be to consider that the presence o f a plastid suggests that T.gondii utilises 
metabolic pathways more commonly associated with algae and higher plants. Indeed, 
in plants, enzymes encoded by nuclear genes are targeted to the plastid where they 
function (Haucke & Schatz, 1997b). Thus, the conservation of plastid genes in 
Apicomplexans implies that there may also be conservation of nuclear genes.
In support of this other ‘plant’-related molecules have been described in 
Apicomplexans. For example, phylogenetic analysis of protozoan calmodulins 
suggests a distant relationship with those of plants (Robson et al., 1993). ‘Plant’-like 
properties of T.gondii microtubules also have been described (Stokkermans et al.,
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1996). Furthermore, the enolase gene of P.falciparum, which encodes a 
metalloenzyme that catalyses one step in the conversion of glucose to lactic acid, 
contains a pentapeptide insertion, EWGWS (Read et al., 1994). This has near identity 
to the EWGWC motif in the enolase molecules of higher plants. This pentapeptide 
motif is not present in any of the enolases sequenced thus far from a wide range of 
other eukaryotic and prokaryotic non-plant organisms. The recently cloned T.gondii 
bradyzoite gene, BAG-1 shows homology with a small heat shock protein o f plants 
(Parmley et al., 1995). The identification o f these ‘plant’-like properties in 
Apicomplexans presents a unique and potentially exploitable difference between host 
and parasite and could prove useful for development of new antimicrobial agents. 
Several herbicides, including dinitroaniline and triazines have already been shown to 
inhibit the growth of T.gondii in vitro at concentrations non-toxic to human cells 
(Hackstein et al., 1995; Stokkermans et al., 1996). Dinitroanilines are potent and 
specific inhibitors of plant microtubules. Triazines target the plant plastid D1 protein 
involved in electron transfer.
The shikimate pathway
The shikimate pathway, responsible for the production of aromatic amino acids, 
ubiquinone and PABA in plants, may also be present in Apicomplexans and provide 
another potential drug target. This pathway occurs in the plastid o f plants (Bentley, 
1990; Haslam, 1993). Previous studies which demonstrate the efficacy o f anti-folates 
for the treatment of toxoplasmosis have implied that T.gondii has the enzymes 
necessary to synthesise folates from PABA (Kovacs et al., 1989). However, the
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biochemical events that lead to PABA acquisition by these parasites have not been 
characterised.
Animals and most protista (e.g. Leishmania) rely exclusively on exogenous folates 
and do not utilise PABA. In algae, plants, bacteria and fungi, PABA is synthesised de 
novo via the shikimate pathway which catalyses the seven step conversion of 
erythrose 4-phosphate and phosphoenol pyruvate to chorismate (Bentley, 1990; 
Haslam, 1993) (Figure 2.4). Chorismate is than used as a substrate for the synthesis of 
aromatic compounds including PABA, ubiquinone and the aromatic amino acids. In 
plants all seven enzymes are encoded in the nucleus made in the cytoplasm and 
targeted to the chloroplasts where they are functional (Gorlach et al., 1993; Haucke 
& Schatz, 1997a). Under certain circumstances this pathway can occur in the 
cytoplasm of higher plants (Bentley, 1990).
The above evidence would suggest that it is entirely possible that T.gondii has the 
enzymes required for PABA synthesis and this will be investigated in this thesis. 
Furthermore, the shikimate pathway has proved to be an excellent target for 
herbicides as demonstrated by the enormous commercial success of glyphosate which 
is a potent and specific inhibitor of EPSP synthase, the sixth enzyme in the pathway 
(Steinrucken & Amrhein, 1980). Therefore, if T.gondii has the enzymes o f the 
shikimate pathway this may prove an ideal target for novel antiparasitic agents.
55
PHOSPHOENOLPYRUVATE +ERYTHROSE 4-PHOSPHATEt DAHP SYNTHASE
DAHP
t DEHYDROQUINATE SYNTHASE
DEHYDROQUINATE
t DEHYDROQUINASE
DEHYDROSHIKIMATE
t SHIKIMATE DEHYDROGENASE
SHIKIMATE
t SHIKIMATE KINASE
SHIKIMATE-3-PHOSPHATE
AROMATIC 
AMINO ACIDS
UBIQUINONE>
t
j
E P S P  SYNTHASE
CHORISMATE SYNTHASE
CHORISMATE
t AMINODEOXYCHORISMATE SYNTHASE
AMINODEOXYCHORISMATE
t AMINODEOXYCHORISMATE LYASE
PABA
t DIHYDROPTEROATE SYNTHASE
DIHYDROFOLATE
t DHFR
TETRAHYDROFOLATE
Figure 2.4 The shikimate pathway which catalyses the seven step 
conversion of erythrose 4-phosphate and phosphoenol pyruvate to 
chorismate. Chorismate is then used as a substrate for the synthesis 
of aromatic compounds including PABA, ubiquinone and the aromatic 
amino acids. PABA is then used for the synthesis of folate.
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The alternative pathway o f respiration
Another plant metabolic pathway worthy of consideration is the alternative pathway 
o f respiration. All higher plants examined to date contain two pathways for 
mitochondrial electron flow: the cytochrome respiratory pathway, which is common 
to all organisms, and the alternative respiratory pathway which is absent from all 
mammals (reviewed, McIntosh, 1994). The alternative pathway of respiration has also
been identified in other types of organisms: in protista such as Trypanosoma 
(Chaudhuri et al., 1995), in certain fungi and in the green algae Chlamydomonas 
(Moore & Siedow, 1991).
The enzyme complexes for both pathways are present on the inner mitochondrial 
membrane (Moore & Siedow, 1991). Conventional mitochondrial respiration via the 
cytochrome pathway is coupled to ATP synthesis (Figure 2.5). Electrons are 
transferred through complexes I or II to ubiquinone and then on to the cytochrome 
oxidases, complexes III and IV. At each of three sites protons are pumped across the 
inner membrane creating a transmembrane potential for energy generation (reviewed 
(Moore & Siedow, 1991). The alternative pathway diverges from the cytochrome 
pathway after the ubiquinone complex. Electrons flowing through the alternative 
pathway are donated directly to oxygen to form water, apparently in a single, four 
electron step. Electron flow via this pathway does not contribute to transmembrane 
potential and two of the three potential coupling sites for proton transport and thus 
ATP production are lost (reviewed, McIntosh, 1994). Since the energy o f electron 
flow through the alternative pathway is not conserved as chemical energy, it is lost as 
heat (Meeuse, 1975).
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The functional significance of the alternative pathway is not clear. The only confirmed 
function for alternative pathway respiration is to supply heat in thermogenic blooms of 
the Araceae, such as Sauromatum gnttatnm, the Voodoo lily (Meeuse, 1975). During 
flowering the production o f heat vaporises odours to attract insect pollinators. In 
Trypanosoma the alternative oxidase is expressed only in bloodstream 
trypomastigotes which are dependent on glycolysis for ATP production (Chaudhuri et 
a l , 1995).
Relapse of toxoplasmic encephalitis is common in AIDS patients receiving 
atovaquone (Durand et al., 1995), which inhibits conventional electron transport after 
ubiquinone. This implies that T.gondii must have some mechanism of circumventing 
the action of this drug. It has been suggested that bradyzoites rely upon glycolysis for 
energy production (Denton et al., 1996). In addition, T.gondii has the enzymes 
necessary to utilises host cell ATP and therefore may have a reduced requirement to 
synthesise ATP (Asai et al., 1995; Sibley et al., 1994). Furthermore there is a 
reduction in the mitochondrial membrane potential of T.gondii after invasion o f host 
cells (Tanabe & Murakami, 1984). The existence of this pathway in T.gondii will also 
be investigated.
2.4 Summary
T.gondii undergoes a complex life-cycle which involves an entero-epithelial cycle in 
the definitive host, the cat, and an extra-intestinal cycle occurring in all other hosts, 
including man. An understanding of events which occur during infection at a cellular 
and molecular level is important to increase our knowledge of the disease process and
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to identify potential aspects which could be targeted to treat this disease. In particular 
the process of cyst breakdown represents the cause of disease reactivation and the 
reason for failure of currently available antiparasitic agents.
The discovery of the plastid organelle and other ‘plant’-like properties in T.gondii as 
well as other Apicomplexan parasites presents a truly novel opportunity for 
identifying targets for antiparasitic agents. This thesis will investigate the shikimate 
pathway and the alternative pathway of respiration in T.gondii.
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CHAPTER 3 
THE HOST
3.1 Immune Response
T.gondii induces a potent immune response that involves macrophages, natural killer 
(NK) cells, T cells and their monokine and cytokine products. In the 
immunocompetent host this immune response controls parasite replication and 
facilitates cyst formation. Different aspects o f the immune response to T.gondii are 
illustrated in Figure 3.1 and described below.
M acrophages and natural killer cells
In common with a number of intracellular pathogens, including Listeria 
monocytogenes (Tripp et al., 1993) and Leishmania major (Reiner et al., 1994), 
T.gondii can directly stimulate macrophages to produce the monokines, interleukin-12 
(IL-12) and tumour necrosis factor- a  (TNF-a) (Gazzinelli et al., 1993). Following 
macrophage activation these monokines, act in synergy to induce NK cells to produce 
interferon- y (IFN-y) (Gazzinelli et al., 1993). IFN-y can then stimulate the 
microbicidal activity of macrophages. The effector mechanisms for macrophage killing 
of T.gondii include; production of reactive oxygen intermediates (reviewed, Hughes, 
1988) and reactive nitrogen intermediates (Adams et al., 1990); products o f 
arachidonic acid metabolism via the 5-lipoxygenase pathway (Yong et al., 1994); and 
degradation of intracellular tryptophan, an essential amino acid for T. gondii, by 
induction of indoleamine 2,3-dioxygenase, (Murray et al., 1989). By this mechanism 
macrophages and NK cells are considered to act as the first line o f defence in 
resistance to T.gondii infection before the development of T cell responses (Khan et 
al., 1994; Sher etal., 1993).
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T cells
Resistance to T.gondii depends on CD4+ and CD8+ T lymphocytes (Gazzinelli et al., 
1992a; Parker et al., 1991). Both T helper 1 (Thl) and T helper 2 (Th2), CD4+ T cell 
subsets, originally defined by (Mosmann et al., 1986) based on their production o f 
cytokines, contribute to immunity against T.gondii. Thl cells produce the pro- 
inflammatory cytokines, IFN-y and IL-2 and are often associated with immunity 
against intracellular pathogens (Reiner & Locksley, 1993). The macrophage activating 
abilities of IFN-y have already been described. IL-2 may facilitate expansion o f CD8+ 
T cells (Gazzinelli et al., 1992a). These can be cytotoxic for target cells infected with 
T.gondii (Hakim et al., 1991). Th2 cells produce IL-4, IL-5 and IL-10 and are 
associated with down regulation of pro-inflammatory Thl cell cytokines. (Mosmann, 
1991; Mosmann & Moore, 1991). Th2 cytokines may down regulate the effects of 
Thl cells and thus promote parasite multiplication. However, they are also essential in 
down modulating a harmful pro-inflammatory immune response during the early 
stages of toxoplasmosis. For example, mice deficient in IL-4 (Roberts et al., 1996a) 
or IL-10 (Gazzinelli et al., 1996) show significantly increased mortality during the 
first 15 days of infection compared with wild-type control mice of the same strains. 
The increase in mortality in these mice was accompanied by increased production of 
IFN-y in stimulated splenocyte cultures. Thus, T cell subsets are able to cross regulate 
each others activity (Reiner & Locksley, 1993; Romagnani, 1992).
The events which lead to a predominant Thl or Th2 response are uncertain although 
initial events in the development of the immune response appear to play a critical role 
(Reiner & Locksley, 1993; Romagnani, 1992). For example, the production o f IFN-y 
by NK cells, and IL-12 by macrophages may be instrumental in preferentially inducing
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a Thl CD4+ T cell response. Local immune responses may also differ from the 
systemic immune response. In vitro studies have shown that cells from the mesenteric 
lymph nodes of mice infected orally with T.gondii produce predominantly Th2 
cytokine (Chardes et al., 1993). In contrast splenocytes from these mice produce Thl 
cytokines (Chardes et al., 1993). The role of different cytokines in resistance to 
T.gondii infection is summarised in Table 3.1
The protective activity of CD8+ T cells is in part mediated through production of 
cytokines such as IFN-y (Suzuki & Remington, 1990). In addition a direct cytotoxic 
effect on extracellular parasites has been reported (Khan et al., 1991; Khan et al., 
1988). CD8+ T cells also show Class I MHC-restricted cytotoxicity for T.gondii 
infected cells (Hakim el al., 1991; Subauste et al., 1991; Yano el a/., 1989).
Humoral immunity
As an obligate intracellular parasite, innate and T cell mediated immunity is the host’s 
major defence against T.gondii infections. Nonetheless, infection with T.gondii 
stimulates production of IgG, IgM, IgA and IgE antibodies (Roberts et a l, 1998a). In 
vitro, extracellular tachyzoites coated with antibody and complement can be lysed via 
the classical complement pathway (Schreiber & Feldman, 1980); or phagocytosed by 
macrophages (Anderson et a l, 1976). In vivo, passive transfer of immune serum will 
protect mice only against less virulent strains of T.gondii (Pavia, 1986). However 
while antibodies may not have a significant role in systemic immunity, they may play a 
protective role by interfering with the initial interaction of the parasite with the host 
cell. For example, human secretory IgA, derived from infected mother’s breast milk
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reduces in vitro infectivity of tachyzoites for murine enterocytes (Mack & McLeod, 
1992).
Immunity and the eye
The immune response to T.gondii infection in the eye is less well studied. The eye is 
an immunologically privileged site, and as such the local immune response is 
suppressed to prevent tissue destruction. Immune responses initiated in the eye tend 
to be dominated by CD8+ T cells and frequently a CD4+ Th2 component (reviewed, 
Streilein, 1997; Streilein et a/., 1997). Induction of this deviant immune response 
depends on multiple factors. For example there is constitutive intra-ocular expression 
of Fas Ligand (Fas-L). This may promote deletion of activated T cells in the eye by 
apoptosis following interaction of Fas molecules on the infiltrating cells with Fas-L 
expressed on parenchymal cells within the eye (Griffith et a!., 1995). This mechanism 
of killing is specific and does not produce damage to adjacent tissues. There is 
expression of complement inhibitors, CD59, MCP and DAF on cells that surround the 
anterior chamber (Bora et al., 1993). Reduced expression of MHC class I and II on 
parenchymal cells also occurs (reviewed, Streilein, 1995). In addition, even under 
normal circumstances intra-ocular fluid has been shown to contain cytokines such as 
transforming growth factor- P (TGF-P) (Cousins et al., 1991; Granstein et al., 1990). 
Other mediators including a-melanocyte stimulating hormone, vasoactive intestinal 
peptide, calcitonin gene-related peptide, free cortisol and IL-1 receptor antagonist 
have also been identified (reviewed, Streilein et al., 1997). All of these compounds 
have immunosuppressive properties.
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These factors which favour immunological unresponsiveness may render the eye 
vulnerable to certain pathogens especially viruses or parasites. Furthermore, T.gondii 
may promote factors which result in abrogation of immune privilege. For example, 
IFN-y, which plays a critical role in resistance to T.gondii infection, antagonises the 
immunosuppressive functions of TGF-P (Hunter et al., 1995a). Indeed, in spite of 
conditions in the eye that would tend to prevent immunity to T. gondii, 
immunological factors, similar to those which protect against disease in other tissues, 
appear to protect against murine eye disease. Using a murine model Gazzinelli et al., 
(1994) found that treatment of chronically infected mice with monoclonal antibodies 
against IFN-y, TNF-a, or CD4+ and CD8+ lymphocytes exacerbated ocular lesions 
and resulted in increased numbers of parasites in the retina. Consistent with a 
protective role for IFN-y and TNF-a, inhibition of nitric oxide production in 
chronically infected mice also results in increased severity of ocular inflammation 
(Roberts et al., 1998c).
In the eye, disease recurrences are often associated with reduced immunity either 
locally or systemically. Immunosuppressive therapy may lead to disease reactivation 
although in patients receiving longterm corticosteroid therapy this is uncommon 
(Nicholson & Wolchok, 1976). Animal models have provided conflicting data 
regarding the role of immunosuppression as an initiating factor for toxoplasmic 
retinochoroiditis. Recurrent retinochoroiditis can be induced in previously infected 
rabbits following administration of antilymphocyte serum (Nozik & O. Connor, 1970) 
or in hamsters following total body irradiation or treatment with steroids (Frenkel, 
1957). However, Holland et al., (1988b) were unable to induce recurrent eye lesions
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in monkeys with healed retinochoroidal lesions by immunosuppression with total body 
irradiation.
Immunity and the fetus
The fetus and neonate are unduly susceptible to infections with intracellular pathogens 
such as T.gondii. Immaturity of the immune response may contribute to this increased 
susceptibility. The most severely affected infants acquire T.gondii infection during the 
first trimester. At this time, the numbers of T cells and their repertoire for antigen 
recognition are limited compared with the fetus in the latter half of gestation (George 
& Schroeder, 1992).
Although NK cells appear early during gestation and are present in normal numbers 
by mid to late gestation the phenotype of over half these cells is immature, lacking the 
CD56 antigen (Phillips et al., 1992). These immature cells have decreased cytotoxic 
activity compared with adult cells (Phillips et al., 1992; Sancho et al., 1991).
Neonatal monocytes show slower migration to sites of infection (Bullock et al., 
1969). In addition both the generation of cytokines and macrophage response to 
cytokines are deficient in the newborn (Wilson & Haas, 1984). Deficient production 
of certain cytokines by lymphocytes may be a critical factor in congenital 
toxoplasmosis. In the normal neonate, while IL-2 is produced in sufficient amounts 
the production of other cytokines, in particular IFN-y and IL-4, is markedly reduced 
compared with adult T cells (Lewis et al., 1991). Since adult virgin T cells also have a 
reduced capacity to produce these cytokines, the apparent deficiency o f neonatal T
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cells may reflect their antigenically naive status rather than an intrinsic immaturity of 
function. Indeed, studies have shown that neonatal T cells, activated and cultured in 
vitro, can acquire a memory T cell surface phenotype and the capacity to produce 
cytokines such as IL-4 and IFN-y (Ehlers & Smith, 1991).
Infants with congenital toxoplasmosis have absent or diminished lymphocyte 
blastogenic responses to T.gondii antigen and production of IL-2 and IFN-y is 
reduced (McLeod et a/., 1990). Their lymphocytes are, however, capable of 
responding normally to other stimuli. This anergy to T.gondii may reflect differences 
in the route of acquisition, cytokine environment or co-stimulatory molecules present 
during gestation. Impairment in the development of antigen-specific T cell responses 
has also been observed in infants with congenital infection due to CMV (Hayward et 
al., 1984) and rubella (Buimovici-Klein elal., 1979).
3.2 Genetics
In mice, resistance to toxoplasmic encephalitis and development of large numbers of 
cysts is controlled by the MHC, Class I, Ld gene (Brown et al., 1995). In contrast 
mice which lack the Ld gene are susceptible to large cyst burdens and encephalitis 
(Brown et al., 1995; Brown & McLeod, 1990). Other genes with a more minor 
influence on parasite burden include Nramp and Class II MHC (reviewed, McLeod et 
al., 1996). Survival of mice following oral T.gondii infection is a polygenic trait 
controlled by at least five genes (McLeod et al., 1989). However, survival following 
intraperitoneal infection is controlled largely by the H-2 histocompatibility complex 
(Williams et al., 1978).
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Until recently there was only circumstantial evidence that host genetic factors played a 
role in resistance to human toxoplasmosis. For example there are significant ethnic 
variations in incidence and severity of disease (McAuley et a!., 1994). In addition, 
clinical studies of twins show that monozygotic twins have a similar incidence and 
severity of disease which is not seen in dizygotic twins (Couvreur et al., 1976). There 
is now strong evidence that host genetic factors, at least in part, determine disease 
severity in humans. In humans, susceptibility to toxoplasmic encephalitis in patients 
with AIDS is associated with the Class II DQ3 allele. Suzuki et al., (1996) found that 
the HLA DQ3 allele was present in 85% of AIDS patients with toxoplasmic 
encephalitis. This allele was present in 40% of AIDS patients who did not develop 
toxoplasmic encephalitis and 51.8% of the general population. There is also an 
association of the DQ3 allele in patients with severe congenital infection and 
hydrocephalus. Mack et al., (1996) found that the HLA DQ3 allele was present in 
79% of congenitally infected infants with hydrocephalus. The frequency o f this allele 
in infected infants without hydrocephalus and the general population was 45% and 
49% respectively. Furthermore this MHC Class II gene has been shown to increase 
susceptibility to T.gondii in a murine model. Class II knock-out mice with the human 
transgene DQ3 have an increased parasite burden and more necrotic lesions in their 
brains, when compared with similar mice with the human transgene DQ1. One study 
which examined a very small number of cases of ocular toxoplasmosis found no 
definite MHC association with disease (Nussenblatt et al., 1989). However, a more 
recent study suggested an association with HLA-Bw62 and severe ocular disease 
(Meenken et al., 1995).
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3.3 Summary
The clinical disease produced by T.gondii is a balance between pathogen and host 
related factors. For example, the more virulent strains of T.gondii may cause more 
severe disease. However, the genetic susceptibility of the host and the ability to mount 
an immune response also affect the severity of disease. In humans the Class II DQ3 
allele appears to be associated with increased severity of congenital infection and in 
increased susceptibility to AIDS related toxoplasmic encephalitis (Mack et al., 1996; 
Suzuki et al., 1996). In addition, the immune response controls parasite replication 
and facilitates cyst formation in the immunocompetent host. However, lack of 
adequate macrophage, NK cell and T cell immune responses renders the immature 
fetus and immunosuppressed AIDS patient particularly vulnerable to this disease. 
Furthermore, certain sites such as the eye have a specialised immune response which 
may be less effective at controlling this parasite.
Congenital toxoplasmosis causes considerable suffering in afflicted individuals and 
their families. In addition there is also a major expenditure for health care. In 1975 it 
was estimated that the lifetime cost for special care of each child with congenital 
toxoplasmosis was $67 000 (approximately £45 000) (Wilson & Remington, 1980). 
The cost in 1998 would be considerably greater. Toxoplasmosis was one of the 
sentinel opportunistic infections observed early in the AIDS epidemic and it remains 
one of the most frequent and treatable opportunistic infections o f the central nervous 
system in AIDS. These facts alone make this a disease worthy of study.
This thesis is written in two parts. The purpose of the first part is to provide 
comprehensive histological documentation of the earliest stages of ocular
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toxoplasmosis in the fetus and infant. The second part of this thesis investigates 
biochemical and potentially pharmacological aspects of this disease by describing new 
pathways in T.gondii which may provide potential drug targets.
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CHAPTER 4
MORPHOLOGICAL FEATURES OF OCULAR 
TOXOPLASMOSIS IN THE FETUS
75
4.1 Specific Objectives
1. To characterise the histopathological features and in addition the nature o f the 
infiltrating inflammatory cells in eyes from fetuses and infants with congenital 
toxoplasmosis.
2. To compare the histopathological findings with those already described and to 
correlate them with the recognised clinical signs and symptoms.
4.2 Background
The ocular lesions o f congenital toxoplasmosis in infants, children and adults have 
been well described. The earlier stages of the ocular lesions in the fetus have not been 
extensively studied. However, much recent work has concentrated on in utero or 
early, postnatal treatment of congenital toxoplasmosis (Berrebi & Kobuch, 1994a; 
Couvreur et a!., 1993; Daffos et al., 1988). Documentation of the ocular lesions in 
fetuses from pregnancies terminated for congenital toxoplasmosis and early neonatal 
deaths could provide a baseline for more accurate assessment of the early treatment of 
this disease. Furthermore insight into the pathogenesis of T.gondii infection may be 
obtained by characterising the early stages of this disease.
The human fetal eyes used in this study have been obtained through multinational 
collaboration and comprise the largest collection of such tissues. There is therefore 
great potential for this study to contribute to our understanding of the early stages of 
this disease.
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4.3 Materials and Methods
Eyes
A total of 20 eyes from 10 fetuses, 2 infants and a 2 year old child were available for 
study. The case histories for the fetuses, infants and child are summarised in Table
4.1. Fetal and infant post mortem findings, where available, are summarised in Table
4.2.
FetaI eyes
Fifteen eyes were collected post mortem from 10 fetuses with congenital 
toxoplasmosis. These eyes came from France where serological screening for T.gondii 
infection has been carried out since 1978. Maternal infections were confirmed by 
seroconversion in both the Sabin-Feldman dye test and the IgM-immunosorbent 
agglutination assay. The Sabin-Feldman dye test detects T.gondii specific IgG and 
may be positive in acute or chronic infection. In contrast, the IgM-immunosorbent 
agglutination assay is positive during acute infection and is usually negative or at low 
titre in chronic infection.
Maternal seroconversion occurred at an average gestation of 12.9 weeks ( Range 10 
to 18.5 weeks). Therefore, the average maximum possible length of infection prior to 
termination of pregnancy was 11.5 weeks (range 6 to 18 weeks).
The fetuses were aborted between 19 and 32 weeks gestation following a positive 
diagnosis of toxoplasmosis by polymerase chain reaction (PCR) which demonstrated 
the presence of the T.gondii B l gene in amniotic fluid. Prior to termination of 
pregnancy, additional evidence of severe T.gondii infection, as demonstrated by
77
intracerebral ventricular dilatation at ultrasound, was obtained in five cases. Following 
abortion, in seven cases, necropsy and/or subinoculation of placental tissue, amniotic 
fluid or cerebral tissue into mice was carried out to confirm the diagnosis. For 
congenital toxoplasmosis, isolation of the organism from the placenta or from fetal 
tissues is considered diagnostic of infection. These tissues were inoculated into the 
peritoneal cavities of mice. After 6 weeks, mice were tested for antibody to T.gondii 
or tissue cysts were demonstrated in brain smears. At necropsy one second trimester 
fetus (Case 8) was also found to be infected with cytomegalovirus (CMV).
In 6 cases the mother received spiramycin therapy in an attempt to prevent 
transplacental transmission of the parasite. Spiramycin cannot cross the placenta and 
does not treat the infection in the fetus. In Case 10 the mother had received 
pyrimethamine and sulphadiazine therapy for 3 weeks prior to abortion.
Infants ' and child's eyes
The infants and the child in this study died from severe congenital toxoplasmosis or its 
complications. Three infant eyes were available from 2 cases. Both infants were born 
prematurely, one at 34 weeks gestation (Case 12), the other unrecorded (Case 11). 
The infants survived 7 days and 5 days respectively. For Case 11 the diagnosis was 
confirmed by necropsy and positive subinoculation of fetal tissues into mice. For Case 
12 the diagnosis was confirmed by serological investigations during life and necropsy 
was not performed.
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The 2 year old child had well documented changes of severe ocular and cerebral 
toxoplasmosis which had been partially treated. These cases were included in the 
study for comparison with the earlier stages of the disease in the fetus.
Control eyes
Eyes from normal, uninfected, age-matched fetuses (age 21, 24 and 26 weeks 
gestation), infants (born at 34 weeks gestation and term) and a 2 year old child were 
used as controls. These cases showed no evidence o f congenital toxoplasmosis or 
other abnormalities.
Histopathology
Cases retrieved from archives were already embedded in paraffin. The remainder of 
the eyes were obtained in 10% buffered formalin. These were opened horizontally, 
processed and embedded in paraffin wax. Microtome sections (6pm) were cut, 
deparaffinised, serially rehydrated and then stained with haemotoxylin and eosin 
(H&E) or periodic acid schiff (PAS).
Immunohistochemistry
For immunohistochemistry, 6pm sections were deparaffinised and serially rehydrated 
to water. Endogenous peroxidase activity was blocked by immersing slides in 3% 
H2O2 in distilled water for 10 minutes. Following this slides were washed in running 
tap water for 5 minutes. For antigen retrieval slides were either pressure cooked or 
microwaved in 0.01 M sodium citrate buffer, pH 6.0. Non-specific antibody binding 
was blocked by incubation in 20% normal goat serum (NGS) or 10% normal swine
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serum (NSS) in Tris Buffered Saline containing 0.1% Tween-20 (TBS/Tween) for 10 
minutes prior to incubation with primary antibodies.
Inflammatory cells
Slides were incubated with primary antibodies diluted in 4% NGS/TBS/Tween for 
either i) 30 minutes at room temperature, ii) 90minutes at 37°C or iii) overnight at 
4°C. After washing in TBS/Tween, slides were incubated with the secondary 
antibody, biotinylated IgG-goat anti-mouse (Ventana, Tucson, AZ, USA) diluted in 
TBS/Tween , at room temperature, for 30 minutes. The slides were again washed and 
then incubated with an Avidin-Biotin complex (Ventana) for 30 minutes at room 
temperature. Immunohistochemical staining was visualised with 3-3’diaminobenzidine 
(DAB) and the slides were then counterstained with haemotoxylin. The primary 
antibodies used were pan-B cell (CD20 ), pan T cell (CD3), CD4+T cells (OPD4), 
CD8+ T cells (CD8), and macrophages (CD68). The primary antibodies were used at 
the following dilutions; CD20 (1:200); CD3 (1:10); OPD4 (1:25); CD8 (1:50); CD68 
(1:100) (all from DAKO, Santa Barbara, CA, USA).
T.gondii antigens
Similarly slides were incubated with murine monoclonal zx\\\-T.gondii, L43 (donated 
by E.Petersen, Statens Seruminstitut, Copenhagen, Denmark) or rabbit polyclonal 
anti-T.gondii (also donated by E.Petersen). Both monoclonal and polyclonal 
antibodies recognise bradyzoite and tachyzoite life cycle stages. The primary 
antibodies were used at a 1:100 dilution. The slides treated with the monoclonal 
antibody were washed and incubated with monoclonal rabbit anti-mouse antibody 
(DAKO). After washing they were incubated with an alkaline phosphatase, anti-
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alkaline phosphatase (APAAP) complex for 30 minutes. The last two steps were then 
repeated. Slides treated with the polyclonal antibody were incubated with mouse anti­
rabbit antibody (DAKO) and then treated as for the monoclonal antibodies. 
Immunohistochemical staining was visualised using APAAP substrate solution (0.2M 
Tris-HCl, pH 9.0 containing 4% new fuschin in 2N HC1, 4% sodium nitrite, and 
napthol-AS-Bl-phosphate dissolved in dimethylformamide). This gives a red reaction 
product which allows distinction of extracellular organisms from melanin granules o f 
the disrupted RPE. The slides were counterstained with haemotoxylin.
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4.4 Results
The histopathological and immunohistochemical findings are summarised in Tables 
4.3 to 4.5 and are illustrated in Figures 4.1 to 4.7.
Fetal eyes
Gross
For eyes obtained in formalin, the gross findings ranged from completely normal to 
white fluffy areas suggestive of acute retinitis accompanied by a cloudy vitreous. The 
eye from the 32 week old fetus showed an established retinochoroidal scar in the 
superior temporal region.
Histopathological features
Two eyes, one from a 21 week old fetus (Case 2), and the other from a 26 week old 
fetus (Case 9) were normal. In all cases there was a mild inflammatory cell infiltrate 
composed principally of lymphocytes and plasma cells in the iris and ciliary body. 
Where present the cornea and lens were normal.
The retina showed appropriate maturation for the gestational age. Focal retinal lesions 
were identified in eight of the 15 eyes. Some lesions consisted of frank retinal necrosis 
with disruption of the underlying RPE (Figure 4.1 A). Free pigment granules were 
scattered throughout the necrotic areas. Other lesions were devoid o f retina and 
consisted of disruption and proliferation of the retinal pigment epithelium with 
scattered pigment granules in the overlying vitreous. The choroid underlying lesions 
was congested with chronic inflammation (Figure 4 .IB). In addition, there was a 
diffuse choroiditis. Lesions varied in size from less than 1mm in a 21 week old fetus to
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over 7mm in a 22 week fetus. Of four cases where both eyes were available, lesions 
were bilateral in only one case. The most frequent locations of lesions was in the 
posterior pole which was involved in 5 eyes. In three of these cases the lesions were 
confined to the peripapillary area. The remaining eyes had lesions in the peripheral 
retina. In 2 cases both peripapillary and peripheral retina were involved.
The lesion in the peripheral retina of the 32 week old fetus was unusual compared 
with other retinal lesions. Unlike other cases, which showed evidence of continuing 
inflammation, this lesion was almost devoid of inflammatory cells. At the edge o f the 
lesion the retina showed abnormal maturation with loss of distinction of nuclear layers 
and formation of Flexner Wintersteiner rosettes (Figure 4.2). Distant from this lesion 
the retina showed appropriate maturation for gestational age. These appearances were 
interpreted as focal retinal dysplasia.
In addition to focal retinal lesions there was retinal gliosis in 5 eyes (Figure 4.3D). In 
3 eyes with no focal lesions, the retina was normal in 2 eyes, but showed widespread 
gliosis in one eye. No CMV inclusions were detected in Case 8 . Inflammation 
extended into the vitreous in 7 eyes with condensation bands, scattered inflammatory 
cells and necrotic debris. Remnants of the tunica vasculosa lentis were identified in 9 
eyes. In addition the hyaloid artery and primary vitreous also were present in 2 eyes 
(Figure 4.4).
The optic nerve was present in sections from 8 eyes and was normal in three cases, 
(Case 1, 9 and 10). In 5 eyes there was a leptomeningitis associated with optic neuritis
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(Figure 4.5). In 3 of the eyes this also had resulted in distortion of the normal nerve 
architecture. In 2 of the eyes with optic neuritis there was a peripapillary lesion.
Infants’ eyes
Gross
Gross examination of both eyes from the 7-day old infant (Case 12) showed bilateral 
retinal detachment with large white fluffy areas in the retina and a cloudy yellow 
vitreous.
Histopathological features
In all three eyes the cornea, angle, iris and ciliary body were normal.
The gross findings in Case 12 were reflected in the histological sections which showed 
a large area of retinal detachment with atrophy of the photoreceptors and a subretinal 
serous exudate. There was bilateral extensive retinal necrosis. In the left eye the 
retinal lesion was over 8mm diameter extending from the pars plana to the posterior 
pole. The other eye showed a 3mm lesion at the posterior pole and a 4mm lesion in 
the peripheral retina, superiorly. Within the areas o f retinal necrosis there were 
scattered pigment granules and foci of calcification.
Underlying the lesions, the RPE was disrupted showing tubuloacinar proliferation and 
there was a diffuse choroiditis. Elsewhere the RPE was intact however, the retina 
showed oedema, gliosis and mononuclear cell infiltration. There was an organisation 
within the vitreous with continuing inflammation. The optic nerve was not present in 
the sections examined.
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In case 11 there was also a large retinal detachment with subretinal exudate and 
atrophy o f photoreceptors (Figure 4.3 A). However, there were only small foci of 
retinal necrosis and the RPE was intact. The retina showed changes similar to those 
described above but in addition there were collections of intracellular organisms 
(Figure 4.3B). The optic nerve showed a leptomeningitis with chronic inflammation 
confined mainly to the prelaminar region and the lamina cribrosa. Condensation bands 
were present in the vitreous with necrotic debris and mononuclear cells.
Child’s  eyes
Gross
Both eyes showed features of end-stage disease. The left eye contained two 
retinochoroidal scars situated in the posterior pole and superior region o f the 
peripheral retina. The larger scar in the posterior pole measured 5x3mm, the smaller 
scar measured 3 mm in maximum diameter. Overlying these lesions the vitreous was 
cloudy.
The right eye was firm, partially collapsed and smaller than the left eye. On opening 
the anterior chamber was shallow with an opaque lens displaced into the posterior 
chamber. In the posterior chamber the vitreous was cloudy and the cavity was 
distorted by firm white material.
Histopathological features
The anterior chamber of the left eye was normal. The anterior chamber o f the right 
eye was collapsed with displacement o f the lens into the posterior chamber. The lens 
showed cataractous degeneration.
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In the right eye there were two well established retinochoroidal scars. The centre of 
the scar consisted of an organising exudate containing foreign body giant cells and 
scattered chronic inflammation. This had destroyed the normal structures o f the retina 
and choroid. The retinal pigment epithelium was disrupted and at the edge of the scar 
showed tubulo-acinar proliferation (Figure 4.1C). The retina at the edge of the scars 
was oedematous and disrupted. Elsewhere it was gliotic. There was focal, mild 
chronic inflammation in the choroid. The vitreous showed evidence o f organisation 
overlying the scars but was otherwise normal.
The left eye showed changes of end-stage disease. The retina was gliotic and the RPE 
was disrupted with tubulo-acinar proliferation. There was a large subretinal exudate 
with cholesterol clefts, foreign body giant cells and scattered pigment. The optic nerve 
showed fibrosis and atrophy.
Control eyes
The uninfected, age-matched, control eyes from the 21, 24 and 26 week old fetuses, 
34 week old and term infants and 2 year old child were normal. They showed no focal 
lesions or inflammation.
Immunohistochemistry
Inflammatory cells
Findings were similar for both fetal and infant eyes. The inflammatory cells present in 
the lesions consisted of lymphocytes, plasma cells and macrophages. 
Polymorphonuclear leucocytes were not present in significant numbers.
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Immunohistochemical staining showed both B and T lymphocytes. Overall T 
lymphocytes predominated with only scattered B lymphocytes. There was a diffuse 
infiltrate of inflammatory cells in the choroid composed of both T and B lymphocytes. 
This infiltrate was most severe in the choroid underlying lesions where it was 
composed almost entirely of T cells (Figure 4.6). These collections of T lymphocytes 
consisted of both CD4+ and CD8+ subtypes although, CD4+ T cells predominated. T 
cells were also present in the retina adjacent to lesions. In addition in the cases with 
optic neuritis the nerve was infiltrated by B and T cells of both CD4+ and CD8+ 
subtypes although, again CD4+ T cells predominated. The eye from the 32 week old 
fetus and both eyes from the 2 year old child contained only rare lymphocytes.
In 2 fetal eyes from Case 5 numerous macrophages were identified in the choroid 
underlying retinal lesions (Figure 4.6F). In all other eyes, only occasional 
macrophages were identified within the choroid. Only very occasional inflammatory 
cells were identified within control eyes.
T. gondii antigens
No tissue cysts were seen by light microscopy in any of the cases although, collections 
of intracellular organisms were identified in Case 11 (Figure 4.7A). 
Immunohistochemistry for T.gondii antigen detected extracellular organisms and 
amorphous antigens in 10 eyes (7 fetal, 3 infant and 0 child) and 9 eyes (6  fetal, 3 
infant and 0 child), respectively. Parasites were almost exclusively confined to the 
retina and necrotic debris (Figure 4.7). In the fetal eyes the parasite were most 
numerous within the retina immediately adjacent to areas of necrosis. Parasites were 
not identified in Case 9 or 10. In Case 11, in addition to the groups of intracellular
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parasites seen on light microscopy, numerous extracellular parasites were apparent 
with immunohistochemical staining, within the abnormal retina. In one area parasites 
were identified surrounding an inner retinal vessel (Figure 4.7B and C). In Case 12 
very few parasites were identified despite the presence o f extensive necrosis.
No parasites were identified within the choroid despite the presence o f numerous 
inflammatory cells in all but one case. In Case 6, a few extracellular parasites were 
iderftified in the perivascular space around the central retinal vessels. However, no 
parasites were identified within the substance o f the optic nerve in any case.
Immunohistochemical staining for T.gondii was negative in all the control eyes.
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F ig u re  4.1 Retinochoroidal Lesions
A Well-demarcated area of retinal necrosis at the posterior pole of 
a 22 week gestation fetus (Case 6). The hyaloid artery (ha) is still 
present. (H&E, x 250). B Focal disruption and proliferation of the 
retinal pigment epithelium in a 22 week gestation fetus (Case 5). The 
underlying choroid show s marked congestion and chronic inflammation. 
(H&E, x 250). C Edge of a large retinochoroidal scar  from the eye of the 
2 year old child. The scar  is well demarcarated with tubulo-acinar 
proliferation of the RPE at the edge of the scar. The centre of the scar  is 
devoid of retina. (H&E, x 250).
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F ig u re  4 .2  Retinal Dysplasia adjacent to retinochoroidal scar  
A Eye from a 32 week gestation fetus (Case 10), showing a large 
hyperpigmented scar, with a white rim, in the superio-temporal 
region of the eye. B The retina from the edge of the sca r  show s 
disorganisation with formation of rosettes (arrows) (H&E, x250). 
C and D Rosettes within abnormal retina (H&E, x 400).
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F ig u re  4 .3  Retinal detachment, retinitis and gliosis 
A and B Retina from a 5 day old infant, (Case12), showing 
detachm ent with an exudate between the retina and choroid (A), 
(H&E,x 100). The inner retinal layers are oedem atous and inflamed 
(B). Collections of intracellular organism s are identified (arrows), 
(H&E, x 400). C Retina from a 21 week gestation fetus, (Case 3), 
showing num erous inflammatory cells within the retina (arrows), 
with prominent inner retinal vesse ls , (H&E, x 400). D Retina from 
a 22 week gestation fetus (Case 6) showing gliosis, (H&E, x 400).
96
1 ''/
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F ig u re  4 .4  Inflammation in the primary vitreous 
A Eye from a 23 week gestation fetus (Case 7) showing a 
m oderate inflammatory cell infiltrate within the primary vitreous 
and surrounding the hyaloid artery (ha). An area of necrosis is 
p resent (arrow) (H&E, x 20). B The inflammatory infiltrate is 
com posed principally of small lymphocytes and plasma cells 
(H&E, x 250). C Immunohistochemical staining show s that the 
majority of lymphocytes are T cells, (CD3, x 250). D A smaller 
proportion of B cells are also present (arrows), (CD20, x 250).
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Figure 4.5 Optic Neuritis
A and B Optic nerve from a 24 week gestation, uninfected fetus 
showing normal nerve architecture. (H&E, x 100 and x 400).
C and D Optic nerve from a 23 week gestation fetus with congenital 
toxoplasm osis. The nerve architecture is disrupted with vacuolation 
and infiltration by inflammatory cells. (H&E, x100 and x400).
E Immunohistochemical staining for T cells show s num erous positive 
lymphocytes within the optic nerve. (CD3, x 400). F Immunohisto­
chemical staining for B cells show  very few positive lymphocytes 
(arrows). (CD20, x 400).
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F igure  4.6 Inflammatory cells present in ocular toxoplasm osis 
A Discrete ocular lesion from a 21 week gestation fetus (Case 2) 
showing disruptionof the RPE, choroidal congestion and 
inflammation (H&E, x 400). B Immunohistochemical negative 
control for sam e case  (Negative, x 400). C and D Numerous 
CD3 positive and CD4 positive T cells are p resent within the 
choroid (CD3 and CD4, x 400). E No CD8 positive T cells are 
p resen t (CD8, x 400). F CD68 positive m acrophages are num erous 
within the choroid underlying the RPE disruption (CD68, x 400).
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Figure 4.7 Presence of T.gondii
A Retina from a 7 day old infant (Case 12) showing a collection 
of intracellular T.gondii within the retina (arrow), (H&E; x 100). The 
insert show s a high power view of these  organisms, (H&E; x 400).
B and C Retina from Case 12 showing immunohistochemical s ta in ­
ing for T.gondii antigen. Many extracellular T.gondii are identified 
(arrows). In addition organism s are p resent in a perivascular location 
(v), (L43; x 100 and x 250). D Gliotic retina from a 22 week gestation 
fetus (Case 5) showing extracellular organism s (arrows), (Polyclonal 
antibody; x250). E Numerous extracellular T.gondii (arrows) within 
necrotic debris from a 23 week gestation fetus (Case 7), (L43; x 400). 
The red staining product allows distinction from melanin pigment 
granules (pg) of disrupted RPE. F Extracellular T.gondii within inflamed 
disrupted retina from a 21 week gestation fetus, (Case 4) (L43; x 400). 
Again the organism s are distinct from pigment granules (pg) of the the 
RPE.
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4.5 Discussion
Retinitis, retinal necrosis, disruption of the RPE with marked choroidal inflammation 
and congestion are the characteristic findings in the eyes of fetuses with congenital 
toxoplasmosis. These lesions represent irreversible in ulero damage to the retina. 
They frequently affect extensive areas including the peripapillary area, posterior pole 
and peripheral retina. The two infants in this study showed severe ocular disease with 
retinal necrosis, retinal detachment and large subretinal exudates. Within the surviving 
retina there was neovascularisation and gliosis. Again much of this damage must have 
occurred in utero since postnatal survival was only a few days.
It is almost impossible to document the kinetics of T.gondii infection in utero. The 
time from maternal seroconversion to fetal diagnosis and subsequent termination of 
pregnancy estimated the maximum length of fetal infection to be on average 11.5 
weeks. In reality, however, it is probably much shorter than this because there is a 
delay between maternal and fetal infection (Remington et al., 1995). The length of 
this delay varies, but can be longer than 16 weeks (Remington et al., 1995). In 
addition, delay between fetal infection and ocular involvement may occur. 
Furthermore, unlike an animal model, it is rarely feasible to precisely document the 
dose, clonal derivation of the parasite (i.e. Type I, II or III, as defined by Sibley & 
Boothroyd, (1992)) or parasite life cycle stage with which the mother has been 
infected. Despite these different parameters the findings in the fetal eyes are 
remarkably similar and appear to represent a continuum of the same process. 
Specifically, retinal necrosis occurs in the acute lesions of ocular toxoplasmosis. As 
these lesions heal they leave an early scar devoid o f normal retina but with 
proliferation of the RPE. The end stage of this process is formation of a
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retinochoroidal scar. This has a hyperpigmented border due to tubulo-acinar 
proliferation o f the RPE at the edge of the lesion. End-stage scars such as these were 
seen in the eyes from the 2 year old child.
Acute retinitis with necrosis may also be seen in children and adults following 
reactivation of ocular toxoplasmosis (Zimmerman, 1961). This is rarely as extensive 
as that seen in the fetus except in the immunocompromised host (Holland et al., 
1988a)
Clinically established retinochoroidal scars have been identified at birth in some 
infants, implying that ocular damage, healing and repair can all occur in utero 
(Guerina et al., 1994; Mets et a l , 1996). Indeed a retinochoroidal scar, almost devoid 
o f inflammatory cells, was the main abnormality detected in the eye of the 32 week 
old fetus. Adjacent to this scar the retinal disorganisation and rosettes, interpreted as a 
form of retinal dysplasia, was an unusual finding. Retinal dysplasia occurs most 
frequently with multiple congenital anomalies associated with chromosomal 
aberrations (Fulton et a l , 1978; Godel et al., 1981). At necropsy this fetus (Case 10) 
was not dysmorphic and showed no evidence o f other malformations. In addition the 
abnormal retina was confined to the area adjacent to the scar. Retinal dysplasia also 
has been described following X-irradiation of the fetus both in clinical situations and 
in animal models (Goldestein & Wexler, 1931; Shively et al., 1970). Various 
cytotoxic agents including 5-iododeoxyuridine (Percy, 1975), cytosine arabinoside 
(Percy & Danylchuk, 1977) and alkylating agents such as methylnitrosourea (Smith & 
Yielding, 1986), can produce retinal dysplasia in animal models. However, this is the 
first report of retinal dysplasia following T.gondii infection .
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There have been several reports of infectious agents other than T.gondii, causing 
retinal dysplasia in animals. For example, retinal dysplasia, develops in 2 day old 
hamsters, but not 25 day old hamsters following intracerebral injection of measles 
virus (Khalifa et al., 1991). However, 25 day old hamsters did show retinal 
haemorrhages and focal retinitis. Similarly, retinal dysplasia was the most common 
finding following intra-ocular injection of feline leukaemia virus into fetal kittens 
(Albert et al., 1977). Finally, canine herpes virus infection in neonatal pups produces 
severe ocular inflammation with subsequent retinal dysplasia (Albert et al., 1976).
The mechanism whereby these infectious agents cause abnormal retinal development 
remains to be determined. It has been postulated that progressive disorganisation of 
the retina and necrosis is followed by differential repair of the retinal layers (Albert et 
al., 1976; Albert et al., 1977; Parhad et al., 1980). Furthermore the RPE appears to 
be important in normal retinal development (Fulton et al., 1978; Godel et al., 1981). 
Therefore disruption of the RPE also may contribute to retinal dysplasia and rosette 
formation, perhaps due to loss of polarity of retinal cells or lack of specific growth or 
maturation factors produced by the RPE (Steinberg, 1985; Tanihara et al., 1997). For 
example, retinoids are transported from the RPE to photoreceptors (Steinberg, 1985) 
and retinal dysplasia is recognised in fetal vitamin A deficiency syndrome (Ghyselinck 
et al., 1997). Both retinal necrosis and RPE disruption occur in ocular toxoplasmosis. 
Retinal dysplasia may therefore represent a rare complication of early T.gondii 
infection where the insult occurs prior to organisation of the retinal layers.
The location o f lesions is important because patients are at risk for blindness if tissues 
critical for vision, such as the macula or optic nerve, are involved. In clinical studies
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there appears to be a definite predilection for the macular region in patients with 
congenital toxoplasmosis. In one study, peripheral scars were present in 64% of 
patients whereas macular scars were present in 58% (Mets et al., 1996). Considering 
the much smaller area of the macula, these results support a definite predilection for 
the macular region in these patients. During embryogenesis, development of the 
macular region is markedly retarded compared with the rest o f the retina and 
differentiation of this region continues for at least the first four years o f life (Yuodelis 
& Hendrickson, 1986). In view of this lack of specialisation and its small size we were 
unable to identify the macular region in the fetal or infant eyes. However where lesion 
were extensive and involved the posterior pole it seems likely that the macula was 
involved.
In congenital infection, T.gondii probably reaches the eye by a haematogenous route. 
The identification of parasites around an inner retinal vessel in Case 11 supports a 
haemotogenous route. Furthermore a predilection for the posterior pole may reflect 
the fact that it is vascularised earlier in development than other portions o f the retina. 
In addition although the macula is avascular, it obtains its blood supply from end 
arterioles which form a capillary plexus surrounding the macula. Lodging of parasites 
in these capillaries may facilitate establishment o f infection in this delicate region of 
the eye.
The optic nerve was present in sections from 8 fetal eyes. Optic neuritis was present 
in 5 of these with distortion of the normal nerve architecture in 3 cases. Furthermore, 
similar to the focal retinal dysplasia, distortion o f the nerve architecture may represent 
another instance whereby inflammation of the nerve early in gestation results in
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abnormal development. Due to a lack of appropriate neural connections optic atrophy 
may be the clinical outcome in surviving patients. In one study, optic atrophy was 
present in 20% of patients with congenital toxoplasmosis (Mets et al., 1996). 
However, fetuses in this study were known to have intracranial disease with 
ventricular dilatation on ultrasound, and it may be that the presence o f optic neuritis 
simply reflects the severity of their encephalitis. Papillitis, papilloedema, and optic 
atrophy are recognised clinical manifestations o f toxoplasmic encephalitis (Mets et al., 
1996; Perkins, 1973). True optic neuritis is a rare complication of disease reactivation 
although T.gondii may involve the optic disc or retina immediately adjacent to the 
optic disc resulting in a papillitis sometimes referred to as Jensen juxtapapillary 
retinitis (Holland et al., 1996). This may represent a clinical correlate of the two cases 
of optic neuritis associated with a peripapillary lesion in the fetal eyes.
Optic neuritis with necrosis and numerous parasites has been described in a patient 
with HIV-associated ocular toxoplasmosis(Holland et al., 1988a) and a patient with 
fulminant congenital infection (Manshot & Daamen, 1965). This has led to the 
suggestion that congenital infections may be transmitted to the eye from the brain via 
the optic nerve. Alternatively, if infection occurs very early in embryogenesis, the 
parasite may accompany the optic anlage from the developing forebrain. However, in 
the fetal cases with optic neuritis, although there was inflammation and distortion of 
the normal nerve architecture there was no necrosis or parasites. Except in a few 
isolated cases, such as those already described, it seems unlikely that the optic nerve is 
the usual means of T.gondii spread to the eye. Indeed the presence of parasites in the 
optic nerve may simply reflect haematogenous spread via the central retinal artery. 
The presence of a few parasites surrounding the central retinal artery in Case 6 and
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inner retinal vessels in Case 12 support a haematogenous route of dissemination to the 
eye for T.gondii.
Effective immunity to T.gondii requires an immune response that involves 
macrophages, NK cells and their monokine and cytokine products (Subauste & 
Remington, 1993). In particular, IFN-y appears to be a critical cytokine for effective 
immunity (Subauste, 1991). The fetus and neonate are unduly susceptible to infections 
with intracellular pathogens such as T.gondii. This is due to multiple factors including 
a limited T cell repertoire for recognition of antigens (George & Schroeder, 1992) 
and reduced production of certain cytokines, in particular, IFN-y and IL-4 (Lewis et 
al., 1991). Nonetheless, the presence of inflammatory cells in the eyes o f infected 
fetuses suggests that the fetus is capable of mounting, albeit a less effective, immune 
response to T.gondii infection. Murine models have shown that the cytokines IFN-y, 
TNF-a and CD4+ and CD8+ lymphocytes are important in acquired ocular 
toxoplasmosis (Gazzinelli et al., 1994). Since T lymphocytes, of CD4+ and to a lesser 
extent CD8+ subtypes, are clearly present in the fetal eye at the time o f infection, a 
decreased production of IFN-y or other cytokines by these lymphocytes may 
contribute to tissue destruction through uncontrolled parasite proliferation. 
Alternatively, it has been suggested that T lymphocytes and their cytokine products 
participate in the retinal destruction associated with ocular toxoplasmosis (Dutton, 
1986). While this may occur during disease reactivation in the immunocompetent 
adult, it is less likely to occur during primary infection of the fetus where the 
magnitude and quality of the immune response is reduced compared with the adult. 
Tissue cysts were not identified in the eyes of any of the fetuses or infants although 
they were identified at necropsy in the brains of 5 out of 7 fetuses. In the
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immunocompetent adult, tissue cysts may be found at the edge of retinochoroidal 
scars or within apparently normal retina at some distance from previous lesions 
(McMenamin et al., 1986). Encystment usually occurs with the onset of effective 
immunity. Studies have shown a role for immune mediators, such as IFN-y, in 
tachyzoite to bradyzoite conversion and thus cyst formation (Bohne et al., 1993). 
Extracellular organisms were present in lesions particularly adjacent to areas of 
necrosis and numerous intracellular parasites were present in one infant case. This 
may reflect the early acute nature of this disease in the eye as well as a lack of 
effective immunity. Despite the extensive areas of retinal necrosis in Case 11 only a 
few parasites were identified. This may be because the infant had received high dose 
pyrimethamine and sulphadiazine during life. Parasites were not identified in the 
choroid in any case, confirming that this is primarily an infection of the retina.
This study has shown that significant irreversible ocular disease can occur in utero 
and has substantial implications for fetal and infant treatment. In countries, such as 
France, which have prenatal screening programs, studies suggest that antimicrobial 
treatment in utero may reduce ocular disease due to T.gondii at least in the short term 
(Hohlfeld et al., 1989; Berrebi et al., 1994). Similarly, early postnatal treatment of 
toxoplasmosis is associated with prompt resolution of active retinochoroiditis (Mets 
et al., 1996). The long term outcome for in utero treatment and early postnatal 
treatment is unknown. Documentation of the early stages of this disease in 
unsuccessful pregnancies is therefore important to accurately assess the effectiveness 
of in utero therapy and to allow comparisons with the long term clinical outcome in 
treated patients.
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CHAPTER 5
NOVEL BIOCHEMICAL PATHWAYS IN T.GONDII
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5.1 Specific Objectives
1. To determine whether T.gondii utilises the shikimate pathway for the synthesis of 
folate.
2. To determine whether T.gondii has an alternative pathway of respiration.
5.2 Background
Toxicity, allergy and intolerance limit the use o f antimicrobial agents currently 
available to treat toxoplasmosis. There is no cure for T.gondii infection and current 
treatments are based on controlling disease reactivation. The quiescent form of the 
parasite, the bradyzoite, which resides in tissue cysts is resistant to all known drugs. 
This is the usual source of recrudescent disease in congenitally infected and 
immunocompromised individuals. Therefore new therapeutic agents and targets are 
urgently needed.
The identification of ‘plant’-like properties in Apicomplexans presents a unique and 
potentially exploitable difference between host and parasite which could prove useful 
for development of new antimicrobial agents. In particular the shikimate pathway 
required for de novo folate synthesis in plants and the alternative pathway of 
respiration were considered potential candidates for further investigation. 
Identification of these novel biochemical pathways in T.gondii would further our 
understanding o f parasite biology and potentially provide new targets for 
antimicrobial agents.
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5.3 Materials and Methods
In vitro experim ents
Cells
Human foreskin fibroblasts (HFF) were grown in tissue culture flasks in Iscoves’ 
Modified Dulbecoes Medium (IMDM), supplemented with 10% heat inactivated 
(60min;56°C) fetal calf serum, L-glutamine (ImM), penicillin (lOOU/ml), streptomycin 
(lOOpg/ml), (all from Gibco, Grand Island, NY, USA), at 37°C in 100% humidity and 
5% CO2. Confluent cells were removed by trypsinisation. Cells were first washed in 
Hanks’ balanced salt solution (HBSS) without magnesium (Gibco). HBSS without 
magnesium containing 0.25% trypsin (Sigma, St Louis, MS, USA) was then added 
and the flask rocked gently for 1 minute. The flask was then agitated to dislodge cells 
from the surface. An equal volume of supplemented IMDM was added to the cells to 
stop enzyme activity. Following centrifugation at lOOOg for 10 minutes, the cell pellet 
was resuspended in supplemented IMDM. Viable cells were counted in a 
haemocytometer by the ability to exclude trypan blue (0.4% solution; Sigma). The cell 
concentration was adjusted to lx l0 4/ml for toxicity or lx l0 5/ml for parasite growth 
inhibition assays.
Parasites
Tachyzoites of the RH strain were obtained from the peritoneal exudate of ND4 mice, 
age 8-12 weeks (Jackson laboratories, Bar Harbor, ME, USA) infected 
intraperitoneally 3 days previously. Following centrifugation at lOOOg for 10 minutes 
the solution containing the tachyzoites was resuspended in supplemented IMDM. 
Aliquots of the tachyzoites were then added to 100% confluent HFF in a 24 well
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plate. Tachyzoites were passed up to 5 times in culture prior to use in the parasite 
inhibition assays.
For parasite inhibition assays, the tachyzoites were grown until moderate numbers o f 
plaques were identified with minimal disruption of the fibroblast monolayer. This 
ensured the maximum number of live parasites. To harvest the parasites, the 
monolayer was disrupted with a sterile pipette tip and the media from the infected 
well collected in a syringe. This media was passed through a 14 gauge needle 3 times 
to disrupt cells and release the tachyzoites. Viable tachyzoites were counted in a 
haemocytometer by their ability to exclude trypan blue. The tachyzoites were then 
diluted to 2xl04/ml in supplemented IMDM for parasite growth inhibition assays.
Inhibitor compounds
N-phosphonomethyl glycine (NPMG) was used as an inhibitor o f EPSP synthase, a 
key enzyme in the shikimate pathway. This compound was dissolved in IMDM to 
make a lOOmM solution (4.23mg/ml) and adjusted to pH 7.0 using ION NaOH.
Salicylhydroxamic acid (SHAM) and 8-hydroxyquinolone (8HQ) were used as 
inhibitors o f the alternative oxidase. SHAM is not water soluble therefore it was 
initially dissolved in 100% ethanol. The ethanol solution was then diluted in 
supplemented IMDM to give a final concentration of 50ng/ml. 8HQ was dissolved in 
supplemented IMDM to give a concentration of 2mg/ml.
A combination o f pyrimethamine and sulphadiazine, the currently recommended 
therapy for toxoplasmosis was used as a control for inhibition o f parasite growth.
I l l
Pyrimethamine was initially dissolved in 100% ethanol then diluted 1 in 1000 in 
IMDM to give a 0.4pg/ml solution. Sulphadiazine was initially dissolved in HBSS 
then diluted 1 in 100 in IMDM to give a 50pg/ml solution. An equal volume o f 
pyrimethamine and sulphadiazine was used in the parasite inhibition assays to give a 
final concentration of 0 .lpg/ml and 12.5|ig/ml, respectively. These doses of 
pyrimethamine and sulphadiazine have been previously shown to be non-toxic to a 
fibroblast monolayer (Mack & McLeod, 1984).
All the inhibitor compounds, pyrimethamine and sulphadiazine were obtained from 
Sigma. After preparation each solution was passed through a 0.2 micron filter 
(Gelman, Ann Arbor, MI, USA) for sterilisation. Stock solutions o f NPMG and 
SHAM were kept at -20°C. 8HQ, pyrimethamine and sulphadiazine were prepared 
fresh for each assay.
Toxicity assays
HFF were obtained from tissue culture flasks. The concentration was adjusted to 
lx l0 4/ml and 200pl per well added to a 96-well tissue culture plate. HFF were then 
incubated until 10% confluent (36 to 48 hours). At this point up to lOOpl o f media 
was removed from each well and replaced by various concentrations o f inhibitor 
compounds which were added to triplicate wells. Similarly ethanol diluted in 
supplemented IMDM to the same concentration as was present in the SHAM solution 
was also added to triplicate wells. The plates were then incubated for four days. 
During the last 18 hours of culture the cells were pulsed with tritiated thymidine 
(2.5|iCi/well)(Amersham, Arlington Heights, IL, USA). The cells were then harvested
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using an automated cell harvester (PHD, Cambridge, MA, USA) and thymidine 
uptake, and thus cell growth was measured by liquid scintillation on a P-counter 
(Packard CA2000, Meridan, CT, USA).
The mean counts per minute (CPM) for each concentration of inhibitor were 
compared with control CPM, using a students t-test. P values less than 0.05 differed 
significantly from control wells and were thus considered toxic to the fibroblast 
monolayer. Maximum concentrations which did not affect cell growth {i.e. p>0.05) 
were used as the starting point for making serial dilutions of inhibitor compounds for 
the parasite growth inhibition assays.
Parasite growth inhibition assays
HFF were grown in tissue culture flasks. The concentration was adjusted to lx l0 5/ml 
and 200pl per well added to a 96-well tissue culture plate. HFF were then incubated 
until fully confluent (48-72 hours). At this point up to 150pl of media was removed 
from each well and the wells were then infected with 2xl03 tachyzoites o f the RH 
strain. Control cultures were left uninfected. Following infection the plates were 
incubated for 1 hour to ensure that parasites were intracellular. Serial dilutions of 
inhibitor compounds (50pl) were then added to triplicate wells and cultures were 
incubated for 4 days. Control cultures were incubated with pyrimethamine and 
sulphadiazine or were left untreated. During the last 18 hours of culture, cells were 
pulsed with tritiated uracil (2.5|iCi/well) (Amersham). The cells were then harvested 
using an automated cell harvester and uracil uptake, and thus parasite growth 
measured by liquid scintillation on a P-counter.
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The mean counts per minute (CPM) for each concentration of inhibitor were 
compared with control CPM, using a students t-test. P values less than or equal to 
0.05 were considered significant inhibition of parasite growth.
In addition, 1x10s HFF were grown in four 1ml chamber Lab-Tek slides (Miles, 
Naperville, IL, USA). When fully confluent (48-72 hours) up to 750pl o f media was 
removed from each well. Cultures were infected with lxlO4 tachyzoites o f the RH 
strain and incubated for one hour as for the 96-well plates. Inhibitor compounds (250 
pi) were added and the slides were incubated for four days. After this time each well 
was washed 3 times in HBSS. The slides were then fixed in 0.4% aminoacridine in 
50% ethanol for 1 hour, stained with 10% giemsa for 10 minutes and mounted with a 
cover slip for microscopic evaluation.
Product rescue assay to evaluate the specificity o f NPMG
To confirm that NPMG was inhibiting the shikimate pathway and ultimately PABA 
synthesis, parasite inhibition assays were performed in the presence o f exogenous 
PABA, a product of the shikimate pathway. PABA (Sigma) was initially dissolved in 
100% ethanol and then diluted in IMDM to give a lOmM solution. The solution was 
adjusted to pH 7.0 with 10N NaOH and filter sterilised. A toxicity assay was 
performed for PABA and for ethanol at corresponding dilutions.
In the parasite growth inhibition assay 2xl03 tachyzoites were added to confluent 
HFF in a 96 well plate. After an incubation period of one hour, PABA was added at 
concentrations ranging from 2.5pM to lOOpM to triplicate wells followed 
immediately by NPMG (4.5mM), sulphadiazine (12.5pg/ml) or pyrimethamine
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(O.lpg/ml). Cultures were incubated for four days. During the last 18 hours of 
culture, cells were pulsed with tritiated uracil (2.5|iCi/well). The cells were then 
harvested and tritiated uracil uptake measured by liquid scintillation on a P-counter.
Synergy assays
The ability o f NPMG to act in combination with conventional anti-folate drugs and 
SHAM was tested. Using the parasite growth inhibition assay, a concentration which 
achieved approximately 50% inhibition o f parasite growth was identified for NPMG 
(3.125mM), pyrimethamine (0.025|ig/ml), sulphadiazine (6.25fig/ml) and SHAM 
(0.19pg/ml). These concentrations were then used in the parasite growth inhibition 
assay alone and in combination to determine whether combinations o f these drugs 
resulted in an additive, synergistic or inhibitory interaction. Inhibitor compound 
combinations were considered synergistic if the actual to predicted ratio of parasite 
growth inhibition was less than 0.5. The predicted inhibition of parasite growth was 
calculated as [(CPM Drug A x CPM Drug B)/CPM of untreated cultures].
In vivo survival experim ents
The highly virulent RH strain of T.gondii was used in survival experiments. 
Tachyzoites of the RH strain were obtained from the peritoneal exudate of ND4 mice 
(Jackson laboratories) infected intraperitoneally 3 days previously. ND4 mice, age 8- 
10 weeks, were then infected intraperitoneally with 500 tachyzoites. This inoculum is 
lethal in untreated mice, usually by day 8 to 10. Immediately following infection, mice 
were administered either NPMG (1 OOmg/kg/day), pyrimethamine (12.5mg/kg/day) or 
sulphadiazine (85mg/kg/day) as a drinking water additive. SHAM (40mg/kg/day) was
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administered by intraperitoneal injection. A combination o f NPMG (lOOmg/kg/day) 
and pyrimethamine (12.5mg/kg/day) was also given as a drinking water additive. 
Mortality was then recorded daily. After 30 days the drugs were withdrawn from 
surviving mice. The number o f surviving mice in untreated control and treated groups 
was compared using a non-parametric Mann Whitney U-test.
Sequencing of chorism ate synthase from T.gondii
The WashU-Merck Toxoplasma EST project database (Washington University, 
St.Louis, MO, USA) was searched for sequences with homology with any shikimate 
pathway enzyme. A clone was found with homology to chorismate synthase o f 
tomato. This EST clone, TgESTzyllc05.rl, (putative chorismate synthase), was 
obtained from the T.gondii EST project, . This clone was supplied as a phage stock 
which contained a cDNA insert from the tachyzoite stage (RH strain). The insert had 
been cloned into the Xhol (3’) to EcoRI (5’) site of the Lambda Zap II phage 
(Stratagene, La Jolla, CA, USA).
In vivo excision
Kcoli for use in the in vivo excision protocol were prepared as follows. E.coli (XL1- 
Blue, Stratagene) were grown in NZY (Select agar, Gibco, casamino acids and yeast 
extract, both from Becton-Dickinson, Franklin Lakes, NJ, USA) containing 0.2% 
maltose and lOmM MgS04 in a shaking incubator at 37°C until an ODeoo of 0.5 was 
obtained. Cells were then centrifuged for 10 minutes at lOOOg and the resulting pellet 
resuspended in half the original volume of lOmM MgS04. These cell suspensions were 
then stored at 4 °C until ready for use.
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Phagemid particles containing the putative chorismate synthase clone were obtained 
by following the in vivo excision protocol as recommended by Stratagene. Briefly 
200fil o f the E.coli, XL 1-blue, cell suspension was combined with 200fil o f the 
Lambda Zap II phage stock, containing the EST clone and 1 pi o f R408 helper phage 
(Stratagene). This mixture was incubated at 37°C for 15 minutes. Following this, 5mls 
of 2 times YT media (yeast extract, Becton-Dickinson, and tryptone extract, Difco) 
was added and cells suspensions incubated for a further 3hours at 37°C with shaking. 
Next, the cell suspension was placed in a water bath at 70°C for 20 minutes to lyse the 
cells, and then centrifuged for 5 minutes at 4000g. The resulting supernatant which 
contained the pBluescript phagemid as filamentous phage particles was decanted and 
stored at 4°C until ready for use.
Cloning
Aliquots (200pl) of the supernatant containing pBluescript phagemid were used to 
infect 200pl of XL 1-blue host cells. Following a 15 minute incubation, lOOpl of each 
suspension was plated onto Luria Broth Agar (Gibco) containing ampicillin (50pg/ml) 
(LB/Amp) and incubated overnight at 37°C. Colonies were picked from these plates 
and used to inoculate 5ml cultures of LB/Amp. These cultures were incubated 
overnight at 37°C with shaking. Plasmid DNA was purified from these cultures using 
a Wizard mini-prep kit (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions.
The cDNA insert was then obtained from the plasmid DNA by simultaneously 
digesting the plasmid with restriction enzymes, Xhol and EcoRl (Boehringer
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Mannheim, Indianapolis, IN, USA). The digests were performed for 1 hour at 37°C. 
Digest products were separated by 1% agarose gel electrophoresis and visualised 
using ethidium bromide. Analysis revealed an insert of approximately 2.4kB in 8 out 
o f 10 cultures examined.
A sample of one of these original cultures was used to subinoculate 25mis cultures o f 
LB/Amp and incubated at 37°C, overnight with shaking. Sequencing quality plasmid 
DNA was purified from this culture using a Qiagen maxi-prep kit (Qiagen, Santa 
Clarita, CA, USA). The absorbance of the resulting DNA was measured at 260 and 
280nm and purity assessed by OD26o/OD2go. The concentration o f the DNA was then 
calculated as OD26ox50x100 (dilution factor). The concentration of the DNA was then 
adjusted to 200pg/ml for sequencing.
Sequencing
Sequencing was performed using the automated sequencer at the University of 
Chicago, Molecular Biology Facility. Templates consisted of the full length clone or 
subclones in Bluescript SK or KS plasmids (Stratagene). Primers were M l3, or 
reverse (Stratagene), or were custom made according to sequencing information 
already obtained. The sequence of custom made primers is shown in Table 5.1.
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Table 5.2 Nucleotide sequences of custom designed primers
PRIMER SEQUENCE
1 5* TGT CCA AGA TGT TCA GCC T 3 '
2 5 ' AGG CTG ATC ATC TTG GAC A 3 '
3 5 ' TCG GGT CTG GTT GAT TTT 3 '
4 5 ' GAG AGA GCG TCG TGT TCA T 3 '
5 5 ' ATG AAC ACG ACG CTC TCT C 3 '
6 5 ' CAT GTC GAG AAG TTG TTC 3 '
7 5 ' GAA CAA CTT CTC GAC ATG 3 '
8 5 ' ACT TGT GCA TAC GGG GTA C 3 '
9 5 ' GTA CCC CGT ATG CAC AAG T 3*
10 5 ’ TGA ATG CAA CTG AAC TGC 3 '
11 5 ' GCA GTT CAG TTG CAT TCA 3 '
12 5 ' AGC CGT TCC GTG TAT AAT C 3 '
13 5 ' CTA CGG CAC CAG CTT CAC 3 '
14 5 ' CGT CCT TCC TCA ACA CAG TG 3
15 5 ' GTG AAG CTG GTG CCG TAG 3 '
16 5 ' CGC CTC TGA TTT GGA AGT G 3 '
17 5* TCT GCC GCA TTC CAC TAG 3 '
18 5 ' GAA GCC AAG CAG TTC AGT T 3 '
Sub-cloning
The plasmid DNA was then digested with combinations of PstI, EcoRI, HincII, and 
Xhol (Boehringer Mannheim). Specifically, simultaneous digestions were performed 
on 10pg of the plasmid DNA with HincII and PstI, and PstI and Xhol for 1 hour at 
37°C. Digest products were separated by 1% agarose gel electrophoresis and 
visualised using ethidium bromide. Analysis o f the HincII and PstI digest showed 3 
bands o f 500kB, 800kB, 300kB and a >4000kB band corresponding to the 
pBluescript. Analysis o f the PstI and Xhol digest showed 2 bands o f 800kB and 
1600kB as well as a >3000kB band corresponding to the pBluescript. This allowed 
construction o f a restriction map (Figure 5 .1).
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pBluescript
Hindi
HincII
E coR I
PstI
F i g u r e  5.1 Restriction map for putative T.gondii chorismate 
synthase  cDNA insert in pBluescript SK plasmid.
The large arrowheads indicates restriction si tes on the plasmid. The 
T.gondii cDNA insert has been cloned into the Xhol (3’) to EcoRI (5’) 
site. The small arrows indicate restriction sites identified within the 
cDNA insert by simultaneous enzyme digests. The sizes of the 
resulting fragments are shown in kB.
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The 800bp fragment from the HincII and PstI digest (corresponding with 800- 
1600bp) and the 800bp fragment from the PstI and Xhol digest (corresponding with 
the last 800bp) were purified from this gel using a Qiax gel purification kit according 
to the manufacturer’s instructions (Qiagen). These portions o f cDNA were then 
ligated into Bluescript SK (Stratagene) using T4 ligase (Promega) at 14 °C overnight. 
These ligation reactions were then used to transform subcloning efficiency D H 5a 
competent cells (Gibco). Specifically 10|il o f ligation reactions were added to 50p.l o f 
competent cells and gently mixed. The cells were incubated on ice for 30 minutes after 
which they were heat shocked for 20 seconds at 37°C . Following heat shock, cells 
were placed on ice for 2 minutes after which 0.95mls of room temperature LB was 
added. The cells were then incubated for 1 hour at 37°C with shaking.
A 50|il aliquot of the transformation mixture was spread on an LB agar plate 
containing lOOpg/ml o f ampicillin and 50|ig/ml of X-gal (Sigma). The plate was 
incubated overnight at 37°C. The following day white colonies were picked and used 
to inoculate 5ml LB/Amp cultures. These cultures were incubated overnight at 37°C 
with shaking. Plasmid DNA was purified from these cultures using a Wizard mini- 
prep kit (Promega) according to the manufacturer’s instructions.
To confirm the identity of the subclones, restriction enzyme digests were performed 
on the plasmid DNA followed by agarose gel electrophoresis as before. Samples o f 
corresponding cultures was then used to subinoculate 25mls cultures o f LB/Amp for 
the preparation o f sequencing quality plasmid DNA. Sequencing o f the subclones was 
performed as previously described.
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Analysis o f cDNA and predicted amino acid sequences
Sequencing chromatograms were edited and nucleotides assembled using Sequencer 
Version 3.1 (Gene Codes Corporation, Ann Arbor, MI, USA). Both strands o f the 
entire clone were sequenced at least once but usually twice. The resulting nucleotide 
sequence was analysed for open reading frames (ORF) using Sequencer. A list o f 
chorismate synthases from other organisms was obtained from Genbank (Accession 
numbers. Synechocystis, P23353; Solatium lycopersicum, Z21796; Saccharomyces 
cerevisiae, P28777; Neurospora crassa, Q 12640; Haemophilus influenza, P43875; 
Plasmodium falciparum, AF008549). The predicted amino acid sequence was aligned 
with chorismate synthases o f other organisms using CLUSTAL X (Thompson et al., 
1997).
Demonstration of alternative oxidase by SDS-PAGE and w estern 
blotting
Samples
Tachyzoites (RH) were obtained from the peritoneal exudate of infected ND4 mice. 
After centrifugation the pellet was subjected to 3 cycles of freeze thawing. Protein 
concentration was measured using the Bradford assay (Bradford, 1976). 30pg of 
tachyzoites were loaded for each centimetre of gel.
A T.gondii mitochondrial enriched extract was donated by Stan Tomavo, Pasteur 
Institute, France. 10pg o f protein was loaded for each centimetre o f gel.
Sauromatum guttatum (Voodoo lily) mitochondrial protein (donated by Lee 
McIntosh, Michigan State University, USA) and T.bruceii mitochondrial protein
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(donated by George Hill, Meharry Medical College, Tennessee, USA) were used as 
positive controls. 30pg of Voodoo lily mitochondrial protein and 10 (ig of T.bruceii 
mitochondrial protein were loaded for each centimetre of gel.
Prior to use samples were stored at 4°C. For SDS-PAGE they were boiled for 5 
minutes in sample buffer (75mM Tris, 5% glycerol, 1% SDS and 0.001% 
bromophenol blue, pH 6.8). For Urea-SDS-PAGE samples were boiled for 10 
minutes in sample buffer containing 6.0M urea. 2-mercaptoethanol (1%) was added to 
all samples immediately before loading.
Primary Antibodies
Murine polyclonal antibody to T.bruceii alternative oxidase (serum), murine 
monoclonal antibody to T.bruceii alternative oxidase (7D3) and murine monoclonal 
antibody to T.bruceii alternative oxidase (IA2) (both hybridoma tissue culture 
supernatants) were all donated by George Hill, Meharry Medical College, Tennessee, 
USA. The polyclonal antibody was used at a dilution of 1 in 1000. Both monoclonal 
antibodies were used at a 1 in 100 dilution.
Murine polyclonal antibody to Voodoo lily alternative oxidase (serum) and murine 
monoclonal antibody to Voodoo lily alternative oxidase (a hybridoma tissue culture 
supernatant) were donated by Lee McIntosh, Michigan State University, USA. The 
polyclonal and monoclonal antibodies were used at a dilution of 1 in 1000 and 1 in 
500 respectively.
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All primary antibodies were diluted in Phosphate Buffered Saline, 0.1%TWEEN-20 
(PBS/Tween).
Secondary Antibody
Horse Radish Peroxidase (HRP) conjugated goat anti-mouse antibody (Sigma) was 
diluted 1 in 800, in PBS/TWEEN.
SDS-PAGE
Gels containing 10% (separation gel) or 3% (stacking gel) acrylamide were prepared 
from a stock solution o f 30% acrylamide and 0.8% N,N’-bis-methylene acrylamide. 
The separation gel also contained 0.375M Tris-HCl (pH 8.8) and 0.1% sodium 
dodecylsulphate (SDS). Similarly the stacking gel contained 0.125M Tris-HCl (pH 
6.8) and 0.1 % SDS. The gels were polymerised by the addition of 0.025% 
tetramethylethylenediamine (TEMED) (Sigma) and ammonium persulphate (Sigma). 
When polymerised the gel was immersed in electrode buffer (pH 8.3) containing 
0.025M Tris, 0.192M glycine and 0.1% SDS. Samples were loaded onto the gel and 
electrophoresed for 1 hour at 200V. Following electrophoresis the samples were 
transferred to a PVDF membrane (Micron Separations Inc., Westborough, PA,USA) 
at 4°C using a semi-dry electro-blotter.
Urea- SDS-PAGE
Urea-SDS-PAGE was performed as for SDS-PAGE with the addition o f 2.5M urea 
to both separation and stacking gels.
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Western blotting
After protein transfer, the PVDF membrane was blocked in PBS, 10% dried milk, 
0.1%TWEEN 20, for 1 hour at room temperature. Following three washes in 
PBS/TWEEN the membrane was incubated with primary antibody for 1 hour at room 
temperature on a shaking plate. Negative controls were incubated in PBS/TWEEN 
without primary antibody. The membrane was then washed three times in 
PBS/TWEEN prior to a similar 1 hour incubation with the secondary antibody. The 
membrane was washed a further 3 times in PBS/TWEEN followed by a final wash in 
PBS.
Detection o f proteins was performed by enhanced chemoluminesence (ECL). The 
membranes were incubated with ECL reagents 1 and 2 (Amersham) for 2 minutes. 
The membrane was then immediately applied to Hyperfilm ECL (Amersham) and left 
in the dark for up to 1 hour before developing.
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5.4 Results
The Shikimate Pathway
In vitro experim ents
Toxicity assays
NPMG was found to be non-toxic to HFF at doses of lOmM and below, p>0.304 
(Figure 5.2A). Serial dilutions of NPMG (4.5 to 1.56mM) were then used in the 
parasite growth inhibition assays.
Parasite growth inhibition assays
NPMG inhibited the growth of T.gondii tachyzoites in a dose dependent manner 
(4.5mM, p<0.0001), (Figure 5.2B). Similarly inhibition of parasite growth was 
visualised in giemsa stained preparations. Only small numbers o f parasites were seen 
in NPMG treated cultures and the fibroblast monolayer was otherwise intact and 
appeared normal. In contrast, in control cultures there was extensive destruction o f 
the monolayer and remaining groups of cells infected with tachyzoites (Figure 5.2C).
Product rescue assays
PABA was found to be non-toxic to HFF at doses o f 5mM and below, (p>0.956). 
Ethanol was also non-toxic to HFF at this dilution (1 in 73; p>0.977). Addition o f 
exogenous PABA ablated the inhibitory effects o f NPMG on the growth of T.gondii 
in a dose-dependant manner (Figure 5.3 A). For example, at a concentration o f lOpM, 
PABA reduced NPMG inhibition of parasite growth by 60%. However 2.5pM PABA 
was unable to ‘rescue’ parasites from the inhibitory effects of NPMG. As a direct 
antagonist, PABA was also able to ablate the effects o f sulphadiazine in a dose
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dependent manner. However, as anticipated, it was unable to ablate the effects of 
pyrimethamine which acts on dihydrofolate reductase an enzyme further downstream 
in the folate synthesis pathway (Figure 5.3B).
Synergy assays
NPMG was found to act synergistically with both sulphadiazine and pyrimethamine to 
restrict the growth of T.gondii in vitro (Table 5.1). Thus at a concentration of 
3.25mM NPMG and 6.25pg/ml sulphadiazine both inhibited parasite growth by 60%. 
In combination they were able to inhibit 97% of parasite growth which was greater 
than the 86% predicted if the effect was purely additive. Similarly pyrimethamine was 
completely ineffective at restricting parasite growth at a concentration o f 0.025pg/ml. 
However in combination with NPMG it increased the inhibition o f parasite growth 
from 60% to 86%.
In vivo survival experim ents
The survival o f mice treated with NPMG or pyrimethamine alone was not significantly 
enhanced compared with that of untreated control mice. However, simultaneous 
administration of NPMG and pyrimethamine protected approximately 50% of mice 
from death. This difference in survival was significant when compared with untreated 
mice or mice administered NPMG or pyrimethamine alone (p<0.05), (Figure 5.4). 
Furthermore, surviving mice showed no apparent illness and remained sleek and 
healthy in appearance during the 30 days o f treatment after infection. Following 
withdrawal o f the drugs the mice remained well and showed no signs o f disease 
reactivation. Control mice treated with high dose sulphadiazine all survived.
127
A
25000
20000 -
^  15000 -
Q.
O
10000 -
5 0 0 0 -
o
B
log.concentration (mM)
o
80000 -i
60000 -
40000 -
20000  -
"T"------1---------1---------r
X  x  CO co c \ j  in
= = 3: * 5  *
NPMG (mM)
F ig u re  5 .2  A The toxicity of NPMG to HFF a s  m easu red  by 
uptake  of tritiated thymidine. Concentrat ions  of 10mM and 
below were non-toxic to the  fibroblast monolayer  (p>0.304).
(O, control cultures;  □,  NPMG treated cultures). B The effect of 
NPMG on the  growth of T.gondii in HFF a s  m easured  by 
uptake  of tritiated uracil. At a concentrat ion of 4.5mM NPMG 
inhibited over 85% of parasi te  growth (p<0.0001). 
Abbreviations: No RH, uninfected control cultures;  RH, control 
cu l tu res  infected with RH; P/S infected control cu l tures  t rea ted  
with pyrimethamine  and sulphadiazine .
1 2 8
F igure  5.2 continued C The effect of NPMG on the growth 
of T.gondii in HFF. (i) Control cultures showing large groups 
of parasites, destruction of the fibroblast monolayer and 
numerous extracellular parasites (arrow), (ii) Cultures treated 
with NPMG (4.5mM). Only small groups of parasites are identified 
and the fibroblast monolayer is intact. (Giemsa, x 250).
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F ig u re  5.3 A Product rescue  of the inhibitory effect of NPMG on 
the growth of T.gondii. Addition of PABA reduced the effects of 
NPMG and sulphadiazine  in a d o se  d ependen t  manner. PABA had 
no effect on pyrimethamine treated cultures. Key: PABA(O); 
PABA+NPMG(G); PABA+sulphadiazine(B);  and PABA+ 
p y r im e th a m in e (# ) .  Abbreviations: No RH, uninfected control 
cultures;  RH, control cultures infected with RH; P/S, infected 
cu l tu res  t reated with pyrimethamine and sulphadiazine;  S, P and 
NPMG, infected cul tures  treated with sulphadiazine,  pyrimeth­
amine  and NPMG, respectively. B Diagram of the shikimate 
pathway and folate syn thes is  pathway showing site of action of 
NPMG, su lphad iaz ine  and pyrimethamine.  NPMG inhibits  EPSP 
sy n th a s e  above  PABA in the  shikimate pathway. Sulphadiazine  
co m p e te s  with PABA for d ihydropteroate  sy n th a se  (DHPS). 
Pyrimethamine ac ts  below PABA on dihydrofolate  r ed u c ta se  
(DHFR).
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Figure 5.4 In vivo activity of NPMG and pyrimethamine 
a ga ins t  T.gondii infection in mice. Treatment with either drug 
a lone  w as  not sufficient to prevent death  (■, NPMG;#, 
pyrimethamine) compared  with control mice (O). In contras t  
50% of mice administered NPMG and pyrimethamine 
s im ul taneous ly  (□) survived infection (at 7 days  p o s t ­
infection,  p<0.05).
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Sequencing of chorism ate synthase from T.gondii
Both strands o f the putative T.gondii chorismate synthase were sequenced and found 
to be 2312 bases in length (Figure 5.5a). Analysis revealed a large open reading frame 
o f 1608 base pairs which would encode a 536 amino acid protein. The deduced amino 
acid sequence has considerable identity (44.5 to 51.4%) with chorismate synthases of 
diverse species (Figure 5.5b). Furthermore the putative T.gondii chorismate synthase 
shares all the amino acids known to be highly conserved in chorismate synthases of 
other organisms. The main difference between the putative T.gondii protein and other 
known chorismate synthases is in length. Chorismate synthases from other organisms 
range in length from 357 to 432 amino acids. The larger size o f the T.gondii protein is 
mainly due to a number of insertions which on the basis of their amino acid 
composition appear to form exposed loops.
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ACT TTT CTT TGA GTG CCT GTG TGA GAG
TCC TCC GCT CAC GCC TTT CCT CAC AGT
ACA CAT CCC GCT CGT TCC GCT GCA TCT
ATG TCT TCC TAT GGA GCC GCT CTG CGC
M S S Y G A A L R
CAC GGC TCA GCC GTT GGG TGT ATA ATC
H G S A V G C I I
CCT CTT TCT GTC GAA GAT GTT CAG CCT
P L S V E D V Q P
GGC CAA GGG CCT CTC TCG ACG CAG CGG
G Q G P L S T Q R
ATA CTC TCC GGT GTT GAA GAC GGA TAT
I L S G V E D G Y
ATG CTC GTC TGG AAT GAA GAC CGG CGG
M L V W N E D R R
GCG ACA GTC CCG CGT CCA GGT CAC GGG
A T V P R P G H G
TAG CAC ATT CAC GCG AAA AGC GGG GGC
Y H I H A K S G G
ACT TTG GCG CGC GTC GCC GCT GGA GCA
T L A R V A A G A
ATG CAC TAC GGC ACC AGC TTC ACA GCT
M H Y G T S F T A
GTC TCT GTG CCC CGA TCG CTC CGA AGA
V S V P R S L R R
ACT CGC CAA GAC GTC GAT CGC CTT GGC
T R Q D V D R L G
GGA ACC ACA TTT CTC GAC GCG AAC AAC
G T T F L D A N N
GAG GAA CTC GTC GAG GAG GAA GAC AAA
E E L V E E E D K
GGA GTC GAC AAC CCG ACG CCA GGA GAA
G V D N P T P G E
CCG TGC CCC TCC ACA GCT GTT CGC ATG
P C P S T A V R M
CGA TCT CTG GGC GAT TCG ATT GGC GGA
R S L G D S I G G
CGG CCA CCG CTG GGC CTC GGC GAG CCG
R P P L G L G E P
GAG CTG GCG AAG GCG ATG ATG TCG CTC
E L A K A M M S L
ATT GGC CAG GGC TTT GCG AGT GTC ACG
I G Q G F A S V T
GAC CGC TTC ATT CCC TTC GAG AGA GCG
D R F I P F E R A
GCC GCG AGC ACG ATC AAG CAT GAA AGA
A A S T I K H E R
CTC TCA CGG GAG CGA GCG AGT GAC GGT
L S R E R A S D G
GAG GAG GTG GAA AGG GGG CGG GAG CGC
E E V E R G R E R
GTT ACT GGT GTA GAT CAG CAA AAC GGC
V T G V D Q Q N G
CT CAT CTT CTC GGT TTC 17
ACG GTC GTC GCA ACA AGA ATC 65
CCT GTT TTT CCT CCA GCT GTC 113
CCT CAC ATT TCT TGC AGT CAG 161
ATA CAC ACT TTC GGT GAA TCT 2 0 9
I H T F G E S 16
GAC GGG CTG CCT CCT CGC CTC 2 5 7
D G L P P R L 32
CAA TTA AAT CGC AGA AGA CCC 3 0 5
Q L N R R R P 48
AGA GAG AAA GAT CGA GTC AAC 3 5 3
R E K D R V N 64
ACA CTC GGT ACT CCC CTG GCG 4 0 1
T L G T P L A 80
CCC CAG GAC TAC CAC GCC CTC 4 4 9
P Q D Y H A L 96
GAT TTC ACC TAC CAT GCA AAG 4 9 7
D F T Y H A K 112
GGT CGG AGC AGC GCG CGG GAG 5 4 5
G R S S A R E 128
GTC GTT GAG AAG TGG CTA GGC 5 9 3
V V E K W L G 144
TGG GTC TGT CAG GTT GGT GAT 6 4 1
W V C Q V G D 160
AAG TGG GAG CGG CAG CCG CCA 6 8 9
K W E R Q P P 176
GTG GTC CGC GTG AGC CCA GAT 7 3 7
V V R V S P D 192
CGC CTT TAC GAC GAG CGA GGA 7 8 5
R L Y D E R G 208
GCC AGG CGT CGG CTT CTT TTC 8 3 3
A R R R L L F 224
ACA GTG ATT GAG ACC AGG TGC 8 8 1
T V I E T R C 240
GCT GTG AAA ATC AAC CAG ACC 9 2 9
A V K I N Q T 256
TGC ATC TCC GGT GCA ATC GTG 9 7 7
C I S G A I V 272
TGT TTC GAC AAA GTG GAG GCG 1 0 2 5
C F D K V E A 288
CCT GCT ACG AAA GGG TTT GAG 1 0 7 3
P A T K G F E 304
TTG CGA GGC AGC GAG CAC AAC 1 1 2 1
L R G S E H N 320
TCG TGT TCA TTC TCG GAA TCA 1 1 6 9
S C S F S E S 336
GAT GGG TGT TCA GCT GCT ACA 1 2 1 7
D G C S A A T 352
AGA ACA ACT TCT CGA CAT GAA 1 2 6 5
R T T S R H E 368
ATA CAG CGC GAT ACC CTC CAT 1 3 1 3
I Q R D T L H 384
AAC TCC GAA GAT TCA GTT CGA 1 3 6 1
N S E D S V R 396
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TAC ACT TCC AAA TCA GAG GCG TCC ATC ACA AGG CTG TCG GGA AAT GCT 1 4 0 9
Y T S K S E A S I T R L S G N A 416
GCC TCT GGA GGT GCT CCA GTC TGC CGC ATT CCA CTA GGC GAG GGA GTA 1 4 5 7
A S G G A P V C R I P L G E G V 432
CGG ATC AGG TGT GGA AGC AAC AAC GCT GGT GGA ACG CTC GCA GGC ATT 1 5 0 5
R I R C G S N N A G G T L A G I 448
ACA TCA GGA GAG AAC ATT TTT TTT CGG GTG GCC TTC AAG CCT GTT TCT 1 5 5 3
T S G E N I F F R V A F K P V S 464
TCC ATC GGC TTG GAA CAA GAA ACT GCA GAC TTT GCT GGT GAA ATG AAC 1 6 0 1
S I G L E Q E T A D F A G E M N 480
CAG CTA GCT GTG AAA GGC CGC CAC GAT CCC TGC GTC CTT CCG CGA GCC 1 6 4 9
Q L A V K G R H D P C V L P R A 496
CCT CCT CTG GTT GAG AGC ATG GCT GCC CTT GTG ATT GGC GAT CTG TGC 1 6 9 7
P P L V E S M A A L V I G D L C 512
CTC CGC CAG CGC GCC CGG GAA GGG CCG CAC CCC CTT CTC GTC CTT CCT 1 7 4 5
L R Q R A R E G P H P L L V L P 528
CAA CAC AGT GGT TGC CCA TCT TGC TGA GCT CTA CCT TGT TCC AAA AAC 1793
Q H S G C P S C * 536
TTG TGC ATA CGG GGT ACA CCA GGT TCC TCA CAA GGA GAA TCG TGA GGC 184 1
GGT GAC TGG CCA GCG CCA CAG ATT GCT GTT CAT GCA CAA GAA AGA AAA 1889
CAG CGC ATT TCC GCC ACA ACC CAG CTG CAT GAA GTT GCT GGA TAT CGT 1937
TCC GGC GGT GCT CGG CCT TCT TCT CTA CGC TCG CGA TGA TAC GTC GCG 1985
AGC TTC ATC AAG CTC CTT TTG CAT TGT TAG TGG CTC CCA ACA GAA CCC 203 3
TTT GTG GAA GGG AAT CTG GTC TCA CGC TTG CAG GAG AGA GTT CGC CTT 2 0 8 1
TGT TCA CGA AAT AAC GAA GCC AAG CAG CTC AGT TGC ATT CAG CCT GCA 212 9
CAC AGT TGC ATT CAG CCT GCA CAC TAA ACA CGG GCG AAA TCG TCG CGT 2 1 7 7
GAT ATG TAG TTC TTC GGT TGT CAC GGT GAT TGT CGT CGT GTT TGA ACA 2 2 2 5
ACT AAA CGT TTC TAA TGC TGG ATC TTA AAA AAA AAA AAA AAA AAA AAA 2273
AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2 3 1 2
Figure 5.5A The cDNA and deduced amino acid sequences of T.gondii 
chorismate synthase. The cDNA sequence was found to be 2312 base 
pairs in length. It contains a long open reading frame of 1608 base pairs 
(bold) that encodes a 536 amino acid protein. The deduced amino acid 
sequence of this open reading frame is shown beneath the cDNA 
sequence.
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S y n e c h o c y s t i s   MGNTFG
S . l y c o p e r s i c u m  MASFVPTKQFVGASSSSDIGSSRLVSLQLPSKFSSSNFHLPSRPSQLKRLEIQAAGSTFG
S . c e r e v i s i a e   MSTFG
N.  c r a s s a   MSTFG
H. i n f l u e n z a   MAGNTIG
T . g o n d i i   MSSYG
P . f a l c i p a r u m   MSTYG
*
S y n e c h o c y s t i s  SLFRITTFGESHGGGVGVIIDGCPPRLEISPEEIQVDLDRRRPGQSKITTPRKEADQCEI
S . l y c o p e r s i c u m  NYFRVTTFGESHGGGVGCIIDGCPPRLPLSESDMQVELDRRRPGQSRITTPRKETDTCKI
S . c e r e v i s i a e  KLFRVTTYGESHCKSVGCIVDGVPPGMSLTEADIQPQLTRRRPGQSKLSTPRDEKDRVEI
N . c r a s s a  HYFRVTTYGESHCKSVGCIVDGVPPGMELTEDDIQPQMTRRRPGQSAITTPRDEKDRVII
H . i n f l u e n z a  QLFRVTTFGESHGIALGCIVDGVPPNLELSEKDIQPDLDRRKPGTSRYTTPRREDDEVQI
T . g o n d i i  AALRIHTFGESHGSAVGCIIDGLPPRLPLSVEDVQPQLNRRRPGQGPLSTQRREKDRVNI
P . f a l c i p a r u m  TLLKVTSYGESHGKAIGCVIDGFLSNIEINFDLIQKQLDRRRPNQSKLTSNRNEKDKLVI
*  *  *  *  *  *  *  *  *  *  *  *  *  *  *
S y n e c h o c y s t i s  LSGVFEGKTLGTPIAILVRNKDARSQDYN--EMAVKYRPSHADATYEAKYGIRNWQGGGR
S . l y c o p e r s i c u m  SSGTADGLTTGSPIKVEVPNTDQRGNDYS- -EMSLAYRPSHADATYDFKYGVRSVQGGGR
S . c e r e v i s i a e  QSGTEFGKTLGTPIAMMIKNEDQRPHDYS--DMDKFPRPSHADFTYSEKYGIKASSGGGR
N . c r a s s a  QSGTEFGVTLGTPIGMLVMNEDQPPKDYGNKTMDIYPRPSHADWTYLEKYGVKASSGGGR
H . i n f l u e n z a  LSGVFEGKTTGTSIGMIIKNGDQRSQDYG--DIKDRFRPGHADFTYQQKYGIRDYRGGGR
T . g o n d i i  LSGVEDGYTLGTPLAMLVWNEDRRPQDYH- -ALATVPRPGHGDFTYHAKYHIHAKSGGGR
P . f a l c i p a r u m  LSGFDENKTLGTPITFLIYNEDIKKEDYN- -SFINIPRPGHGDYTYFMKYHVKNKSGSSR
* * A A ★ ★ ★ ★ *★ *★ ★ ★ ★ * ★ ★
S y n e c h o c y s t i s  
S . l y c o p e r s i c u m  
S . c e r e v l s l a e  
N . c r a s s a  
H . i n f l u e n z a  
T. g o n d i i  
P . f a l c i p a r u m
S SARETIGRVAAGAIAKKILAQFNGVEIVAYVKSIQDI.......................
S S ARETIGRVAAGAVAKKILKL Y S GAEVLAYV S Q V H QWL P  -.............
ASARETIGRVASGAIAEKFLAQNSNVEIVAFVTQIGEIKMN....................
SSARETIGRVAAGAIAEKYLKPRYGVEIVAFVSSVGSEHLFPPTAEHP............
SSARETAMRVAAGAIAKKYLREHFGIEVRGFLSQIGNIKIAP..................
SSARETLARVAAGAWEKWLGMHYGTSFTAWVCQVGDVSVPRSLRRKWE-RQPPTRQDVD 
FSGRETATRVAAGACIEQWLYKSYNCSIVSYVHSVGNIKIPEQVSKELENKNPPSRDLVD 
*  *  *  *  * * * * *  *
S y n e c h o c y s t i s  
S . l y c o p e r s i c u m  
S . c e r e v i s i a e  
N. c r a s s a  
H . i n f l u e n z a  
T . g o n d i i  
P . f a l c i p a r u m
............ EATVDSNTVTLE-
............EDLIDHQNVTLE•
..... RDSFDPEFQHLLNTITRE■
..... SPSTNPEFLKLVNSITRE■
.............. QK-VGQIDWE-
RLGWRVS PDGTTFLDANNRLYDE ■
SYGTVRYNEKEKIFMDCFNRIYDMNASMLKTDEYNKNTLTIPSIDNTYINVKTNECNINQ
S y n e c h o c y s t i s  
S . l y c o p e r s i c u m  
S . c e r e v i s i a e  
N. c r a s s a  
H . i n f l u e n z a  
T. g o n d i i  
P . f a l c i p a r u m
VESN.......................... IVRCPDEECAEKMIERIDQVLRQKDSIGGW
IESN.......................... IVRCPDPEYAEKMIAAIDAVRVRGDSVGGW
VDSMG......................... PIRCPDASVAGLMVKEIEKYRGNKDSIGGW
VDSFL......................... PVRCPDAEANKRMEDLITKFRDNHDSIGGTV
VNSN.......................... PFFCPDESAVEKFDELIRELKKEGDSIGAKL
GEELVEEEDKARRRLLFGVDNPTPGETVIETRCPCPSTAVRMAVKINQTRSLGDSIGGCI 
VDNNHNNYINDKDN-TFNNSEKSDEWIYLQTRCPHPYTAVQICSYILKLKNKGDSVGGIA
*  *  *  *  *  *
S y n e c h o c y s t i s  
S . l y c o p e r s i c u m  
S . c e r e v i s i a e  
N. c r a s s a  
H . i n f l u e n z a  
T. g o n d i i  
P . f a l c i p a r u m
ECAIRNAPKGLGEPVFDKLEADLAKAMMSLPATKGFEFGSGFAGTLLTGSQHNDEYYLDE
TCIVRNLPRGLGTPVFDKLEAELAKACMSLPATKGFEFGSGFAGTFMTGSEHNDEFYMDE
TCWRNLPTGLGEPCFDKLEAMLAHAMLSIPASKGFEIGSGFQGVSVPGSKHNDPFYFEK
TCVIRNVPSGLGEPAFDKLEAMLAHAMLSIPATKGFEVGSGFGGCEVPGSIHNDPFVSAE
TVIAENVPVGLGEPVFDRLDADLAHALMGINAVKGVEIGDGFAWEQRGSEHRDEMTPNG
SGAIVRPPLGLGEPCFDKVEAELAKAMMSLPATKGFEIGQGFASVTLRGSEHNDRFIPFE
TCIIQNPPIGIGEPIFDKLEAELAKMILSIPPVKGIEFGSGFNGTYMFGSMHNDIFIPVE
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S y n e c h o c y s t i s  AGE.............................................................
S . l y c o p e r s i c u m  HGR..............................................................
S . c e r e v i s i a e  ETN..............................................................
N . c r a s s a  NTEIPPSVAASGAARNGI.............................................
H . i n f l u e n z a  FES..............................................................
T. g o n d i  i RASCSFSESAASTIKHERDGCSAATLSRERASDGRTTSRHEEEVERGRERIQRDTLHVTG
P.  f a l c i p a r u m  NMSTKKESDLLYDDKGECKNMSYHSTIQNNEDQILNSTKGFMPPKNDKNFNNIDDYNVTF
S y n e c h o c y s t i s   WRTRTNRSGGVQGG
S . l y c o p e r s i c u m  .................................................IRTRTNRSGGIQGG
S . c e r e v i s i a e   RLRTKTNNSGGVQGG
N. c r a s s a   PRPKLTTKTNFSGGIQGG
H . i n f l u e n z a   NHAGGILGG
T . g o n d i i  VDQQNGN S ED S VR YTS K S EASITRL S GNAAS GGA P VCR IPLGEGVRIRCG SNNAGGTLAG
P.  f a l c i p a r u m  NNN..........................................EEKLLITKTNNCGGILAG
* * ★ *
S y n e c h o c y s t i s  ISNGEPIIMRIAFKPTATIGQEQKTVSNIG - EETTLAAKGRHDPCVLPRAVPMVEAMAAL
S .  l y c o p e r s i c u m  ISNGEVINMRIGFKPTSTISRKQQTVTRDK-HETELIARGRHDPCWPRAVPMVEAMVAL
S . c e r e v i s i a e  ISNGENIYFSVPFKSVATISQEQKTATYDG - EEGILAAKGRHDPAVTPRAIPIVEAMTAL
N. c r a s s a  ISNGAPIYFRVGFKPAATIGQEQTTATYDGTSEGVLAAKGRHDPSWPRAVPIVEAMAAL
H . i n f l u e n z a  ISSGQPIIATIALKPTSSITIPGRSINLNG - EAVEWTKGRHDPCVGIRAVPIAEAMVAI
T . g o n d i i  ITSGENIFFRVAFKPVSSIGLEQETADFAG- EMNQLAVKGRHDPCVLPRAPPLVESMAAL
P . f a l c i p a r u m  ISTGNNIVFRSAIKPVSSIQIEKETSDFYG-NMCNLKVQGRHDSCILPRLPPIIEASSSM
* ★ * * * ★ ★ ★ * ★ * *
S y n e c h o c y s t i s  VLCDHLLRFQAQCKTL................................ .
S . l y c o p e r s i c u m  VLVDQLMAQYSQCMMFPINPELQEPLQSSPESAEVTL...........
S . c e r e v i s i a e  VLADALLIQKARDFSRSWH..............................
N . c r a s s a  VIMDAVLAHEARVTAKSLLPPLKQTINSGKDTVGNGVSENVQESDLAQ
H . i n f l u e n z a  VLLDHLLRFKAQCK....................................
T . g o n d i i  VIGDLCLRQRAREGPHPLLVLPQHSGCPSC...................
P . f a l c i p a r u m  VIGDLILRQISKYGDKKLPTLFRNM........................
*  *
Figure 5.5 B Comparison of the deduced amino acid sequence of T.gondii 
chorismate synthase with chorismate synthase from other organisms. The 
deduced amino acid sequence has considerable identity with chorismate 
synthases of diverse species: Plasmodium falciparum (49.7%);
Synechocystis (51.4%); Saccharomyces cerevisiae (49.6%); Solanum 
lycopersicum (47.2%); Neurospora crassa (45.0%) and Haemophilus 
influenza (44.5%). * indicates an amino acid which is conserved in all 6 
species.
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The Alternative Pathway of Respiration
In vitro experim ents
Toxicity assays
SHAM was found to be non-toxic to HFF at doses o f 3.12fig/ml and below, 
(p>0.375), (Figure 5.6a). Ethanol was also non-toxic at this dilution, (p>0.375).
8-HQ was non toxic to HFF at a concentration of 0.5|ig/ml and below, (p>0.225), 
(Figure 5.7A). Serial dilutions of SHAM (0.19 to 0.78pg/ml) and 8-HQ (0.25 pg/ml 
and 0.12pg/ml) were then used in the parasite growth inhibition assays.
Parasite growth inhibition assays
SHAM inhibited the growth of T.gondii tachyzoites in a dose dependent manner 
(0.78pg/ml, p<0.0001), (Figure 5.6B). Similarly inhibition o f parasite growth was 
visualised in giemsa stained preparations. Parasites were not seen in SHAM treated 
cultures and the fibroblast monolayer was intact and appeared normal. In contrast, 
control cultures showed extensive destruction o f the monolayer and remaining groups 
o f cells infected with tachyzoites (Figure 5.6C).
8-HQ also inhibited parasite growth in a dose dependent manner (0.25pg/ml, 
p<0.005), (Figure 5.7B).
Synergy assays
SHAM was found to act synergistically with NPMG to restrict the growth of T.gondii 
in vitro (Table 5.1). Thus at a concentration of 3.25mM NPMG and 0.19pg/ml 
SHAM inhibited parasite growth by 60% and 32% respectively. In combination they
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were able to inhibit 88% of parasite growth which was greater than the 73% predicted 
if the effect was purely additive.
In vivo survival experim ents
The survival of mice treated with SHAM was not significantly enhanced compared 
with that o f untreated control mice (Figure 5.8). Control mice treated with high dose 
sulphadiazine all survived.
Demonstration of alternative oxidase by SDS-PAGE and w estern 
blotting
All five antibodies to the alternative oxidase recognised a protein in T.gondii o f 
approximately 66kD, the same molecular weight as T.bruceii and Voodoo lily 
alternative oxidases (Figure 5.9). Furthermore, under strong reducing conditions two 
bands o f 66 and 33 kD were recognised (Figure 5.9). This suggests that similar to 
alternative oxidase in T.bruceii and Voodoo lily the presumed alternative oxidase 
protein in T.gondii is a 66kD dimer composed of two 33kD monomers.
These bands were also recognised in the mitochondrial enriched fraction o f T.gondii. 
although it was not of increased intensity. This is probably in part due to the lower 
protein concentration and lack of purity of this fraction.
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F ig u re  5.6 A The toxicity of SHAM to HFF a s  m easured  by 
up take  of tritiated thymidine. C oncen tra tions of 3.12jig/ml and 
below were non-toxic to the  fibroblast m onolayer (p>0.375). 
(O, control c u ltu re s ;^ ,  SHAM trea ted  cultures). B The effect of 
SHAM on the  growth of T.gondii in HFF a s  m easu red  by 
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SHAM inhibited over 90% of pa rasite  growth (p<0.0001). 
Abbreviations: No RH, uninfected control cultures; RH, control 
cu ltu res  infected with RH; P/S infected control cu ltu res  
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Figure 5.6  continued C The effect of SHAM on the growth 
of T.gondii in HFF. (i) Control cultures showing large groups 
of parasites, destruction of the fibroblast monolayer and 
num erous extracellular parasites (arrow), (ii) Cultures treated 
with SHAM (0.8|ag/ml). No parasites are identified and the 
fibroblast monolayer is intact. (Giemsa, x 100).
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inhibited over 80% of parasite  growth (p<0.005). 
Abbreviations: No RH, uninfected control cultures; RH, control 
cu ltu res  infected with RH; P/S infected control cu ltu res  
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5.5 Discussion
These studies provide evidence for two previously undescribed biochemical pathways 
in T. gondii. These pathways, the shikimate pathway and the alternative pathway o f 
respiration appear to be essential for the replication of T. gondii. Thus inhibition of 
either pathway is able to substantially restrict parasite growth. Since neither pathway 
is present in mammals they may prove to be excellent targets for new antimicrobial 
agents.
In bacteria, fungi, algae and higher plants the shikimate pathway is essential for the 
biosynthesis o f aromatic compounds including folate, ubiquinone and the aromatic 
amino acids (Bentley, 1990). The herbicide, glyphosate (NPMG), which inhibits the 
action o f EPSP synthase and thus the shikimate pathway, has been used with great 
success to kill higher plants (Haslam, 1993; Kishore & Shah, 1988). These studies 
demonstrate that inhibition of EPSP synthase by NPMG is able to restrict the growth 
o f intracellular T. gondii. In addition, collaborative studies have shown that NPMG 
was able to restrict the growth of two other medically important Apicomplexans, 
P.falciparum and C. parvum (Appendix 1). Furthermore, NPMG was equally 
effective in vitro against both pyrimethamine sensitive and pyrimethamine resistant 
Pfalciparum strains. This further emphasises the potential therapeutic value of 
targeting alternative enzymes of the folate biosynthetic pathway.
In these studies it was found that simultaneous administration of PABA to NPMG 
treated T. gondii cultures antagonised the inhibitory effect o f this compound. 
Similarly, collaborative studies have shown that PABA can antagonise the inhibitory
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effect of NPMG on P. falciparum (Appendix 1). This suggests that the shikimate 
pathway plays an essential role in the supply of folates for these parasites.
The role of the shikimate pathway in supplying chorismate for the synthesis o f 
ubiquinone and aromatic amino acids in these parasites remains to be determined. 
T.gondii is certainly incapable o f synthesising the aromatic amino acid, tryptophan 
(Pfefferkorn, 1984). However, tryptophan is not essential for the survival o f 
P.falciparum for which tyrosine is an essential aromatic amino acid (Divo et al., 
1985). The synthesis of these two amino acids occurs by divergent enzymatic 
pathways from chorismate (Bentley, 1990). Interestingly, the addition o f PABA did 
not ablate the effects of NPMG on the growth of C. parvum. The reason for this 
apparent difference between closely related parasites is uncertain but may reflect poor 
transport of PABA into the parasite. Alternatively, it may be that in C. parvum, the 
shikimate pathway is an absolute requirement for the supply o f ubiquinone or 
aromatic amino acids. These observations imply that only certain pathways originating 
from chorismate, the end product o f the shikimate pathway, may be conserved in 
different Apicomplexans. This may reflect the different evolutionary pressures acting 
on phylogenetically related parasites living in diverse environments.
These studies also provide the first cDNA and protein sequence of an Apicomplexan 
shikimate pathway enzyme, chorismate synthase. This information has already proven 
useful as it was used to find an homologous P. falciparum EST which has also now 
been sequenced. The deduced amino acid sequence of the Pfalciparum chorismate 
synthase gene is included in the multiple sequence alignments shown in Figure 5.5b. 
Based on the gene sequences, the putative T.gondii and P. falciparum chorismate
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synthase proteins differ from other known chorismate synthases in length. This is 
mainly due to a number of insertions which on the basis of their amino acid 
composition appear to form exposed loops. The function of these insertions remain to 
be determined.
In addition collaborative studies have detected four shikimate pathway enzymes in 
extracts of T.gondii. The enzymes detected were 3-dehydroquinate dehydratase, 
shikimate kinase, EPSP synthase, and chorismate synthase. These represent the third, 
fifth, sixth and seventh enzymes in the pathway, respectively (Figure 2.4). 
Furthermore the inhibitory effect of NPMG on T.gondii EPSP synthase was 
confirmed in these enzyme assays. The details of these experiments are summarised in 
Appendix 2. In addition, very low levels of three shikimate pathway enzymes have 
previously been reported in crude extracts o f P.falciparum, albeit from the use of a 
rather non-specific colorimetric assay (Dieckmann & Jung, 1986). The enzymes 
identified were 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase, shikimate 
dehydrogenase and shikimate kinase, the first, fourth and fifth enzymes in the 
shikimate pathway, respectively. Thus, there is evidence for all o f the shikimate 
pathway enzymes, except 3-dehydroquinate synthase, in Apicomplexan parasites.
The discovery of the shikimate pathway in T.gondii therefore provides new 
opportunities for the development of drugs against this parasites. The ability of 
NPMG to act in synergy with conventional antifolate drugs in vitro further 
emphasises the potential benefits of targeting this pathway. The inhibitor used in these 
studies (NPMG) may be a valuable lead compound in the development o f new drugs. 
The fact that NPMG, albeit in combination with pyrimethamine, was active against
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T.gondii infection in vivo is encouraging from this point of view. A variety o f 
derivatives of NPMG are currently being used to elucidate structure function 
relationships for inhibitors of plant EPSP synthases (Marzabadi et a/., 1996). A similar 
approach could be useful for characterising the active site of the parasite enzyme. 
Inhibitors of chorismate synthase (Davies et al., 1994) and other enzymes within the 
shikimate pathway are also being developed in the search for new herbicides and 
drugs against bacterial and fungal pathogens.
These studies also provide compelling evidence for the presence of an alternative 
pathway o f respiration in T.gondii. Thus, the growth of T.gondii was inhibited by 
SHAM and 8HQ, both well characterised inhibitors of the alternative oxidase. 
Similarly, inhibitor studies were performed by collaborators on the asexual 
erythrocytic forms of P.falciparum (pyrimethamine sensitive and pyrimethamine 
resistant strains) and C.parvum oocysts. SHAM and 8-HQ were able to inhibit the 
growth of these parasites (Appendix 3). The ability of 5 distinct antibodies, against 2 
different alternative oxidases, to recognise a 66 kD T.gondii protein, further supports 
the presence of a T.gondii alternative oxidase. Pre-immune serum was not available as 
a control for the two polyclonal antibodies. However, non-specific binding by 5 
separate antibodies seems unlikely. Furthermore, the two T.bruceii monoclonal 
antibodies are known to recognise different epitopes or isoforms of the alternative 
oxidase. Moreover, under rigorous reducing conditions the putative T.gondii 
alternative oxidase (66kD) also appears to be composed o f two 33 kD monomers, 
similar to the T.bruceii alternative oxidase (Chaudhuri et al., 1995).
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Since performing these studies, Murphy et a!., (1997) also have found strong 
evidence for the presence of an alternative oxidase in P.falciparum. In these 
experiments parasite oxygen consumption was measured in the absence and presence 
o f cyanide. As cyanide inhibits conventional mitochondrial but not alternative pathway 
respiration, oxygen consumption which occurs in the presence o f cyanide is, by 
implication, alternative pathway respiration. Addition of SHAM inhibited cyanide 
insensitive oxygen consumption by Pfalciparum. Surprisingly, these workers found 
no evidence for cyanide insensitive oxygen consumption by T.gondii tachyzoites 
(RH). However, the tachyzoites used in these assays were extracellular whereas all 
the studies described in this thesis used intracellular organisms. There may be 
significant differences in oxygen metabolism between intracellular and extracellular 
tachyzoites. Indeed a reduction in mitochondrial membrane potential is only evident 
after tachyzoites have invaded the cell (Tanabe & Murakami, 1984). This suggests 
that conventional mitochondrial respiration may be essential for the high energy 
demands of extracellular survival and host cell invasion. Intracellular tachyzoites may 
not require as much energy and may therefore utilise alternative oxidase. This 
hypothesis could be tested by examining cyanide insensitive respiration in intracellular 
tachyzoites, grown in a mitochondrial-deficient cell line. This would ensure that 
parasite and not host cells respiration was measured.
The role o f the alternative oxidase in T.gondii is unclear although in vitro inhibition of 
intracellular growth by SHAM suggests that it is fundamental to parasite survival. A 
survey of the botanical literature provides a few clues as to the possible role o f this 
pathway. There is evidence in plants and other organisms that alternative pathway 
respiration is an adaptive response. The alternative oxidase production o f heat in the
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thermogenic blooms of the voodoo lily appears to be a very specific purpose, unique 
to the Araceae (Meeuse, 1975). In other plants and organisms, alternative oxidase is 
induced or expressed under conditions of ‘stress’. For example, low temperature, 
wounding, pathogen attack, elevated carbohydrate status, cell culture stage, addition 
of ethylene, ripening, and elevation of salicylic acid and pyruvate levels all increase 
alternative pathway respiration in plants (Day & Wiskich, 1995; Hoefnagel et al., 
1995; Moore & Siedow, 1991; Rhoads & McIntosh, 1992).
It is now widely acknowledged that stress, for example, heat, pH or immunological, is 
a key factor in the life-cycle of T.gondii and is responsible for tachyzoite to bradyzoite 
transformation (Soete et a/., 1994). A well-defined, physiologically relevant and 
immunologically important molecule known to induce stage conversion is nitric oxide 
(Bohne et at., 1994). Notably nitric oxide has been demonstrated to inhibit 
conventional cytochrome oxidase but not alternative oxidases in plants (Millar & 
Day, 1996). The alternative oxidase is expressed in the blood stream trypomastigote 
forms and not the insect forms of T.bruceii (Chaudhuri et a/., 1995). The reason for 
this remains to be determined. However, in common with T.gondii tachyzoites and 
the asexual erythrocytic stages of P.falciparum, the blood stream trypomastigote o f 
T.bruceii must survive the effects o f nitric oxide produced by the host’s immune 
system. The alternative oxidase therefore may be a common mechanism used by these 
3 parasites to escape the inhibitory effects of nitric oxide on conventional 
mitochondrial respiration. This ‘escape’ mechanism for the tachyzoite may induce 
conversion to the bradyzoite stage.
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The penalty for using alternative pathway respiration instead of conventional 
mitochondrial respiration is the loss o f the ability to phosphorylate two ADPs. This 
may be o f little consequence to these parasite stages as they are all in a relatively high 
glucose environment and presumably could obtain sufficient energy through 
glycolysis. Under these circumstances the advantage of using the alternative oxidase 
would be the ability to maintain a functional citric acid cycle. The citric acid cycle 
would provide a means o f reducing pyruvate levels and perhaps more importantly, 
supply essential precursors for amino acid synthesis.
Whatever the role o f the alternative oxidase in T.gondii, its presence provides new 
opportunities for the development of drugs against T.gondii. The inability o f SHAM 
to prolong survival in mice infected with RH was disappointing. However, it is 
possible that SHAM may not have reached adequate therapeutic concentrations in 
tissues of these mice. There are no easy means of measuring serum or tissue 
concentrations of this compound. Its effects in vitro are unequivocal and SHAM may 
therefore prove a useful lead compound for development of in vivo drugs. Indeed, 
additional agents which appear to target alternative pathway respiration have recently 
been described. For example, ascofluranone, an isoprenoid antibiotic, specifically 
inhibits the blood stream trypomastigote stage o f T.bruceii in vitro apparently by 
inhibiting alternative pathway respiration (Minagawa el al., 1997).
The two compounds, NPMG and SHAM, used in these studies acted in synergy to 
inhibit T.gondii growth. Drugs may act in a synergistic fashion for a variety of 
reasons, but this phenomenon is most usually attributed to them targeting different 
points of the same pathway (Krogstad & Moellering, 1986). This suggests that the
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shikimate pathway is important for the generation of ubiquinone in T.gondii. If  this is 
the case NPMG, in common with SHAM, may affect parasite mitochondrial 
respiration (Figure 5.10) and ultimately the control of stage conversion. More 
importantly these studies suggest that simultaneously targeting the shikimate pathway 
and alternative pathway respiration may be a useful therapeutic strategy for disease 
caused by Apicomplexan parasites.
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Figure 5.10 Diagram showing the connection between the 
shikimate pathway and the alternative pathway of respiration in 
plants. The observed synergy between NPMG and SHAM su g g es ts  
that these  pathways may also be connected in T.gondii.
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CHAPTER 6
FINAL DISCUSSION
In earlier chapters, I have discussed the morphological features o f congenital ocular 
toxoplasmosis in the fetus and infant and evidence supporting the presence of the 
shikimate pathway and alternative pathway of respiration in T.gondii. In this final 
chapter, I am therefore confining this discussion to the overall implications of my 
studies and their contributions to clinical aspects and potential treatment o f 
toxoplasmosis. In particular, I will discuss (i) the morphological lesions o f the earliest 
stages o f congenital ocular toxoplasmosis and their significance to current strategies 
for prenatal diagnosis and management; (ii) novel therapeutic strategies arising from 
the description of two plant like biochemical pathways in T.gondii and; (iii) 
suggestions for future work.
Although ocular toxoplasmosis is an important cause of ocular disease in both 
immunosuppressed and immunocompetent individuals the histopathological features 
have not been extensively studied. One possible explanation for this may be that 
ocular toxoplasmosis itself is not life threatening and consequently infected eyes are 
rarely available for these studies. Nonetheless, the histopathological features of 
recurrent retinochoroiditis have previously been described in a number o f small series 
and case reports (Bamatter, 1947; Binkhorst, 1948; Heath & Zuelzer, 1944; Hogan, 
1958; Koch et al., 1943; Rao & Font, 1977). A review of such case reports by Hogan 
(1951) described the histopathological findings in 13 infant eyes (ages ranging from 
term to 5 and a half weeks). At that time he stated that ‘there have as yet been no 
descriptions of the earliest stages of toxoplasmic chorioretinitis’. Since then, the early 
stages of ocular toxoplasmosis during acute infection of the fetus had only been 
described in a study of 4 fetuses between the ages of 22 and 27.5 weeks (Brezin et al.,
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1994). In two of these fetuses the eyes were normal, however the other two fetuses 
showed retinal necrosis, neovascularisation and marked chorioretinal inflammation.
The first part of this thesis examined the very early lesions of ocular toxoplasmosis in 
the fetus. This study, the largest of its kind to date, was made possible by 
collaborations between institutions in France and Chicago. The main findings in the 
fetal eyes were o f retinitis, retinal necrosis, disruption of the RPE with marked 
choroidal inflammation and congestion. The two infants in the study showed severe 
ocular disease with retinal necrosis, retinal detachment and large subretinal exudates. 
Many o f the histopathological findings in the fetuses were similar to those previously 
described in infants, children and adults. The features represent an earlier stage o f the 
disease than that seen in the eyes from the 2 year old child. This study emphasises that 
extensive irreversible ocular damage can occur in utero.
Several features which may contribute to our understanding of the pathogenesis of 
ocular toxoplasmosis were also identified. Focal retinal dysplasia identified in the eye 
of the 32 week old fetus suggests that, like other infectious agents, T.gondii can have 
a teratogenic effect on the developing eye. The mechanism may involve disrupting the 
normal relationship of tissues in the eye such as the close association of the retina and 
RPE (Fulton et al., 1978; Godel eta/., 1981).
The frequent presence of optic neuritis or predilection for the posterior pole and 
macular area in utero may be a contributing factors to the often poor visual acuity in 
surviving patients with congenital toxoplasmosis. Optic neuritis may, in part, reflect 
the presence of meningoencephalitis in these fetuses. Montoya & Remington, (1996)
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found that the visual outcome o f patients with acute acquired toxoplasmic 
retinochoroiditis is better than for those with recrudescent congenital disease. This 
may in part reflect the tendency of acquired disease to be unilateral. However, none of 
these patients had clinical symptoms of optic neuritis and only 2 patients had macular 
involvement (Montoya & Remington, 1996).
An inflammatory infiltrate dominated by CD4+ T cells in these eyes demonstrates that 
the fetus and infant are capable o f mounting an immune response to T.gondii 
infection. However, the presence of numerous extracellular forms of T.gondii and 
lack o f tissue cysts suggests that this immune response is less effective than that of the 
immunocompetent adult or child. The fetuses in this study were known to be severely 
affected with evidence of cerebral involvement and they may have experienced an 
overwhelming infection. Less severely affected fetuses, who are more likely to survive 
may go on to develop effective immunity and T.gondii cysts. They may then 
experience reactivations of disease in later life.
The documentation of the early morphological features of ocular toxoplasmosis has 
raised some interesting points with regard to implementation and timing o f screening 
programs. Infection with T.gondii can cause extensive irreversible ocular damage 
early in gestation. This is important information for an expectant mother regarding the 
risks of this infection to her baby. Furthermore, for a pregnant woman who becomes 
infected with T.gondii it provides advice as to the likely severity of disease in her 
baby. This advice will allow a more informed decision regarding continuation or 
termination of a pregnancy in cases where the fetus is infected. Overall, this study 
presents a strong argument in favour of prenatal screening and treatment o f congenital
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toxoplasmosis. If fetuses are infected early in gestation extensive damage occurs to 
the eye in most cases. Thus, to improve the ophthalmic outcome from congenital 
toxoplasmosis treatment would ideally be initiated as soon as possible after infection 
o f the fetus had occurred. At birth much of the damage has already occurred making 
complete resolution of symptoms and signs unlikely even with early postnatal 
diagnosis and treatment.
In France prenatal screening for T.gondii infection has been routinely carried out since 
1978 (reviewed, Hall, 1992). The sensitivity of amniotic fluid PCR for the T.gondii 
B l gene now approaches 100% making rapid diagnosis of fetal infection possible 
(Hohlfeld et a/., 1994). Following a positive diagnosis of infection in the fetus the 
mother may be treated with sulphadiazine and pyrimethamine or may consider 
termination o f the pregnancy if her fetus is severely affected (Couvreur et al., 1993). 
Studies suggest that in the short term in utero treatment decreases the severity of 
congenital toxoplasmosis (Berrebi & Kobuch, 1994b; Hohlfeld et al., 1989). In 
countries where prenatal screening is not routine, early postnatal diagnosis allows 
treatment to be initiated soon after birth and treatment is continued throughout the 
first year of life. Infants who became infected in the first trimester usually have severe 
involvement in the postnatal period and thus early diagnosis is possible (McAuley et 
a/., 1994). Infants who are infected later in gestation may appear to be normal in the 
postnatal period and without routine screening the diagnosis is often missed (Guerina 
et al., 1994). Untreated, more that 90% of these individuals develop ophthalmological 
disease by adolescence (Koppe et al., 1974; Wilson et al., 1980).
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However, my histopathological findings, although important, do not address the main 
clinical problem associated with ocular toxoplasmosis in that it is a recurring, 
progressively destructive disease due to the limitations o f current therapies. Even with 
prompt in utero or early postnatal diagnosis, the treatment o f congenital 
toxoplasmosis is associated with significant problems.
Currently the most effective therapy includes the antifolate agents, pyrimethamine and 
sulphadiazine (Remington et al., 1995). These are both associated with significant 
adverse reactions. Pyrimethamine targets DHFR, an enzyme also present in human 
cells and is consequently, often associated with bone marrow toxicity (Williams, 
1996a). This can in part be counteracted by simultaneous administration o f folinic acid 
(Giles, 1971). Nonetheless, folate is critical to the developing nervous system and the 
use o f pyrimethamine during pregnancy or in infants is not without risk. Sulphadiazine 
is commonly poorly tolerated resulting in problems with compliance and many 
patients develop allergy. Furthermore, therapy is required for long periods o f time. 
Pregnant woman are treated until the birth of their child (Couvreur et al., 1993). 
Congenitally infected infants receive treatment throughout the first year o f life 
(McAuley et al., 1994). Recurrent ocular disease requires treatment for approximately 
6 weeks (Mets et al., 1996; Rothova et al., 1993). Prolonged and repeated therapy is 
required as there are no drugs which can eliminate the quiescent bradyzoite form of 
the parasite. Recent advances in therapy include spiramycin therapy, to reduce the risk 
o f in utero transmission (Couvreur et al., 1988) and clindamycin (Behbahani et al.,
1995) or atovaquone therapy (Haile et al., 1993), in conjunction with pyrimethamine, 
in cases of sulphadiazine intolerance. However, these alternative therapies do not 
address the problems of bone marrow toxicity associated with pyrimethamine therapy
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nor do they eliminate encysted parasites. Identification of new drug targets and 
ultimately new therapies is therefore desirable.
To this end, the plastid organelle has recently received considerable attention as a 
potential drug target in Apicomplexan parasites. Many research studies have been 
based on determining functions based on the residual plastid genome. Indeed, 
prokaryotic ribosomes in the plastid may be the target of the macrolide antibiotics 
including clindamycin, roxithromycin and azithromycin (Fichera & Roos, 1997). In 
addition, these studies on the plastid have emphasised several other so-called ‘plant­
like’ properties of T.gondii (McFadden et a/., 1996). Recognition of these properties 
proffers alternative strategies for drug targeting.
The identification of potential new drug targets has been the focus of the research 
described in the remainder of this thesis. In Chapter 5, I have provided evidence for 
the existence of two previously undescribed biochemical pathways in T.gondii and 
outlined their potential as drug targets. Adopting a more lateral approach to the 
question of plastid function, the herbicide glyphosate (NPMG) was used in an attempt 
to disrupt a key point in the shikimate pathway which occurs in the plastid of higher 
plants. Glyphosate (NPMG) was able to inhibit the growth of T.gondii both in vitro 
and in combination with pyrimethamine in vivo.
The cloning and sequencing of a T.gondii chorismate synthase gene and the 
measurement of shikimate pathway enzyme activity in crude extracts o f T.gondii by 
collaborators provides direct evidence for this pathway in T.gondii (Appendix 2) . 
Similarly, compounds which target the alternative oxidase of higher plants were also
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able to inhibit the growth of T.gondii in vitro. Antibodies to two alternative oxidases 
were able to bind to a T.gondii protein of approximately 66 kD. Furthermore, NPMG 
was able to act in synergy with conventional antifolate agents as well as with SHAM 
suggesting a potential role for related compounds in combined therapy for 
toxoplasmosis.
Thus, both the shikimate pathway and the alternative pathway o f respiration are 
potential new drug targets in T.gondii which are not present in mammalian hosts. It is 
an intriguing possibility that other plant-like or plastid associated pathways may also 
be present in T.gondii. For example, the biosynthetic pathways for porphyrins, are 
confined to the plastids of plants rather than mitochondria as in animals (Kannagara et 
a!., 1988). There may therefore be many enzyme targets in T.gondii, which are not 
present in animals, and which could provide potential drug targets.
The biochemical studies in T.gondii also shed light on possible biochemical processes 
in other Apicomplexans. Similar to T.gondii many of these parasites cause diseases 
which lead to considerable morbidity, mortality and economic losses. There are also 
no ideal antimicrobial agents available for treatment. For example, three to five million 
children and adults die each year from malaria (Krogstad, 1995). Effective treatment 
of malaria is hindered by drug intolerance and continual emergence of drug resistant 
parasites (Krogstad, 1995). Cryptosporidiosis is a common opportunistic pathogen in 
patients with AIDS but may also occur in epidemics (Ungar, 1995). There is currently 
no effective treatment for this parasite. Studies by collaborators have shown that 
NPMG and SHAM are able to inhibit the growth of P.falciparum and C.parvum in 
vitro. The chorismate synthase gene has been cloned from P.falciparum. Furthermore,
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a recent study by (Murphy et al., 1997) has identified cyanide insensitive respiration in 
P.falciparum suggesting it has an alternative pathway of respiration. There is 
therefore gathering evidence for the presence of the shikimate pathway and alternative 
oxidase in other pathogenic Apicomplexan parasites.
Therefore, antimicrobial agents developed to target these pathways in T.gondii may 
be useful against other pathogenic Apicomplexans. Indeed, other microbes that cause 
opportunistic infections in AIDS patients, including Pneumocystis carinii (Banerji et 
al., 1995) and Mycobacterium tuberculosis (Garbe et a!., 1991) also have the 
shikimate pathway. Recent studies suggest that P.carinii may utilise alternative 
pathway respiration (Ittarat et al., 1995). Thus, there is the exciting possibility that a 
single compound could be useful against several opportunistic pathogens 
simultaneously infecting a single individual.
6.1 Summary
In summary the work described in this thesis provides important knowledge in two 
main areas of toxoplasmosis research. First, it describes the morphological features of 
the earliest stages of ocular disease and the inflammatory cells present. This work has 
important implications for the implementation and timing of any proposed screening 
programs for congenital toxoplasmosis. It also provides some insight into the 
pathogenesis of this disease in the fetus. This work forms a basis for further studies 
into the local immune response in both human fetal tissues and in an animal model.
The devastating findings in the eyes of the fetuses and infants described in the first 
part of this thesis confirms the need for effective antimicrobial agents which will cure
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this disease. The second part of this thesis describes two new pathways present in 
T.gondii. These pathways are associated with the so-called ‘plant-like’ properties of 
T.gondii and are therefore not present in human cells. They are thus ideal candidates 
for potential new drug targets. In addition extrapolation of both these pathways in 
plants suggests that they are linked to parasite mitochondrial respiration (conventional 
and alternative). Thus, agents targeting these pathways may be able to eliminate 
bradyzoites. They may therefore be of considerable importance in preventing 
recrudescent disease in immunocompromised patients and those with congenital 
toxoplasmosis.
6.2 Suggestions for Future Work
Studies on hum an tissues
The human ocular tissues studied in this thesis represents the largest collection of its 
kind to date. The collaborations and studies which made it possible to obtain these 
tissues are ongoing. Therefore, there will be opportunities to expand this collection 
when more ocular tissues become available. The initial immunohistochemical studies 
on these eyes have shown that the major infiltrating inflammatory cell is the CD4+ T 
cell. These cells can be classified according to the pattern of cytokines they produce 
(Mosmann et a/., 1986). For example, T.gondii infection is usually associated with a 
T helper 1 pattern of cytokines which includes IFN-y and IL-2 production (reviewed, 
Subauste & Remington, 1993). Previous studies have demonstrated that infants with 
congenital toxoplasmosis often have diminished lymphocyte blastogenic responses to 
T.gondii antigen and production of the pro-inflammatory cytokines IFN-y and IL-2 is 
reduced (McLeod et al., 1990). It would therefore be of interest to study local
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cytokine production in these eyes either by immunohistochemistry or in situ 
hybridisation. A predominance of Th2 cytokines would suggest that congenital 
infections are more severe due to a Th2 response in the fetus. The observed anergy of 
infants lymphocytes in T.gondii antigen may also be related to a lack of co-stimulatory 
molecules in the fetus. In particular B-7 and CD28 co-stimulatory molecules are 
required to effectively stimulate Thl cytokine production and proliferation of 
lymphocytes (Khan et aI., 1996b). Murine studies have demonstrated that T cell non­
responsiveness can be due to excessive nitric oxide (Candolfi et a/., 1994), IFN-y 
(Candolfi et al., 1995), IL-10 (Khan et al., 1995) or IL-12 (Hunter et al., 1995b), 
production. More significantly lack of IL-2 (Haque et al., 1994) or down regulation 
of the co-stimulatory molecule, CD28 (Khan et al., 1996b) have also been noted in 
these circumstances. Future studies will determine the presence or absence of these 
molecules in infected and uninfected fetal eyes by immunohistochemistry.
In addition to studies on fetal eyes, I have collected other tissues from these fetuses 
and infants. Similar histopathological and immunohistochemical studies on brain, liver, 
lung and placenta will provide insight into the local and systemic immune response to 
this disease in the fetus. It may provide information about the organ predilection of 
congenital toxoplasmosis and whether this relates to the site specific immune 
responses.
Studies using an animal model
Studies on human tissues are not without limitations. It is almost impossible to 
document the kinetics of T.gondii infection in utero. The clonal derivation of the
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parasite is varied, the infecting life-cycle stage and dose have not been defined. Thus 
comparison of cases of human congenital ocular toxoplasmosis always carry this 
caveat. Until recently experimental studies of ocular disease have been hampered due 
to the lack of an easily manipulatable experimental model. However, recently 
Gazzinelli et al., (1994) demonstrated that C57/BL6 mice infected intraperitoneally 
with an avirulent strain of T.gondii develop toxoplasmic retinochoroiditis. 1 have been 
able to reproduce this model and will use it to characterise this disease and 
immunological factors which control disease progression in the eye.
Further studies on the shikimate pathway and alternative oxidase
Further characterisation of the two pathways described in Chapter 5 is needed. For 
the shikimate pathway several questions should be addressed. The site of this pathway 
in the parasite should be definitively demonstrated. Although, usually associated with 
the plastid of higher plants and algae, under certain circumstances, this pathway can 
occur outside the plastid (Bentley, 1990). One approach to this would require 
production of antibodies to a key enzyme in the pathway and the site of this enzyme 
could then be localised by immunogold electron microscopy.
The synergistic actions of NPMG and SHAM suggest that the shikimate pathway may 
be important for the generation of ubiquinone precursors. Further studies to identify 
other pathways which branch from the shikimate pathway would be of interest. In 
particular confirmation of this mechanism of ubiquinone synthesis in T.gondii may 
allow specific targeting of mitochondrial respiration. A detailed study of other 
enzymes in this pathway may facilitate the design of more suitable inhibitors.
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Further characterisation of the alternative oxidase is also required. Murphy et al., 
(1997) found no cyanide insensitive respiration in extracellular tachyzoites. It would 
therefore be of interest to compare cyanide insensitive respiration in extracellular and 
intracellular tachyzoites. To circumvent the problems of host cell toxicity these studies 
would be performed with parasites grown in a mitochondrial deficient cell line. 
Identification of an alternative oxidase gene has proved more difficult than for the 
shikimate pathway as no obvious EST sequences have been found. Complementation 
and degenerative primer based PCR techniques using conserved regions in the plant 
or trypanosome genes have not yet yielded a candidate sequence. An alternative 
approach would be to utilise the available alternative oxidase antibodies to screen a 
cDNA library after protein expression. Again, this technique has been tried, but with 
limited success due to the large volumes of antibodies required for such studies. 
Identification and sequencing of a gene would allow assessment of differences in 
expression of this gene between extracellular and intracellular tachyzoites and 
bradyzoites. It would also assist in outlining a potential role in parasite stage 
conversion. Similar to the shikimate pathway the use of more specific inhibitors of the 
alternative oxidase may allow characterisation of the active enzyme site and the 
design of more suitable inhibitory agents.
Finally, NPMG and SHAM may act as useful lead compounds in the design of new 
drugs to treat toxoplasmosis. To assess the ability of these drugs to treat recurrent eye 
disease it may be useful to test new compounds using the mouse model of ocular 
disease.
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APPENDICES
APPENDIX 1
THE EFFECT OF NPMG ON THE GROWTH OF 
P.FALCIPARUM AND C.PARVUM
A1.1 Introduction
To investigate the presence of the shikimate pathway in other Apicomplexan parasites 
the effect of NPMG on the in vitro growth of P.falciparum and C.parvum was 
assessed. In addition, these in vitro assays were performed in the presence of 
exogenous PABA.
The experiments on P.falciparum were performed by D.E.. Kyle and W.K.Milhous of 
the Walter Reed Army Institute of Research, Washington DC, USA. The experiments 
on C.parvum were performed by S.Tzipori, Tufts University School of Veterinary 
Medicine, Boston, USA.
A1.2 Materials and Methods
P.falciparum growth inhibition studies
The effect of NPMG on P.falciparum was measured using a modification of the semi­
automated microdilution technique for assessing anti-folates (Milhous et al., 1985). 
Two clones of P.falciparum were used for these tests; the W2 clone is susceptible to 
mefloquine, but resistant to chloroquine, pyrimethamine , sulphadoxine and quinine; 
the D6 clone is susceptible to chloroquine, pyrimethamine and sulphadoxine but is 
resistant to mefloquine (Oduola etal., 1988). Briefly, NPMG was dissolved in DMSO 
and diluted 400 fold into RPMI 1640 media supplemented with 10% Albumax 1 
(Gibco). Serial dilutions of NPMG were added to parasites in culture. The cultures 
were incubated at 37°C in 5% O2, 5% C 0 2 and 90% N2 for 48hours. [3H]- 
hypoxanthine incorporation was measured as described previously (Milhous et al., 
1985). The I C 50 and I C 90 for each clone was determined.
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The parasite growth inhibition assay was performed in the presence of exogenous 
PABA and folic acid. NPMG was used at a concentration of 1.08mM with serial 
dilutions of PABA or folic acid.
C.Parvum  growth inhibition studies
To assess the effect of NPMG on C.parvum, oocysts were added at 50,000/well to 
confluent MDBK F5D2 cell monolayers in 96 well tissue culture plates, as described 
by Tzipori, 1998. These were incubated at 37°C under air with 8% CO2 in medium 
containing NPMG. After 48 hours the level of infection was determine by an 
immunofluorescence assay. Briefly C.parvum asexual forms were detected by addition 
of rabbit ax\i\-C.parvum serum, followed by fluorescein-conjugated goat anti-rabbit 
antibody. Sixteen fields were counted at x 100 magnification and mean parasite count 
per field determined. The effect of NPMG was compared with that of paromomycin 
(2000|a.g/ml), the standard positive control drug used in these in vitro assays. This 
assay was also performed in the presence of exogenous folate.
A1.3 Results
NPMG was equally effective in vitro against both pyrimethamine-sensitive (W2) and 
pyrimethamine resistant P.falciparum clones. The IC50 and IC90 for each clone is 
shown in Table A l.l. These results are the mean +/- standard deviation of 5 replicate 
experiments. The inhibitory concentrations are comparable to that required to inhibit 
the growth of T.gondii in vitro and are similar to the in vitro activity of antimalarial 
drugs in current clinical use (e.g. proguanil). NPMG was equally effective against 
pyrimethamine-sensitive (D6) and pyrimethamine-resistant (W2) clones. This
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emphasises the potential therapeutic value of targeting alternative enzymes of folate 
biosynthesis. Addition of both PABA and folic acid were able to ablate the inhibitory 
effect of NPMG (Figure A l.l), suggesting that the shikimate pathway is important for 
the supply of folate in P.falciparum.
Table A1.1 The concentration of NPMG required to inhibit the growth 
of pyrimethamine-resistant (W2) and pyrimethamine-sensitive (D6), 
P.falciparum clones
P.falciparum I C 50 (niM) IC9o(mM)
clone
W2 1.1+/-0.04 2.1+/-0.09
D6 0.5+/-0.04 1.6+/-0.1
NPMG was also able to inhibit the growth of C.parvum, in vitro in a dose dependent 
manner and was non-toxic to the MDBK F5D2 monolayer at the concentrations used, 
(4.5, 6, 8, and 9mM). The results are shown in Figure A1.2. However, in this case, 
exogenous PABA was not able to ablate C.parvum growth inhibition by NPMG. This 
may reflect poor transport of exogenous PABA into the parasite. Alternatively, the 
shikimate pathway may be required for synthesis of other compounds e.g. ubiquinone 
or aromatic amino acids, in C.parvum.
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APABA (|iM)
Folic Acid (|iM)
Figure A1.1 Product rescue of the inhibitory effect of NPMG 
on the growth of the asexual erythrocytic forms of 
P.falciparum. In A, addition of PABA reduced the effects of 
NPMG in a dose dependent manner. Similarly, in B, addition 
of folic acid reduced the effects of NPMG in a dose dependent 
manner. Key: PABA, (□); PABA+ NPMG, (O); Folic Acid, (■); 
Folic acid + NPMG, ( • ) ;  Media, control cultures infected with 
P.falciparum ; NPMG, infected cultures treated with NPMG 
(1 .08m M ).
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NPMG (mM)
Figure A1.2 The effect of NPMG on the growth of C.parvum. 
At a concentration of 8mM NPMG inhibited 75% of parasite 
growth. Key: Media, control cultures infected with C.parvum ; 
PRM, infected control cultures treated with paromomycin.
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APPENDIX 2
MEASUREMENT OF SHIKIMATE PATHWAY
ENZYMES IN T.GONDII
1 7 4
A2.1 Introduction
Further confirmation for the presence of the shikimate pathway in T.gondii was 
obtained by directly measuring enzyme activities in parasite lysates. These 
experiments were performed by Dr. J. Coggins, Dr. T. Krell of Glasgow University 
and Dr. C.W. Roberts of University of Strathclyde, Glasgow.
A2.2 Materials and Methods
Parasite extracts were produced at 4°C by suspension of pure tachyzoites in extraction 
buffer (50nM Tris.HCI, pH7.5), containing complete TM protease inhibitor cocktail 
(Boehringer Mannheim, l tablet per 50ml buffer). This was followed by sonication 
and centrifugation. The resulting supernatant was diluted 6-fold with extraction buffer 
and loaded onto a Resource Q column (lml, Pharmacia) equilibrated with extraction 
buffer. The bound protein was eluted in a single step using extraction buffer 
containing 500 mM KC1. The eluted material was used for enzyme assays.
The third enzyme, 3-dehydroquinate dehydratase was detected using a direct 
spectrophotometric assay (Coggins et al., 1987). The fifth enzyme of the pathway, 
shikimate kinase was detected by measuring directly the formation of shikimate 3- 
phosphate from shikimate using a high performance liquid chromatography (hplc) 
based assay (Mousdale & Coggins, 1985). The identity of this product was then 
confirmed by observing its conversion to EPSP after the addition of phosphoenol 
pyruvate and purified Escherichia coli EPSP synthase (Duggan et at., 1995). 
Detection of the sixth enzyme, EPSP synthase entailed monitoring the generation of 
EPSP using hplc. The identity of the product was confirmed by comparing its
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retention time and UV spectrum with authentic samples of EPSP generated by 
biotransformation (Coggins et al., 1987). This assay was also performed in the 
presence of ImM NPMG. Chorismate synthase, the seventh enzyme, was detected 
using an anaerobic assay (Ramjee et al, 1994).
A2.3 Results
The results are shown in Table A2.1 and Figure A2.1.
Table A2.1 Enzyme activity detected in T.gondii extracts
Enzyme Amount present in 
T.gondii extracts
Dehydroquinate synthase 3.0mU/mg protein
Shikimate kinase 1.6mU/mg protein
EPSP synthase 0.34mU/mg protein
Chorismate synthase Low levels
The enzyme activities detected were dehydroquinate synthase (3.0mU/mg protein), 
shikimate kinase (1.6mU/mg protein), EPSP synthase (0.34mU/mg protein). 
Chorismate synthase was detected at low levels in repeated experiments. A precise 
activity could not be accurately determined. EPSP synthase activity was inhibited by 
the addition of NPMG, ImM.
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Figure A2.1 Inhibition of EPSP synthase activity by 1mM 
NPMG. Key: Control EPSP synthase activity (■); EPSP 
synthase activity in the presence of 1mM NPMG ( • ) .
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APPENDIX 3
THE EFFECT OF SHAM AND 8-HQ ON THE GROWTH
OF P.FALCIPARUM AND C.PARVUM
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A3.1 Introduction
To investigate the presence of the alternative oxidase in other Apicomplexan parasites 
the effect of SHAM and 8-HQ on the in vitro growth of P.falciparum and C.parvum 
was assessed.
The experiments on P.falciparum were performed by D.E.. Kyle and W.K.Milhous of 
the Walter Reed Army Institute of Research, Washington DC, USA. The experiments 
on C.parvum were performed by S.Tzipori, Tufts University School of Veterinary 
Medicine, Boston, USA
A3.2 Materials and Methods
The ability of SHAM and 8-HQ to inhibit in vitro growth of P.falciparum and
C.parvum was assessed as described in Appendix 1.
A3.3 Results
Both SHAM and 8-HQ inhibited the growth of P.falciparum. The IC50 and IC90, the 
means of 5 replicate experiments, are shown in Table A3.1. SHAM and 8-HQ also 
inhibited the growth of C.parvum in a dose dependent manner. At a concentration of 
lOmg/ml both SHAM and 8-HQ inhibited over 50% of parasite growth. SHAM and 
8-HQ were non-toxic to the MDBK F5D2 monolayer at a concentration of lOpg/ml. 
At 100|ig/ml these compounds showed mild toxicity to the monolayer. The results are 
shown in Figure A3.1
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T able A3.1 The concentration of SHAM and 8-HQ required to  inhibit 
the  growth of pyrim etham ine-resistant (W2) and pyrim etham ine- 
sensitive  (D6), P.falciparum c lones___________________________________
P.falciparum
clone
Inhibitor IC5o (|ig/ml) IC90 (ng/ml)
W2 SHAM 5.7 43
8-HQ 1.6 4.5
D6 SHAM 6.2 25
8-HQ 1.2 1.9
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ASHAM (|ig/ml)
2 1000
8-HQ ( ( i g / m l )
F ig u re  A3.1 A The effect of SHAM on the  growth of 
C.parvum. At a concen tra tion  of 10|ig/ml SHAM inhibited over 
50% of p a ra s ite  growth. B The effect of 8-HQ on the  grow th of 
C.parvum . At a concen tra tion  of 10jig/ml 8-HQ inhibited over 
50% of p a ra s ite  grow th. Key: Media, control cu ltu res  infected  
with C.parvum ; PRM infected control cu ltu res trea ted  with 
p a ro m o m y cin .
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